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Cardiovascular implantable electronic devices (CIEDs) are life-saving devices programmed
to detect cardiac arrhythmias and intervene with pacing or shocks to avoid cardiac death.
Currently, three to four million Americans rely on CIEDs and this number is growing rapidly
with approximately 400,000 new device implantations each year. Worldwide, around one
million new device implantations are performed annually.
CIEDs consist of battery-powered pulse generators connected to the heart by one or more
electrode wires, called “leads,” embedded within a patient’s vein. To achieve the maximum
possible clinical benefit, modern CIEDs can automatically transmit data to the clinician’s of-
fice through various media, such as email and text messaging, to allow for remote monitoring.
This dissertation concentrates on improving the quality of care of patients with CIEDs,
i.e., maximizing the expected lifetime of these patients, by focusing on three major challenges
inherent to these devices: (i) cardiac leads fail stochastically and it is not clear whether to
abandon them or to extract them, either immediately or at a later time; (ii) the average life
span of CIED batteries is not as long as the average patient’s expected lifetime and it is not
clear when to replace the battery-powered pulse generators; (iii) the remote monitoring of
CIEDs can adversely affect the battery’s remaining lifetime and it is not clear how frequently
the remote transmissions should be performed.
We use methodologies including Markov decision processes as well as applied probability
and statistics to formulate and analyze decision models that enable clinicians to provide
patients with better quality of care. Using clinical data and expert opinion, we carefully cal-
ibrate the models concerning challenges (i) and (ii); for (iii), we provide insightful numerical
iii
examples for a stylized model. Our results suggest that behaving optimally can significantly
extend patients’ lives while simultaneously decreasing the burden on the healthcare system
by reducing the number of surgeries, in-office visits, and so on, without compromising the
patients’ well-being.
Keywords: Markov decision processes (MDPs), medical decision making, cardiovascular
implantable electronic devices (CIEDs), maintenance optimization, optimal replacement,
threshold policy, virtual age, remote transmission, finite horizon
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1.0 INTRODUCTION
This dissertation addresses the optimization of implanted cardiac device follow-up care.
Currently, three to four million Americans rely on cardiovascular implantable electronic de-
vices (CIEDs), i.e., pacemakers, implantable cardioverter defibrillators (ICDs) and cardiac
resynchronization therapy (CRT) devices. This number is growing rapidly with approxi-
mately 400,000 new device implantations each year (Buch et al. 2011). Worldwide, around
one million new device implantations are performed annually (Neelankavil et al. 2013).
CIEDs are comprised of battery-powered pulse generators and electrode wires, called
“leads,” which are embedded within a patient’s vein and are connected to the heart. CIEDs
continuously monitor the patient rhythm for cardiac arrhythmias, which they treat with
pacing or shock therapy to avoid cardiac death. To improve the clinical benefits of these
life-saving devices, modern CIEDs can automatically transmit data to the clinician’s office
through various media, such as email and text messaging, to allow for remote monitoring.
The term CIED captures a wide variety of devices including pacemakers, ICDs and CRT
devices. Pacemakers are used for bradyarrhythmia treatment, i.e., they detect slow rhythms
and send an electronic impulse to the heart to maintain a normal rhythm. ICDs are mainly
used for tachyarrhythmia management, i.e., they detect a very fast, potentially lethal heart
rhythm, and deliver a shock(s) or charge(s) to the heart muscle to restore a normal rhythm.
Both pacemakers and ICDs can be of single-chamber or dual-chamber type. Single- and dual-
chamber devices are connected to the heart with one and two leads, respectively, delivering
the therapy to the respective heart chamber(s). Because of the extra lead attaching the device
to one of the heart’s upper chambers, dual-chamber ICDs can also function as pacemakers,
i.e., they can treat bradyarrhythmia.
1
CRT devices are used to coordinate the contraction of heart chambers in both sides of
the heart to improve the blood flow into the body. That is, instead of only sending impulses
to the right side of the heart, as other standard CIEDs do, they also send electronic impulses
to the lower left chamber of the heart to help the chambers beat synchronously. CRT devices
are of two major types. CRT devices that are only capable of pacing the heart are called
CRT-P and those that are also equipped with an integrated defibrillator are called CRT-D.
This dissertation concentrates on improving the quality of care of CIED patients, i.e.,
maximizing the expected lifetime of the patients, by focusing on three major challenges
inherent to CIEDs:
(i) cardiac leads fail stochastically and it is not clear whether to abandon them or to extract
them, either immediately or at a later time;
(ii) the average life span of CIED batteries is not as long as the average patient’s expected
lifetime and it is not clear when to replace the battery-powered pulse generators;
(iii) the remote monitoring of CIEDs can adversely affect the battery’s remaining lifetime
and it is not clear how frequently the remote transmissions should be performed.
Unfortunately, little work has been done to assess how the decision making processes
regarding the follow-up care of patients with CIEDs may be improved, let alone optimized.
As a result, current practice varies widely from clinic to clinic. However, there is a growing
need for healthcare providers to justify their actions and policies. Indeed, the results estab-
lished through my research will significantly impact society by informing clinical practice,
reducing healthcare expenditures and improving patient safety.
In this dissertation, we use Markov decision processes (MDPs) as well as applied probabil-
ity and statistics to address the three major challenges inherent to CIEDs. More specifically,
in Chapter 2, we address the maintenance of cardiac leads, “the weakest link” in CIED treat-
ment, for four major device types. Chapter 3 addresses the mismatch between the average
patient’s expected lifetime and the average device’s lifespan. Next, in Chapter 4, we obtain
lifetime-reward-maximizing policies for performing life-depleting data transmissions under
various settings. Finally, we conclude in Chapter 5.
2
2.0 DYNAMIC ABANDON/EXTRACT DECISIONS FOR FAILED
CARDIAC LEADS
2.1 INTRODUCTION
As discussed in Section 1, CIEDs including pacemakers, ICDs and CRT devices are
implanted in the patient’s chest and attached to wires called “leads” connected to the heart.
These leads, which consist of small sensors that monitor the heart rhythm and deliver therapy
to the heart, fail stochastically at a significant, increasing rate over time (Dorwarth et al.
2003, Gradaus et al. 2003, Kleemann et al. 2007). In fact, lead failure rates are so pronounced
that cardiac leads are often referred to as “the weakest link” in CIED treatment (Bongiorni
et al. 2012, Maisel 2007).
Depending on the type of CIED, one, two or three functioning leads must be in place
at all times to properly deliver the required therapy. Therefore, whenever one lead fails
or multiple leads fail simultaneously, to ensure the functionality of the device the patient
undergoes a surgical lead replacement procedure. During the procedure, the patient receives
new, functioning lead(s). Implanting new leads carries rare, but life-threatening risks. Fur-
thermore, during each lead replacement procedure, the physician has the option of extracting
one or more of the failed leads, including the previously abandoned ones. Extracting leads
also carries life-threatening risks. However, if extraction is postponed, it becomes more dif-
ficult as fibrosis start to grow around leads attaching them to the adjacent heart and blood
vessels (Buch et al. 2011, Pe´rez Baztarrica et al. 2012). Hence, the risk of complications,
and consequently death, following lead extraction increases in the dwell time of the lead.
Although lead extraction involves risks (Henrikson and Brinker 2008c, Henrikson et al.
2010), there are situations in which the extraction of one or more leads is mandatory, namely,
reaching a physical constraint or developing an infection. More specifically, the total num-
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ber of implanted leads (including failed and functioning leads) is subject to a maximum
limit, typically five, due to physical space constraints (Buch et al. 2011, Wilkoff et al. 2009).
Hence, lead extraction is mandatory if this limit is reached with fewer functioning leads
than required by the device. Furthermore, patients are at risk of developing life-threatening
infections which prompt mandatory device extraction(s), i.e., extraction of all parts of the
CIED including all leads. One major cause of infection is the lead replacement procedure
itself; patients may develop a lead replacement procedure-induced infection shortly after lead
addition with or without extraction. However, patients may also acquire “unrelated” infec-
tions due to a wide array of other reasons, from generator replacement surgeries to a simple
scratch (Uslan et al. 2007). If an infection occurs, either lead replacement procedure-induced
or unrelated, the entire CIED including all implanted leads must be extracted (Henrikson
and Brinker 2008a). When the infection is cleared, the patient receives a new device (with
new lead(s)), typically within a few days to a month after extraction (Bongiorni et al. 2012,
Chua et al. 2000, Sohail et al. 2007a). Hence, choosing to abandon leads, i.e., leave leads in
place at the time of failure, may result in risky, mandatory future extractions.
Therefore, at the time of each lead failure a trade-off exists between abandoning the
failed lead(s) to minimize the short-term risks of complication and extracting one or more of
the failed leads to minimize the long-term risks of mandatory lead extractions. For instance,
although abandoning a failed lead lowers the short term risks of complication, extracting a
“young” failed lead now to “save space” or to avoid having to extract the lead due to infection
when it is “old” in the future, may increase the benefits in the long run (Buch et al. 2011).
The decision to abandon versus extract a failed lead persistently challenges clinicians
(Henrikson 2010, Maytin and Epstein 2010). In fact, there are no clear guidelines concern-
ing CIED lead maintenance and as a result, surveys of the current practice show a large
variation from clinic to clinic (Henrikson et al. 2010, Xu et al. 2009); some clinics favor ex-
tracting the failed leads over abandoning them (Bongiorni et al. 2008, Jones IV et al. 2008,
Kennergren et al. 2009), whereas some clinics are more inclined to abandon the failed leads
unless an extraction is mandatory (Glikson et al. 2009, Venkataraman et al. 2009). Although
clinical aspects of lead extraction are widely discussed in the literature (Bode et al. 2012,
Bongiorni et al. 2008, Bracke 2009, Buch et al. 2011, Gradaus et al. 2003, Glikson et al.
2009, Henrikson and Brinker 2008b, Henrikson 2010, Jones IV et al. 2008, Kennergren et al.
2009, Levine 2000, Maytin and Epstein 2010, Venkataraman et al. 2009, Xu et al. 2009), to
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the best of our knowledge, there is no work that compares the risks involved in making such
decisions from a quantitative perspective.
In this chapter, we formulate a collection of mathematical models to adaptively determine
the optimal treatment actions as a function of patient age and the age of every implanted
lead at the time of lead failure(s), given the individual’s clinical characteristics and device
specifications. More specifically, we use four Markov decision process (MDP) models to
maximize the total expected lifetime of any given patient wearing either one of the four
most popular types of CIEDs, i.e., single-chamber pacemakers, dual-chamber ICDs, dual-
chamber pacemakers and CRT defibrillator (CRT-D) devices. First, we develop a model for
single-chamber pacemakers which require exactly one working lead (of pacemaker type) to
function at all times. Next, we generalize our model to dual-chamber ICDs which require
two functioning leads, one pacemaker lead and one ICD lead. Pacemaker leads can only
deliver pacing therapy, whereas ICD leads have the additional function of delivering defibril-
lation shocks to the patient’s heart. We next simplify the model for dual-chamber ICDs to
dual-chamber pacemakers, with two identical pacemaker leads. Finally, we develop a model
for CRT-D devices that engage three chambers of the heart and require two pacemaker leads
and one ICD lead. We calibrate all these models using clinical data and execute numerical
experiments to determine patient-specific optimal policies as a function of patient age and
the age of every implanted lead. We then use several performance measures to compare
these policies with the ones commonly used in practice.
In terms of the operations research literature, the problem of interest touches on multiple
bodies of work within the reliability and maintenance optimization area including oppor-
tunistic maintenance optimization, k-out-of-n systems and damage-inducing maintenance
activities. Most relevant to our problem is the so-called opportunistic maintenance opti-
mization literature. Opportunistic maintenance, surveyed by Nicolai and Dekker (2006)
and Wang (2002), explores the opportunity of performing preventive maintenance (PM) on
functioning components of multi-component systems while its failed component(s) are being
repaired to exploit economies of scale. In our problem, the opportunity lies in the possibility
of “preventively” extracting one or more of the failed leads at the time of each lead addition,
before such action may become mandatory due to the space constraint or an infection. In
our context, the “cost” of PM is the risk of death from extracting the lead(s).
The problem at hand can be loosely viewed as a k-out-of-n system, in which the sys-
tem functions while at least k out of n typically identical components remain non-failed
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(Nicolai and Dekker 2006). In the context of this problem, n corresponds to the maximum
number of “positions” in the vein, i.e., five, and k is the number of required functioning leads,
i.e., k = 1, 2, 3 for single-chamber, dual-chamber and CRT-D devices, respectively. Despite
the cosmetic similarity of this problem with traditional k-out-of-n systems, our system is
different from these systems in important ways. In k-out-of-n systems, the status of the n
components is binary, i.e., the components are either failed or working. In this problem,
their status is expanded to include “empty” as well, which changes the underlying dynamics
of the system altogether. Additionally, the working components are not necessarily identical
in all the systems considered, e.g., in dual-chamber ICDs.
Lastly, the problem of interest shares a common feature with the damage-inducing main-
tenance literature, surveyed by Pham and Wang (1996). In practice, a maintenance action
may degrade the system or cause a breakdown, typically due to human error. Similarly, in
our problem the corrective action of adding a lead or the preventive action of extracting a
failed lead may give rise to life-threatening complications. Additionally, infection may occur
as a result of surgery, which may cause premature problem termination due to patient death.
In summary, despite a few attributes that our problem shares with bodies of work within
the reliability and maintenance optimization area, it does not entirely align with any of them
as it encompasses a unique combination of features, mainly due to the problem’s context
and consequently, its objective. Our problem is motivated by the need to manage failed car-
diac leads and its objective function strives to maximize the patient’s total expected lifetime,
whereas, in a typical maintenance optimization, the objective is to minimize the cost or max-
imize the availability of machinery. Furthermore, our problem, which, different from typical
maintenance optimization problems, has a finite horizon to begin with, may be prematurely
terminated as the patient may die from various reasons, including the corrective action itself.
The remainder of this chapter is organized as follows. In Section 2.2, we formulate four
models for the four most prevalent implanted cardiac devices. Next, to put the results in
perspective, we open Section 2.3 with an example optimal policy, which we compare and
contrast with the policies commonly used in practice. We continue Section 2.3 with present-
ing three heuristic policies as benchmarks. In Section 2.4, we calibrate the developed models
using clinical data, the existing medical literature and expert opinion and design a large
numerical experiment by establishing patient classes. In Section 2.5, we report the compre-
hensive results of our experiment, including the optimal lead abandon/extract policies for
various patient classes. Finally, we conclude in Section 2.6.
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2.2 MODEL FORMULATION
In this section, we first formulate an MDP model for single-chamber devices (Section
2.2.1). We then expand this model to account for dual-chamber devices with both identical
and heterogeneous leads (Section 2.2.2). Finally, we generalize our model to consider the
most prevalent type of three-chamber cardiac devices, i.e., CRT-D devices (Section 2.2.3).
2.2.1 Single-Chamber Devices
Let st = (`, θ) denote the state of the process for a patient of age t, T ≤ t ≤ T , where
T and T are the minimum and maximum ages, respectively, ` is the ordered vector of ages
for the leads currently implanted (both functioning and failed) and θ indicates whether the
decision epoch is due to a failure or an infection. That is, ` = [`(1), `(2), . . . , `(L)], where L
denotes the maximum number of leads that may be simultaneously implanted at any given
time due to space limitations, and `(i), i ∈ {1, . . . , L}, denotes the age of the ith oldest lead,
if present, and is assigned the value −1, otherwise. Note that the vector ` includes lead ages
only and not any additional information on leads’ “positions” within the vein as the latter
do not have any significant effect on the dynamics of the problem. When θ = 1, the decision
epoch is due to a failure and a decision must be made; when θ = 0, the “decision epoch” is
due to an infection and the entire CIED must be replaced, but no decisions must be made.
We introduce these “false” θ = 0 decision epochs strictly for mathematical convenience.
At every failure decision epoch, a new lead must be implanted for the device to function;
hence, the decision to be made is simply which lead(s) to extract. That is, the available
actions in state st, Ast , correspond to the set of all possible subsets of the lead indices to be
removed, i.e., a ⊆ {1, 2, . . . , L} for all a ∈ Ast . However, not all combinations of lead indices
constitute a feasible action, e.g., a lead that is nonexistent may not be extracted. For θ = 1,
A(`,1) =
{
a :
L∑
i=1
1{`(i)=−1} + |a| ≥ 1, 1{`(i)=−1} · 1{i∈a} = 0, i = 2, . . . , L
}
, (2.1)
where the first constraint in (2.1) guarantees that at least one position is available for im-
planting the new lead, and the second constraint in (2.1) prohibits the extraction of all
nonexistent leads. For θ = 0, the only possible action is to extract all existing leads, i.e.,
A(`,0) = {a : 1{`(i)>−1} · 1{i∈a} = 1, i = 1, 2, . . . , L} ≡ {a¯(`)}. (2.2)
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Let β1 denote the probability of death following lead addition and β−1(`(·)) denote the prob-
ability of death following extraction of a lead of age `(·). Let µ(`, a) denote the probability of
surviving the lead replacement procedure-induced complications starting from state (`, ·) un-
der action a. We assume procedural complications related to different leads are independent.
Hence,
µ(`, a) = (1− β1) ·
∏
i∈a
(
1− β−1(`(i))
)
. (2.3)
Next, let the random variable X with p.m.f. pX , c.d.f. FX and survival function F¯X denote
the time to failure for a new lead, i.e., a lead of age 0. We assume that all leads survive up to
a specified maximum age, ¯`≥ T −T , with some positive probability, i.e., pX(x) > 0 ∀x < ¯`.
We make several assumptions regarding the order of events between decision epochs.
First, we assume that failures, when they occur, do so at the end of the year. As discussed in
Section 2.1, patients may develop an infection following a lead replacement procedure or ac-
quire an “unrelated” infection. Because lead replacement procedure-induced infections typi-
cally develop within two to three months following the procedure (Kleemann et al. 2010) and
the model is formulated in yearly time increments, we assume lead replacement procedure-
induced infections occur immediately after the procedure. In agreement with the published
clinical literature, e.g., Chua et al. (2000), we also assume that once an infection is cleared,
another infection may not immediately develop. Consistent with the failure assumption, we
let unrelated infections, if they occur, do so at the end of the year, but assume that failures
precede unrelated infections, i.e., if a failure occurs in a given year, the patient may experience
a lead replacement procedure-induced infection, but not an unrelated infection in that year.
Let λ(t) denote the likelihood of surviving the competing risks of death (e.g., due to
comorbidities) between ages t− 1 and t. Thus, the likelihood of surviving these competing
risks for m periods starting from age t is given by
λ¯(t,m) ≡
t+m∏
j=t+1
λ(j). (2.4)
Next, let κ denote the annual probability of acquiring an unrelated infection. Given that the
next decision epoch is due to an unrelated infection, let ρ(m) denote the probability that
this decision epoch occurs in m years; similarly, given that the next failure occurs in n years,
let η(n) denote the probability that the next decision epoch is due to a failure, i.e.,
ρ(m) = λ¯(t,m) · (1− κ)m−1 · κ and η(n) = λ¯(t, n) · (1− κ)n−1. (2.5)
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Finally, let γ be the probability that the patient survives the risk of sudden cardiac
death at the time of a lead failure; α denote the probability of developing a lead replacement
procedure-induced infection; and δ be the probability that the patient survives the risk of
death due to acquiring an infection (separate from any required lead procedures).
Now consider Vt(`, θ), the maximum total expected reward starting from state st = (`, θ).
Clearly, the maximum total expected reward for a patient of age T is simply zero, i.e.,
VT (`, θ) = 0.
Decision epoch due to infection. For t < T , first consider the case in which θ = 0,
i.e., the decision epoch is due to an infection. Let `′(m) denote the lead age vector m years
after an infection, i.e., `′(m) = [m,−1,−1,−1,−1]. Given that the next failure is in n years,
let rt(n) denote the immediate expected reward starting from patient age t, i.e.,
rt(n) =
n∑
m=1
λ¯(t,m) · (1− κ)m−1. (2.6)
Additionally, let the function νt(n) denote the total expected reward obtained starting from
state st = (`, 0), conditional on surviving the infection and the requisite lead procedures,
weighted by the likelihood of the next lead failure occurring in n periods, i.e.,
νt(n) =

pX(n) ·
(
rt(n) +
∑n−1
m=1 ρ(m) · Vt+m(`′(m), 0)
+η(n) · γ · Vt+n(`′(n), 1)
)
, if n < T − t,
F¯X(n− 1) ·
(
rt(n) +
∑n−1
m=1 ρ(m) · Vt+m(`′(m), 0)
)
, if n = T − t.
(2.7)
Starting from patient age t, the first expression in equation (2.7) gives the total expected
reward when the next failure occurs in n years at patient age t + n < T . First, the patient
earns the immediate expected reward rt(n) corresponding to the expected number of years
survived, possibly fewer than n years. If an unrelated infection occurs in m < n years, the
total expected reward to go is Vt+m(`
′(m), 0). Note that m 6= n as we assume that failures
precede unrelated infections within each period. Finally, given that the patient survives all
risks to experience a failure at age t + n, the total expected reward to go is Vt+n(`
′(n), 1).
Starting from patient age t, the second expression in equation (2.7) gives the total expected
reward if the next failure occurs at or after the patient’s maximum age. In this case, the
patient reaches the maximum age T and the problem terminates before the next lead failure
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occurs. Similar to the first expression in equation (2.7), the patient earns the immediate ex-
pected reward rt(n), plus the total expected reward to go associated with possibly developing
an infection prior to the maximum age. Lastly, note that because all leads are extracted
due to an infection, νt(n) is only a function of the patient age t and the time to next failure
n, and not the ages of the leads. Hence, for t < T , using (2.3)-(2.7) the maximum total
expected reward at a decision epoch with θ = 0 is given by
Vt(`, 0) = δ · µ(`, a¯(`)) ·
T−t∑
n=1
νt(n). (2.8)
Decision epoch due to failure. Next, for t < T , consider the case in which θ = 1,
i.e., the decision epoch is due to a failure. Starting from state st = (`, 1), suppose action a
is taken and the next decision epoch occurs m years later. Let `′′(a,m) denote the lead age
vector at this decision epoch, i.e., `′′(a,m) = [`′′(1), `
′′
(2), . . . , `
′′
(L)], where `
′′
(i), i ∈ {1, . . . , L},
denotes the age of the ith oldest lead at patient age t+m, if present, and assumes the value
−1, otherwise. Furthermore, let
ψ(`, a,m) ≡
{
`(i) +m : 1 ≤ i ≤ L, i /∈ a, `(i) 6= −1
}
∪ {m}, (2.9)
i.e., ψ(`, a,m) is the set of lead ages at patient age t + m after taking action a in state
st = (`, 1). The vector `
′′(a,m) is hence given by the non-increasingly ordered members of
the set ψ(`, a,m), with the unfilled components of vector `′′(a,m) set to −1. For example, let
¯`= 40 and consider a decision epoch at which the process is in state s60 = ([9, 5, 3,−1,−1], 1).
Because all three implanted leads are failed, a ⊆ {1, 2, 3}. Now suppose action a = {2} is
taken and the newly implanted lead fails 4 years later. Therefore, from equation (2.9), we
have ψ([9, 5, 3,−1,−1], {2}, 4) = {13, 4, 7} and at the next decision epoch, the process is in
state s64 = ([13, 7, 4,−1,−1], ·), i.e., `′′(1) = 13, `′′(2) = 7, `′′(3) = 4 and `′′(4) = `′′(5) = −1.
Now, let ut(`, a, n) denote the total expected reward obtained starting from state st =
(`, 1) under action a, conditional on the next lead failure occurring in n periods and weighted
by its likelihood, i.e.,
ut(`, a, n) =

pX(n) ·
(
rt(n) +
∑n−1
m=1 ρ(m) · Vt+m(`′′(a,m), 0)
+η(n) · γ · Vt+n(`′′(a, n), 1)
)
, if n < T − t,
F¯X(n− 1) ·
(
rt(n) +
∑n−1
m=1 ρ(m) · Vt+m(`′′(a,m), 0)
)
, if n = T − t.
(2.10)
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Equation (2.10) is similar in structure to equation (2.7); the only difference is in the lead age
vector at the next decision epoch, i.e., `′′(a,m) and `′′(a, n) in equation (2.10) as opposed
to `′(m) and `′(n) in equation (2.7). Therefore, when θ = 1 the maximum total expected
reward is given by
Vt(`, 1) = max
a∈A(`,1)
{
µ(`, a) ·
(
(1− α) ·
T−t∑
n=1
ut(`, a, n) + α · Vt(`′′(a, 0), 0)
)}
, (2.11)
where µ(`, a) and Vt(`
′′(a, 0), 0) are given by (2.3) and (2.8), respectively. At a decision
epoch with θ = 1, a new lead is added and a subset of the failed leads may be extracted.
Given that the patient survives the lead replacement procedure-induced complications, if no
lead replacement procedure-induced infection occurs and the next failure occurs in n years,
n = 1, . . . , T − t, the patient earns the total expected reward of ut(`, a, n), given by equation
(2.10). Otherwise, if a lead replacement procedure-induced infection occurs, the process in-
stantaneously enters state (`′′(a, 0), 0) at which point the patient receives the total expected
reward of Vt(`
′′(a, 0), 0), given by equation (2.8).
2.2.2 Dual-Chamber Devices
In this section, we generalize the model developed in Section 2.2.1 to account for dual-
chamber devices. First, we formulate a model for dual-chamber ICDs, with two heterogenous
leads, in Section 2.2.2.1. Then, we simplify this model in Section 2.2.2.2 to obtain a formu-
lation for dual-chamber pacemakers, in which we exploit the fact that the leads are identical
to reduce the size of the state space.
2.2.2.1 Dual-Chamber Devices with Heterogeneous Leads
Here, we consider dual-chamber ICDs which, to function, require exactly two working,
heterogenous leads at all times. In the remainder of the chapter, for simplicity, we refer to
pacemaker and ICD leads as ‘P’ and ‘D’ leads, respectively. First, we augment the state
definition from Section 2.2.1 to include w (i.e., st = (`, w, θ)), where w ∈ W = {0, 1, 2}
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indicates the working lead at the time of lead failure with the value zero corresponding to
the simultaneous failure of both leads. That is,
w =

0, none of the leads are functional,
1, a P lead is functional,
2, a D lead is functional.
(2.12)
Furthermore, we redefine the lead age vector to be ` = [(`(1), `(2)), `(3), . . . , `(L)], where com-
ponents `(1) and `(2) denote the ages of the “current,” i.e., not previously abandoned, P and
D leads, respectively, and `(i), i ∈ {3, . . . , L}, denotes the age of the ith oldest, previously
abandoned lead, if present, and is assigned the value −1, otherwise. Because all failed leads
may be treated identically, the values of `(i), i ∈ {3, . . . , L}, are ordered non-increasingly in
vector ` regardless of their associated lead types. Note that in this redefined lead age vector,
at least one of the current P and D leads is always the youngest lead. For example, consider
s60 = ([(3, 8), 5, 4,−1], 2, ·). In this state, the patient and the current P and D leads are 60,
3 and 8 years old, respectively, and the only working lead is the D lead. The current P lead
is added last, hence is the youngest lead, and two previously abandoned leads of ages 5 and
4 are also present.
Let the random variable Xj, j = 1, 2, with p.m.f. pXj , c.d.f. FXj and survival function
F¯Xj denote the time to failure for a new P lead and a new D lead, respectively. Similar to
Section 2.2.1, we assume that all leads survive up to a specified maximum age, ¯`≥ T¯ − T ,
with some positive probability. Furthermore, consistent with Section 2.2.1, we assume that
failures and infections, if they occur, do so at the end of each year.
For dual-chamber ICDs, at every failure decision epoch, the value of w determines the
number and type(s) of the lead(s) that must be implanted. Let φ(w, θ) denote the required
number of leads to add in state (`, w, θ), i.e.,
φ(w, θ) =
2, if θ = 0,2− 1{w>0}, otherwise. (2.13)
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Analogous to Section 2.2.1, Ast corresponds to the set of all possible subsets of the lead
indices to be removed; however, not all combinations of lead indices constitute a feasible
action. For θ = 1, we redefine Ast in equation (2.1) to be
A(`,w,1) =
{
a :
L∑
i=1
1{`(i)=−1} + |a| ≥ φ(w, 1), if w > 0 : 1{w∈a} = 0,
1{`(i)=−1} · 1{i∈a} = 0, i = 3, . . . , L
}
, (2.14)
where the first constraint in (2.14) guarantees that enough positions are available for im-
planting the new lead(s), the second constraint in (2.14) prevents the extraction of a working
lead and the last constraint in (2.14) prohibits the extraction of nonexistent leads. For θ = 0,
because the only possible action is again to extract all existing leads, Ast remains unchanged
and is given by equation (2.2), i.e., A(`,w,0) = A(`,0) = {a¯(`)}.
Next, we redefine µ(·, a), previously given by (2.3), to denote the probability of surviv-
ing the lead replacement procedure-induced complications starting from state (`, w, θ) under
action a, i.e.,
µ((`, w, θ), a) = (1− β1)φ(w,θ) ·
∏
i∈a
(
1− β−1(`(i))
)
, (2.15)
where φ(w, θ) is given by equation (2.13). Lastly, we redefine Vt(`, w, θ) to denote the max-
imum total expected reward starting from state st = (`, w, θ). Clearly,
VT (`, w, θ) = 0. (2.16)
Decision epoch due to infection. For t < T , first consider the case in which θ = 0.
Redefine `′(m) to denote the lead age vector m years after an infection for a dual-chamber
ICD, i.e., `′(m) = [(m,m),−1,−1,−1]. Also, redefine νt(n), previously given by equation
(2.7), to denote the total expected reward obtained starting from state st = (`, w, 0), condi-
tional on surviving the infection and the requisite lead procedures, weighted by the likelihood
of the next lead failure occurring in n periods, i.e.,
νt(n) =

∑
i∈{0,1,2} ϕi(t, n), if n < T − t,
ϕ∆(t, n), if n = T − t,
(2.17)
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where
ϕi(t, n) = pX1(n)
1{i∈{0,2}} · pX2(n)1{i∈{0,1}} · F¯X1(n)1{i∈{1}} · F¯X2(n)1{i∈{2}}
·
(
rt(n) +
n−1∑
m=1
ρ(m) · Vt+m(`′(m), w, 0)
+η(n) · γ · Vt+n(`′(n), i, 1)
)
, i ∈ {0, 1, 2} (2.18a)
ϕ∆(t, n) = F¯X1(n− 1) · F¯X2(n− 1) ·
(
rt(n) +
n−1∑
m=1
ρ(m) · Vt+m(`′(m), w, 0)
)
.(2.18b)
The probabilities ρ(m) and η(n) and the immediate expected reward, rt(n), are given by
equations (2.5) and (2.6), respectively. Starting from patient age t, for i ∈ {0, 1, 2}, equation
(2.18a) gives the total expected reward when the next failure occurs in n years at patient
age t+n < T . More specifically, equations (2.18a) corresponds to the total expected reward
obtained when the next failure is caused by the simultaneous failure of both working leads
(i = 0), the failure of the working D lead (i = 1), and the failure of the working P lead
(i = 2), respectively, at patient age t + n. Starting from patient age t, equation (2.18b),
analogous to the second expression in equation (2.7), gives the total expected reward if the
next failure occurs at or after the patient’s maximum age. Finally, for t < T , the maximum
total expected reward at a decision epoch with θ = 0 is given by
Vt(`, w, 0) = δ · µ((`, w, 0), a¯(`)) ·
T−t∑
n=1
νt(n), ∀w ∈ W. (2.19)
Decision epoch due to failure. Next, for t < T , consider the case in which θ = 1. We
redefine `′′(a,m) from Section 2.2.1 to denote the lead age vector m years after a transition
from state st = (`, w, 1) under action a, i.e., `
′′(a,m) = [(`′′(1), `
′′
(2)), . . . , `
′′
(L)], where `
′′
(1) and
`′′(2) denote the ages of the current P and D leads at patient age t+m, respectively, and `
′′
(i),
i ∈ {3, . . . , L}, denotes the age of the ith oldest, previously abandoned lead at patient age
t+m, if present, and assumes the value −1, otherwise. For j = 1, 2, we have
`′′(j) =
m, if j 6= w,`(j) +m, otherwise. (2.20)
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We augment the set definition previously given by (2.9) to include w (i.e., ψ(`, a,m,w)) and
redefine it to be the set of the ages of previously abandoned leads at patient age t+m after
taking action a in state st = (`, w, 1), i.e.,
ψ(`, a,m,w) =
{
`(i) +m : 1 ≤ i ≤ L, i /∈ a, `i 6= −1, i 6= w
}
. (2.21)
Hence, the first two components of vector `′′(a,m) are given by equation (2.20) and its
remaining components are given by the non-increasingly ordered members of the set ψ(`, a,m,w),
with the unfilled components set to −1. For example, let ¯` = 40 and consider a decision
epoch at which the process is in state s60 = ([(3, 8), 5, 4,−1], 1, 1), i.e., `(1) = 3, `(2) = 8,
`(3) = 5, `(4) = 4, `(5) = −1, w = 1 and θ = 1. Because the only working lead is the current
P lead, a ⊆ {2, 3, 4}. Now, suppose action a = {3} is taken and the newly implanted D lead
fails 3 years later. Therefore, from equation (2.20), `′′(1) = 6 and `
′′
(2) = 3 and from equation
(2.21), ψ([(3, 8), 5, 4,−1], {3}, 3) = {11, 7}; hence, at the next decision epoch, the process is
in state s63 = ([(6, 3), 11, 7,−1], ·, ·), i.e., `′′(1) = 6, `′′(2) = 3, `′′(3) = 11, `′′(4) = 7, `′′(5) = −1.
Now, we redefine ut(`, w, a, n), previously given by equation (2.10), to denote the total
expected reward obtained starting from state st = (`, w, 1) under action a, conditional on
the next lead failure occurring in n periods and weighted by its likelihood, i.e.,
ut(`, w, a, n) =

∑
i∈{0,1,2} υi(t, `, w, a, n), if n < T − t,
υ∆(t, `, w, a, n), if n = T − t,
(2.22)
where for w = 0, υi(t, `, 0, a, n), i ∈ {0, 1, 2,∆}, is given by an equation similar to equation
(2.18), in which `′(m) and `′(n) are substituted with `′′(a,m) and `′′(a, n), respectively,
and for w > 0, υi(t, `, w, a, n), i ∈ {0, 1, 2,∆}, is given as follows. Namely, if w > 0, let
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w¯ = 1 + 1{w=1}; hence,
υi(t, `, w, a, n) = Pr(Xw = `(w) + n|Xw > `(w))1{i∈{0,2}} · pXw¯(n)1{i∈{0,1}}
·Pr(Xw > `(w) + n|Xw > `(w))1{i∈{1}} · F¯Xw¯(n)1{i∈{2}}
·
(
rt(n) +
n−1∑
m=1
ρ(m) · Vt+m(`′′(a,m), w, 0)
+η(n) · γ · Vt+n(`′′(a, n), 0 + 1{i∈{1}} · w + 1{i∈{2}} · w¯, 1)
)
, i ∈ {0, 1, 2}
(2.23a)
υ∆(t, `, w, a, n) = Pr(Xw > `(w) + n− 1|Xw > `(w)) · F¯Xw¯(n− 1)
·
(
rt(n) +
n−1∑
m=1
ρ(m) · Vt+m(`′′(a,m), w, 0)
)
. (2.23b)
That is, when w is positive, either the current P or the current D lead is working; hence, to
ensure the functionality of the device, a new lead of the other type must be added. Starting
from patient age t, equation (2.23a) gives the total expected reward when the next failure
occurs in n years at patient age t + n < T . More specifically, when i = 0, equation (2.23a)
corresponds to the total expected reward obtained when the next failure is caused by the
simultaneous failure of both working leads at patient age t + n. When i = 1 and w = 1
(w = 2), the current P lead (the current D lead) is functional at patient age t and equation
(2.23a) corresponds to the total expected reward obtained when the next failure is caused
by the failure of the newly implanted lead at patient age t, which is of type D (respectively,
P). Similarly, when i = 2 and w = 1 (w = 2), the current P lead (the current D lead) is
functional at patient age t and equation (2.23a) corresponds to the total expected reward
obtained when the next failure is caused by the failure of this lead at patient age t + n.
Lastly, starting from patient age t, equation (2.23b) gives the total expected reward if the
next failure occurs at or after the patient’s maximum age. Therefore, when θ = 1, the
maximum total expected reward is given by
Vt(`, w, 1) = max
a∈A(`,w,1)
{
µ((`, w, 1), a) ·
(
(1− α) ·
T−t∑
n=1
ut(`, w, a, n)
+ α · Vt(`′′(a, 0), w, 0)
)}
, (2.24)
where µ((`, w, 1), a) and Vt(`
′′(a, 0), w, 0) are given by equations (2.15) and (2.19), respec-
tively.
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2.2.2.2 Dual-Chamber Devices with Identical Leads
In this section, we consider dual-chamber pacemakers which require exactly two function-
ing pacemaker leads at all points in time. To formulate a model for dual-chamber pacemakers,
we simplify the model formulated for dual-chamber ICDs in Section 2.2.2.1. For the sake of
brevity, we only include the state and action space definitions in this section. The complete
discussion on the model formulation is included in Appendix A.1.
We redefine the lead age vector from Section 2.2.2.1 to be ` = [(`(1), `(2)), . . . , `(L)], where
`(1) and `(2) denote the ages of the current P leads. Because the two current leads are
identical, we let `(1) and `(2) be ordered non-increasingly to reduce the size of the state
space. Next, we modify the definition of w ∈ W = {0, 1, 2} to indicate the working lead at
the time of lead failure with the value zero corresponding to the simultaneous failure of both
leads, i.e.,
w =

0, none of the leads are functional,
1, the older, current P lead is functional,
2, the younger, current P lead is functional.
(2.25)
The action space, Ast , remains the same as in Section 2.2.2.1.
2.2.3 CRT-D Devices
In this section, we consider CRT-D devices that require exactly two functioning pace-
maker leads and one functioning ICD lead at all points in time. We formulate a model
for CRT-D devices by generalizing the models presented in Section 2.2.2. For the sake of
brevity, we only include the state and action space definitions in this section. The complete
discussion on the model formulation is included in Appendix A.2.
We redefine the lead age vector from Section 2.2.2 to be ` = [(`(1), `(2), `(3)), . . . , `(L)],
where `(1) and `(2) denote the ages of the current P leads, when ordered non-increasingly,
`(3) denotes the age of the current D lead, and `(i), i ∈ {4, . . . , L}, denotes the age of the ith
oldest, previously abandoned lead, if present, and is assigned the value −1, otherwise. Next,
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we modify the definition of w ∈ W = {0, 1, 2, . . . , 6} to indicate the working lead(s) at the
time of lead failure, i.e.,
w =

0 none of the leads are functional,
1, the older, current P lead is functional,
2, the younger, current P lead is functional,
3 the current D lead is functional,
3¯, both current P leads are functional,
2¯, the older, current P lead and the current D lead are functional,
1¯, the younger, current P lead and the current D lead are functional.
(2.26)
For example, consider s60 = ([(6, 3, 4), 9,−1], 2¯, ·). From this example, the patient, the cur-
rent P leads and the current D lead are 60, 6, 3 and 4 years old, respectively, and the
only working leads are the older, current P lead and the current D lead. One previously
abandoned lead of age 9 is also present.
Similar dual-chamber ICDs, the value of w determines the number and type(s) of the
lead(s) that must be implanted for CRT-D devices. Redefine φ(w, θ) to denote the required
number of leads to add in state (`, w, θ), i.e.,
φ(w, θ) =
3, if θ = 0,3− 1{w∈{1,2,3}} − 2 · 1{w∈{3¯,2¯,1¯}}, otherwise. (2.27)
Analogous to Sections 2.2.1 and 2.2.2, Ast corresponds to the set of all possible subsets of
the lead indices to be removed; however, not all combinations of lead indices constitute a
feasible action. For θ = 1, let the set B(w), w ∈ {3¯, 2¯, 1¯}, denote the indices of the working
leads when exactly two leads are functional, i.e.,
B(w) =
{
b : b ∈ {1, 2, 3},1{w=3¯} · 1{b=3} = 0,1{w=2¯} · 1{b=2} = 0,1{w=1¯} · 1{b=1} = 0
}
. (2.28)
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Hence,
A(`,w,1) =
{
a :
L∑
i=1
1{`(i)=−1} + |a| ≥ φ(w, 1), (2.29a)
if w ∈ {1, 2, 3} : 1{w∈a} = 0, if w ∈ {3¯, 2¯, 1¯} : 1{B(w)∩a=∅} = 1, (2.29b)
1{`(i)=−1} · 1{i∈a} = 0, i = 4, . . . , L
}
, (2.29c)
where the constraint in (2.29a) guarantees that enough positions are available for implanting
new lead(s), the constraints in (2.29b) prevent the extraction of a working lead and lastly,
the constraint in (2.29c) prohibits the extraction of all nonexistent leads. For θ = 0, Ast
remains unchanged and is given by equation (2.2), i.e., A(`,w,0) = A(`,0).
2.3 LEAD MAINTENANCE POLICIES
In this section, we first present an example optimal policy. We discuss several interesting
properties of this policy that are consistently observed throughout our numerical experimen-
tation. Next, we review the policies commonly used in current practice. Finally, inspired by
current practice, we introduce three heuristic policies which later act as benchmarks.
An example optimal policy. Figures 1a-1e illustrate the optimal lead abandon/extract
policy for an example single-chamber pacemaker patient. In these figures, the dark and light
squares correspond to the states in which it is optimal to extract and abandon the lead,
respectively. The blank squares correspond to the states that are unreachable considering
the parameter settings or problem dynamics, e.g., a 31-year-old patient may not have a lead
of two years or older when T = 31.
Figures 1a-1e show the optimal abandon/extract policy as a function of the lead age and
the patient age when exactly one–five leads are implanted, respectively. The plots that do
not carry any information are removed from Figure 1. That is, the plots corresponding to the
second youngest lead (the older of the two) in Figure 1b, the third youngest lead in Figure
1c, the third and fourth youngest leads in Figure 1d, and the fourth and fifth youngest leads
in Figure 1e are removed as it is never optimal to extract these leads. Similarly, the plot
corresponding to the youngest lead in Figure 1e is removed as it is always optimal to extract
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this lead. Recall that the number of implanted leads is limited to five, hence in Figure 1e
the youngest lead is always extracted to make room for adding a new lead.
As seen in Figure 1, the optimal action is to extract a lead when the lead and patient are
both “young.” The former is due to the fact that the risk of death following lead extraction
increases in lead age and the latter is mainly because younger patients are more likely to
eventually reach the maximum number of implanted leads, and hence require a “forced”
extraction. Interestingly, we observe that under the optimal policy, the abandon/extract
decision for each lead only depends on its age, patient age, its age rank among the lead ages
and the total number of implanted leads, i.e., the decision does not depend on the exact ages
of all implanted leads. Additionally, the decision is of threshold type in the lead age, patient
age and the lead’s age rank among the lead ages, hence making it easier to implement.
Throughout the numerical experimentation, we consistently observe that, similar to
single-chamber devices, in multi-chamber devices the abandon/extract decision for each lead
also depends on its age, patient age, its age rank among the lead ages and the total number
of implanted leads. Recall that in multi-chamber devices, not all required, working leads may
be failed at the time of a lead failure. As a result, different from single-chamber devices,
we observe that in multi-chamber devices the abandon/extract decision for each lead also
depends on the age of the working lead(s). Clearly, the “older” the working lead(s), the
larger their hazard rate(s); hence, consistent with the intuition, we observe that the optimal
policy prescribes to extract failed leads at “younger” ages when working leads are “older,”
in anticipation that the next failure occurs shortly.
Current clinical practice. In contrast to patient-specific optimal policies generated
by the models in Section 2.2, the policies used in clinical practice are overly simplified; they
not only fail to take into account both sides of the trade-off with which decision makers are
generally faced, but are not tailored to individuals. Recall from Section 2.1 that at the time
of each lead failure a trade-off exists between abandoning the failed lead(s) to minimize the
short-term risks of complication and extracting one or more of the failed leads to minimize the
long-term risks of mandatory lead extractions. Despite this trade-off and regardless of impor-
tant patient/device characteristics, two current approaches to lead maintenance include ei-
ther extracting all failed leads (see Bongiorni et al. (2008), Jones IV et al. (2008), Kennergren
et al. (2009)), or abandoning all failed leads unless an extraction is mandatory (see Glikson
et al. (2009), Venkataraman et al. (2009)). In the following, inspired by the approaches used
in various clinics, we introduce three heuristic policies which we later use as benchmarks.
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Figure 1: Optimal lead maintenance policy for a single-chamber device when T = 31, T = 100,
pX(x) is obtained using the hazard function in Table 20 (in Appendix A.3) for ω = 0.55, α = 0.03,
κ = 0.015, β1 = 0.00075, β−1(`) is of type “average” in Table 21 (in Appendix A.3), and δ = 0.98.
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Table 1: Three heuristic lead maintenance policies when a decision epoch is due to a failure (θ = 1).
Heuristic
Description
policies
C Only add lead(s) if possible. If not possible, extract the youngest failed lead(s) only.
H Only add lead(s) if possible. If not possible, extract all failed leads.
A Extract all failed leads.
As discussed in Sections 2.1 and 2.2, if a decision epoch is due to an infection, i.e., θ = 0,
the extraction of all leads is mandatory. Hence, what differentiates various policies is their
recommendation on which leads to abandon/extract when a decision epoch is due to a failure,
i.e., θ = 1. Here, we introduce three policies, referred to as policies C, H, and A for “conser-
vative,” “hybrid” and “aggressive,” respectively. Policies C andA are widely used in practice.
Physicians are typically reluctant to extract leads due to the risks involved. Therefore,
many tend to abandon failed leads until extraction becomes inevitable due to reaching the
physical space constraint with fewer functioning leads than required by the device. Once
mandatory, depending on the device type and the number of working leads, one to three
leads are extracted to make space for implanting the required number of new leads. Clearly,
to reduce the risk of death, the lead(s) that are extracted are the youngest(s). We capture
this “conservative” lead maintenance scheme in policy C. Policy H is similar to policy C in
that extraction decisions are not made until the space constraint is reached; however, under
policy H, once mandatory, all failed leads are extracted. Finally, policy A is “aggressive” in
that it advises to extract all failed leads at every decision epoch. Table 1 summarizes the
three heuristic lead abandon/extract policies. In the remainder of this chapter, we denote the
total expected reward obtained under policy pi ∈ {C,H,A} by Vt,pi(`, θ) for single-chamber
devices and Vt,pi(`, w, θ) for multi-chamber devices.
2.4 MODEL CALIBRATION AND EXPERIMENTAL DESIGN
In this section, we use a combination of the existing medical literature, clinical data
and expert opinion to calibrate the mathematical models formulated in Section 2.2. We
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Table 2: Experimental-design factors and their corresponding levels. The values of pX(x)(or pX1(x))
and pX2(x) are obtained using the hazard function values for pacemaker and ICD leads, respectively,
presented in Table 20 in Appendix A.3. For the values of β−1(`), refer to Table 21 in Appendix
A.3.
Factor No. of levels Levels
pX(x)(or pX1(x)) 3 for ω ∈ {0.45, 0.5, 0.55}
pX2(x) 3 for ω ∈ {0.4, 0.45, 0.5}
α 4 0.01, 0.02, 0.03, 0.04
κ (for PM1 and PM2) 3 0.005,0.01,0.015
κ (for ICD) 4 0.005,0.01,0.015,0.02
κ (for CRT-D) 5 0.005,0.01,0.015,0.02,0.025
β1 3 0.00075, 0.001, 0.00125
β−1(`) 3 low, average, high
δ 3 0.94,0.96,0.98
then design a large numerical experiment to analyze the effects of the patient-specific pa-
rameters on the optimal policy. In the remainder of the chapter, for simplicity we refer
to single-chamber and dual-chamber pacemakers (i.e., dual-chamber devices with identical
leads) with acronyms PM1 and PM2, respectively. Table 2 summarizes the factors of the
experiment and their corresponding levels that are estimated and thoroughly discussed in
this section and Appendix A.3.
Maximum number of leads, L. From the clinical guidelines (Buch et al. 2011, Wilkoff
et al. 2009), the maximum number of leads implanted at any given point in time should be
limited to five, i.e., L = 5.
Probability of surviving the risk of sudden cardiac death due to lead failure,
γ. Based on expert opinion, this probability is very close to one. To the best of our knowl-
edge, there are no published data on the probability of surviving the risk of sudden cardiac
death due to lead failure. Therefore, we use recalled lead-induced deaths as a proxy for this
probability. A recall is typically issued in response to increased rates of lead failure, fracture
or externalization. As a result, recalled leads may be extracted before they fail; however,
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for the purpose of estimating γ, we assume patients continue using these leads until they
fail. According to a report by Samsel 2009, out of patients with 268,000 recalled leads, 9
(equivalently, 0.005%) instances of death may be attributed to lead fracture. Therefore, we
let γ = 0.99995.
Minimum patient age at the time of lead failure, T ; maximum patient age at
the time of lead failure, T ; maximum lead age, ¯`. In most clinical studies, the mean
age at initial CIED implantation is between 57 and 76 years (Johansen et al. 2011, Lee et al.
2010, Remmelts et al. 2009, Saxon et al. 2010). To obtain comprehensive results for a wide
range of adult cardiac patients, we consider individuals who undergo initial implantation
at or after age 30 and assume no patient survives beyond 100 years. That is, T = 31 and
T = 100. Recall from Section 2.2 that we assume ¯`≥ T−T ; hence, without loss of generality,
we let ¯`= 69.
Probability of surviving the competing risks of death, λ(`). To estimate values of
λ(`), we use the United States total population life table provided by the Centers for Disease
Control and Prevention (CDC) (Arias 2012). Pacemaker patients live almost as long as the
average population (Brunner et al. 2004, Udo 2013); hence, for these patients the values of
λ(`) directly follow from the life table. Patients with ICD and CRT-D devices, however,
have shorter life expectancies than the average population. Therefore, to obtain values of
λ(`) for each subpopulation of interest, we use the disease-specific excess rate of mortality
to decrease the survival probabilities of the total population. More specifically, the per-year
survival probability of patients with a particular disease is set equal to the complement of the
probability of death from competing risks for the average population in that year, plus the
disease-specific excess rate of mortality. We estimate the annual excess rate of mortality for
patients with ICD and CRT-D devices by applying the DEALE method (Beck et al. 1982)
to single-point survival data reported by Saxon et al. (2010). The estimated rates are 0.025
and 0.075, respectively. Further details are included in Appendix A.3.
Distribution of the time to failure of a new lead, pX(x) (or pX1(x)) and pX2(x).
Because advances in technology have not necessarily translated into higher lead reliability
(Emory Healthcare 2012), we may safely use longitudinal studies as a means of estimat-
ing pX(x). More specifically, here we use a combination of manufacturers’ reports on lead
survival probabilities in the past decade or so, expert opinion and mathematical modeling
tools to estimate the distribution of the time to failure for both pacemaker and ICD leads.
We assume that leads fail at a constant rate for all ` ≥ `. This assumption alleviates the
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problem of data sparsity for leads older than 12-14 years, for which annual lead survival
probabilities are not readily available. Additionally, the assumption reduces the computa-
tional burden and memory requirements by limiting the maximum lead age to `. Considering
the specifications of our computers, we let ` = 16 years in the remainder of the chapter.
Note that to exploit the constant hazard property of pX(x) after age `, we update the
models in Section 2.2. That is, we slightly modify the models to limit the lead age to `. For
instance, in Section 2.2.1, we alter `′(m), previously defined as `′(m) = [m,−1,−1,−1,−1],
to `′(m) = [min{`,m},−1,−1,−1,−1] and substitute `(i) + m with min{`(i) + m, `} in
equation (2.9). We make a series of similar changes to the models in Sections 2.2.2 and 2.2.3.
We obtain annual lead survival probabilities using a combination of manufacturers’ re-
ports and expert opinion. For pacemaker and ICD leads, we use publicly available empirical
data on Medtronic CapSureFix model 4068 and Medtronic Transvene model 6936/6966, re-
spectively (Medtronic August 06, 2012). These models are widely used in practice and their
survival probabilities are recorded for a substantial length of time (i.e., almost 14 years).
From the data, the ICD lead is much less reliable than the pacemaker lead, which is because
ICDs leads are generally more technologically complex than pacemaker leads (Schiariti et al.
2011, Van Dessel 2010). To more accurately predict the behavior of these survival probabil-
ities for older leads, we then use expert opinion to add a point estimate, ω, at lead age 20
to each dataset. To account for disparity in lead technology, we use a range of values for ω,
i.e., ω ∈ {0.45, 0.5, 0.55} for pacemaker leads and ω ∈ {0.4, 0.45, 0.5} for ICD leads.
Next, to obtain pX(x), we fit a Gompertz distribution (Cox and Oakes 1984) to the ap-
pended data and discretize to obtain a p.m.f., pX˜(x), which we then adjust so that it exhibits
constant hazard after age `. Further details are included in Appendix A.3.
Figure 2a plots the augmented data, the Gompertz distribution and the estimated sur-
vival distribution, pX , for a pacemaker lead when ω = 0.5. Figure 2b reports the correspond-
ing p.m.f., c.d.f. and hazard function for the lead represented in Figure 2a.
Probability of lead replacement procedure-induced infection, α. The overall
incidence rate of infection among patients with cardiac devices is widely published in the
clinical literature (Baddour et al. 2003, Chua et al. 2000, Kleemann et al. 2010, Voigt et al.
2010, Kirmani et al. 2012). However, the incidence rate of infection that is specifically caused
by lead replacement is not typically reported. According to Kleemann et al. (2010), the inci-
dence rate of generator replacement- and lead replacement procedure-induced infection are
approximately equal. In the following, we use this fact to estimate α.
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Figure 2: An estimated pacemaker lead failure distribution when ω = 0.5.
In a study by Poole et al. (2010), 0.7% (0.5%) of patients who underwent generator
replacement with (respectively, without) lead addition acquired infection that resulted in
device removal. In a study by Kleemann et al. (2010), out of 122 patients who underwent
lead replacement and/or generator replacement, five (4%) acquired infection.
The rate of infection is a function of the patient’s comorbidities (Kleemann et al. 2010)
and the type of the device (Baddour et al. 2003, Uslan et al. 2007). Duration of surgery and
the number of implanted leads are also conjectured to be risk factors for infection (Kleemann
et al. 2010, Sohail et al. 2007b). Hence, to account for a wide range of patients and device
types, we let α ∈ {0.01, 0.02, 0.03, 0.04}.
Annual probability of acquiring unrelated infection, κ. Recall from Section 2.1
that patients may acquire unrelated infections due to a wide range of reasons unrelated to
lead replacement procedures (e.g., generator replacements, procedures to treat comorbidi-
ties). The prominent cause of these infections is, however, generator replacement surgery
(Kleemann et al. 2010). As mentioned above, according to Kleemann et al. (2010), the like-
lihood of infection as a result of generator and lead replacements are approximately equal.
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Hence, we reuse the estimated range of values of α, i.e., {0.01, 0.02, 0.03, 0.04}, for the like-
lihood of infection following generator replacement surgery.
To convert these values to annual probabilities, we first obtain each device’s average life
span. On average, pacemaker generators last between 5 and 8 years (Wood and Ellenbogen
2002). ICD generators life span is on the order of 2.5 to 6 years (Hauser et al. 2006, Thijssen
et al. 2012). CRT-D generators typically have a shorter life expectancy than ICD generators
with a reported 2 to 5 years of life (Hauser et al. 2006, Thijssen et al. 2012). However, more
recent data for CRT-D generators have demonstrated improved longevity (Thijssen et al.
2012); Alam et al. (2014) report four-year survival rates of 67%-94% for CRT-D generators
by different manufacturers. Hence, we use an average life expectancy of 2 to 6 years for
CRT-D generators.
To obtain point estimates for the annual probability of generator replacement-induced
infection for each CIED type, we divide the rate of infection following these replacements by
the device’s average life span. As a result, the annual probability of generator replacement-
induced infection for pacemaker (single- or dual-chamber), ICD and CRT-D devices are in
the ranges of 0.001-0.008, 0.002-0.016 and 0.002-0.020, respectively.
Based on expert opinion, the risk of acquiring unrelated infection due to reasons other
than generator replacement is quite low; the cause of approximately 90% of unrelated infec-
tions is generator replacement surgery. Therefore, to consider a wide range of cases, we let κ
assume values in {0.005,0.01,0.015}, {0.005,0.01,0.015,0.02} and {0.005,0.01,0.015,0.02,0.025}
for pacemaker (i.e., PM1 and PM2), ICD and CRT-D devices, respectively.
Probability of death following lead addition, β1. We let the probability of death
following lead addition include all immediate and short-term complications that cause pa-
tient death. Based on expert opinion, this probability is fairly low and on the order of 0.1%.
To capture the variability of this probability for a wide range of patients and devices, we let
β1 ∈ {0.00075, 0.001, 0.00125}.
Probability of death following extraction of a lead of age `, β−1(`). As discussed
in Section 2.1, the probability of death following lead extraction increases in lead dwell time
(Buch et al. 2011, Pe´rez Baztarrica et al. 2012); however, in the literature, this probability
is generally reported in a form of a constant or a range, e.g., according to Henrikson et al.
(2011), the rate of mortality following lead extraction is between 0.2% and 0.8%. Therefore,
we use the clinical literature to estimate the probability of death following lead extraction
as a function of lead dwell time as follows.
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Table 3 summarizes the published data on lead extraction procedure-induced mortality
(see Appendix A.3 for the details). To estimate β−1(`), we fit a Gompertz function to the
observed probability of death following lead extraction as a function of mean lead dwell time
as reported in Table 3. We use a Gompertz function because the main cause of increased rate
of complication in lead dwell time is the growth of fibrosis around the leads attaching them to
the adjacent heart and blood vessels (Pe´rez Baztarrica et al. 2012) and the Gompertz function
can aptly describe tissue growth (Waliszewski and Konarski 2005). Finally, because ` is the
maximum lead age that is used in computations, we truncate the function at lead age `.
The probability of major complications, and consequently death, also varies based on
patient characteristics and surgeon expertise (Pe´rez Baztarrica et al. 2012). To capture a
wide range of scenarios, we shift the Gompertz function by ±10% of its mid-range value,
β−1(`/2) = β−1(8), i.e., for all ` ≤ `, we increase/decrese the estimated β−1(`) values by
0.1 × β−1(8) = 0.000511. We refer to the three resulting functions as “low,” “average” and
“high.” Table 21 in Appendix A.3 reports the estimated probabilities. It is worth mention-
ing that the final probabilities are consistent with the published range of lead extraction
mortality risks, e.g., the 0.2% to 0.8% rate of mortality following lead extraction as reported
by Henrikson et al. (2011).
We use the estimated values of β−1(`) (and β1) for individual leads to estimate the proba-
bility of surviving the lead replacement procedure-induced complications when implementing
action a in state (`, ·), µ(`, a), by assuming that complications associated with different leads
are independent. We make this assumption for two reasons (1) no data exist on interactions
between procedural outcomes and (2) based on expert opinion, this assumption does not
compromise the clinical implications of the model.
Probability of surviving infection, δ. The probability of surviving infection depends
on the type of the infection (e.g., localized versus systemic) and can vary dramatically from
one type to another. For instance, infective endocarditis, i.e., infection of the endocardial
surface of the heart, which causes 10%-23% of CIED infection incidents (Kantharia et al.
2000, Sohail et al. 2008, Uslan and Baddour 2006) is associated with an in-hospital mortality
rate of 7.6%-14% (Klug et al. 1997, Sohail et al. 2008); however, not all types of infection
are as risky. In the following, we estimate the average probability of surviving infection, δ.
Recall from Section 2.1 that whenever an infection occurs, the entire CIED is extracted
and new leads are implanted after the infection is cleared. To the best of our knowledge,
there are no published data on the probability of death due to the infection alone; rather, the
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Table 3: Observed lead extraction mortality from clinical literature.
Reference
Mean lead
dwell time
(yrs)
Number of
extractions
Number of
patients
Number of
reported
deaths
Pr. of death
following lead
extraction
Byrd et al. (1999) 3.92 3,540 2,338 1 0.000282
Epstein et al. (1999) 6.92 413 248 7 0.016949
Epstein et al. (1999) 5.25 201 177 1 0.004975
Epstein et al. (1999) 6.58 671 438 6 0.008942
Kennergren (1999) 5.69 179 149 0 0.000000
Wilkoff et al. (1999) 5.42 244 153 1 0.004098
Byrd et al. (2002) 6.33 2,561 1,684 13 0.005076
Saad et al. (2003) 2.45 161 161 1 0.006211
Roux et al. (2007) 7.8 270 175 1 0.003704
Bongiorni et al. (2008) 5.78 2,065 1,193 3 0.001453
Jones IV et al. (2008) 7.5 975 498 0 0.000000
Agarwal et al. (2009) 5.7 456 212 1 0.002193
Kennergren et al. (2009) 5.75 1,032 592 2 0.001938
Wazni et al. (2010) 6.84 2,405 1,449 4 0.001663
published probabilities always include the risks involved in extracting the leads and adding
new ones. Therefore, in the following we use the estimated probabilities of death following
lead addition/extraction to estimate the probability of death due to the infection alone.
From a study by Sohail et al. (2007a), almost 95% of 189 patients with infected pace-
maker or ICD devices survived the risk of death from infection, extraction of on average 1.6
leads (details in Appendix A.3), each with a risk of death ranging between 0.2% to 1.2% (Ta-
ble 21), or addition of one to two leads, each with a risk of death around 0.1% as estimated
earlier in this section. Hence, because the devices in Sohail et al. (2007a) are of single- or
dual-chamber types, we expect δ to be between
0.95
(1− 0.002)1.6 · (1− 0.001)1 ' 0.95 (2.30)
and
0.95
(1− 0.012)1.6 · (1− 0.001)2 ' 0.97. (2.31)
Clearly, the number and ages of the leads as well as the infection types and underlying condi-
tions may vary from one patient to another. Therefore, to capture a wide variety of patients
we let δ assume multiple values in our numerical experiment, i.e., δ ∈ {0.94, 0.96, 0.98}.
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2.5 COMPUTATIONAL STUDY
In this section, we first define additional metrics that facilitate policy comparisons (Sec-
tion 2.5.1). Next, we report the results obtained under the optimal policy and compare
them with those obtained under the three heuristic polices defined in Section 2.3 (Section
2.5.2). Finally, we conduct extensive sensitivity analyses to examine how parameter changes
affect the results (Section 2.5.3). All of the computational results reported in this section are
obtained by executing the backward induction algorithm (see Puterman (1994), page 92).
2.5.1 Additional Metrics
For single-chamber devices, let the optimal action in state st = (`, 1) be denoted by
at,∗(`). Similarly, for multi-chamber devices, let the optimal action in state st = (`, w, 1) be
denoted by at,∗(`, w). For each policy pi ∈ {C,H,A}, let at,pi(`) and at,pi(`, w) denote the
corresponding actions for single- and multi-chamber devices, respectively.
Probability of death due to CIED-related causes, χt(s). In addition to expected
lifetime, we are interested to learn how the probability of death due to CIED-related causes
changes under various lead maintenance policies. To obtain this probability, we first calcu-
late the probability of death from competing risks and then report its complement as χt(s).
For each device type, we redefine the reward functions provided in Section 2.2 and use the
finite-horizon policy evaluation algorithm to recursively evaluate the expected reward of any
given policy (see Puterman (1994), page 80). To avoid repetition, here we only present the
equations used to obtain the metric for PM1. The methods are analogous for PM2, ICD
and CRT-D.
Let λ(t,m) denote the likelihood of death due to competing risks after exactly m periods
for a patient of age t, i.e.,
λ(t,m) = λ¯(t,m− 1) · (1− λ(t+m)), (2.32)
and redefine rt(n) to denote the immediate probability of death due to non CIED-related
causes starting from patient age t, given that the next failure is in n years, i.e.,
rt(n) =
n∑
m=1
λ(t,m) · (1− κ)m−1. (2.33)
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Additionally, redefine Vt(`, θ) to denote the probability of death due to non CIED-related
causes starting from state st = (`, θ). Clearly, VT (`, θ) = 1. Finally, modify νt(n) and
ut(`, a, n), given by equations (2.7) and (2.10), for PM1, as follows:
νt(n) =

pX(n) ·
(
rt(n) +
∑n−1
m=1 ρ(m) · Vt+m(`′(m), 0)
+η(n) · γ · Vt+n(`′(n), 1)
)
, if n < T − t,
F¯X(n− 1) ·
(
rt(n) +
∑n−1
m=1 ρ(m) · Vt+m(`′(m), 0) + η(n) · γ
)
, if n = T − t,
(2.34)
and
ut(`, a, n) =

pX(n) ·
(
rt(n) +
∑n−1
m=1 ρ(m) · Vt+m(`′′(a,m), 0)
+η(n) · γ · Vt+n(`′′(a, n), 1)
)
, if n < T − t,
F¯X(n− 1) ·
(
rt(n) +
∑n−1
m=1 ρ(m) · Vt+m(`′′(a,m), 0)
+η(n) · γ
)
, if n = T − t,
(2.35)
where rt(n) is given by equation (2.33).
For t < T , when θ = 0, Vt(`, 0) is given by equation (2.8), in which rt(n) and νt(n) are
given by equations (2.33) and (2.34), respectively. When θ = 1, Vt(`, 1) is given by (2.11),
where in each state st = (`, 1) the action is predetermined for any given policy, i.e., the action
is at,pi(`) where pi ∈ {∗, C,H,A}, and rt(n) and ut(`, a, n) are given by equations (2.33) and
(2.35), respectively. Finally, the probability of death due to CIED-related causes starting
from state st, denoted by χt(s), is given by
χt(s) = 1− Vt(s). (2.36)
Average difference between the total expected life years under the optimal
and heuristic policies starting from first failure, Γt1,t2,d,pi(`, y). This metric measures
the increase in total expected lifetime that patients earn by following the optimal policy as
opposed to a given heuristic policy, starting from the first lead failure after implantation.
Let Γt1,t2,d,pi(`, y) denote the difference between the total expected lifetime under the optimal
policy and heuristic policy pi ∈ {C,H,A} averaged over all patient ages between t1 and
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t2 for device type d ∈ {PM1,PM2, ICD,CRT-D} and first lead failure ` years after initial
implantation at which point y leads are functional. For PM1, y is always zero and we have
Γt1,t2,PM1,pi(`, 0) =
1
t2 − t1 + 1 ·
t2∑
t=t1
(
Vt([`,−1,−1,−1,−1], 1)
−Vt,pi([`,−1,−1,−1,−1], 1)
)
, (2.37)
where Vt(s) is given by equation (2.11). For PM2, ICD, and CRT-D, the value of Γt1,t2,d,pi(`, y)
is obtained from an equation analogous to (2.37) in which the value of y, the state s and the
functions Vt(s) and Vt,pi(s) are adjusted to reflect the device type.
Maximum difference between the total expected life years under the optimal
and heuristic policies, Φt1,t2,d,pi(j, y). We are also interested in comparing the maximum
benefit an individual receives from following the optimal policy as opposed to a given heuristic
policy, starting from any given state in which the device is failed. We introduce Φt1,t2,d,pi(j, y),
which denotes the maximum difference between the total expected reward obtained under
the optimal policy and the heuristic policy pi ∈ {C,H,A} across all states in which the device
is failed, y out of j implanted leads are functional, the patient is between t1 and t2 years old
and has a cardiac device of type d ∈ {PM1,PM2, ICD,CRT-D}, i.e., for PM1,
Φt1,t2,PM1,pi(j, 0) = max
t∈{t1,...,t2}
{
Vt(`, 1)− Vt,pi(`, 1) :
∑
i
1{`i>0} = j
}
(2.38)
and for multi-chamber devices, d ∈ {PM2, ICD,CRT-D},
Φt1,t2,d,pi(j, y) = max
t∈{t1,...,t2}
{
Vt(`, w, 1)− Vt,pi(`, w, 1) :
∑
i
1{`i>0} = j,
y = 1{w∈{1,2,3}} + 2 · 1{w∈{3¯,2¯,1¯}}
}
,(2.39)
where Vt(s) is given by equation (2.11) for PM1 and equation (2.24) for PM2, ICD, and
CRT-D.
Maximum percentage difference between the probability of death due to
CIED-related causes under the optimal and heuristic policies, Ξt1,t2,d,pi(j, y). Fi-
nally, we introduce Ξt1,t2,d,pi(j, y), which allows to compare the percentage difference in the
probability of death due to device related causes under the optimal policy and the heuristic
policy pi ∈ {C,H,A} across all states in which the device is failed, y out of j implanted leads
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are functional, and the patient is between t1 and t2 years old and has a cardiac device of type
d ∈ {PM1,PM2, ICD,CRT-D}. The formulations are analogous to those of Φt1,t2,d,pi(j, y) in
equations (2.38) and (2.39), except that the function Vt(s) in (2.38) and (2.39) is substituted
with χt(s), given by equation (2.36), and percentage differences are calculated.
2.5.2 Policy Comparisons
In this section we compare the performance of the optimal policy to that of the three
heuristic policies. We present insightful numerical results using the metrics defined in Section
2.5.1 for various device types and discuss the intuition behind the observations.
Figure 3 plots the increase in expected lifetime that a patient gains by following the
optimal policy as opposed to the three heuristic policies as a function of the time of the
first lead failure when T = 31, T = 100 and the other parameters assume their average
values as given by Table 4. In Figure 3, we present the results for device types of PM1
and PM2 (rows) and three patient age groups (columns). That is, the figures in the first
column report Γ30,49,PM1,pi(`, 0), Γ30,49,PM2,pi(`, 1) and Γ30,49,PM2,pi(`, 0) for all pi ∈ {C,H,A}
and ` = {1, . . . , 16}, respectively from top to bottom.
In each row, as intuition would suggest, the older the patients (left to right), the less sig-
nificant the results. Clearly, younger patients have longer remaining expected lifetimes and
experience more lead failures; hence, they benefit more from following the optimal policy,
which aims to balance the risks involved in “elective” versus “forced” lead extractions.
In each column of Figure 3, the increase in expected lifetime for any given lead dwell time
increases from top to bottom. Clearly, for PM1, only one lead is in place at the time of the
first lead failure, as opposed to two leads for PM2. Hence, because patients with PM1 are less
likely to the reach the space constraint of five in comparison to patients with PM2, it is less
important for them to follow the optimal policy as opposed to a heuristic policy. With PM2,
a patient is intuitively worse off at the time of simultaneous lead failure as opposed to single
lead failure, hence the improved effect of following the optimal policy as opposed to a heuristic
policy in the third row. The results for ICD and CRT-D are similar in spirit to the results for
PM1 and PM2. Generally speaking, the greater the number of failed leads or the greater the
number of leads that the device requires, the more beneficial it is to follow the optimal policy.
However, because patients with ICD and CRT-D have more severe heart disease than patients
with PM1 and PM2, the increase in expected life days is less pronounced compared to PM2.
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Figure 3: Average increase in expected lifetime, Γt1,t2,d,pi(`, y), gained by following the optimal
policy as opposed to the three heuristic policies starting from the first failure when T = 31,
T = 100 and the other parameters are given by Table 4.
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Table 4: Parameter values for Figures 3-5. For pX(x) and β−1(`) values refer to Tables 20 and 21
in Appendix A.3, respectively.
Device Type pX(x), pX1(x) pX2(x) α κ β1 β−1(`) δ
PM1 ω=0.5 - 0.03 0.01 0.001 average 0.96
PM2 ω=0.5 - 0.03 0.01 0.001 average 0.96
ICD ω=0.5 ω=0.45 0.03 0.01 0.001 average 0.96
CRT-D ω=0.5 ω=0.45 0.03 0.015 0.001 average 0.96
Figure 3 also suggests that the increase in expected life days under the optimal policy as
opposed to the conservative policy is relatively small (i.e., on the order of zero to 43 days);
the performance of the conservative policy is close to optimal. On the other hand, compared
to the aggressive policy, the expected lifetime can increase by up to nine months under the
optimal policy. Overall, the aggressive policy is almost always the worst performing policy.
Moreover, its performance worsens in the time of the first lead failure due to the fact that
the probability of death following lead extraction increases in lead dwell time.
Additionally, in Figure 3 the hybrid policy, which typically performs at least as well as
the aggressive policy, underperforms the aggressive policy in the case of PM2 with simultane-
ous lead failure when the leads and the patient are young on the order of 1-3 years and 30-49
years, respectively. In these cases, under the hybrid policy both failed leads are abandoned
and two new leads are added, which leaves the patient with four leads in place at a very
young age. It is not unlikely that this young patient would experience two additional lead
failures that would prompt the extraction of all implanted leads under the hybrid policy,
which can be very dangerous.
The results in Figure 3 assume that patients follow a certain policy from implantation.
Next, consider the case in which patients may switch between follow-up policies, which is
often the case in practice; hence, patients can reach a wide combination of lead ages at
the time of lead failure. Figure 4 plots the maximum increase taken over all reachable
combinations of lead ages in expected lifetime gained by following the optimal policy as
opposed to the three heuristic policies, stratified across the number of implanted leads and
the patient age group when T = 31, T = 100 and the other parameters are given by Table 4.
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Figure 4 reports these results for all four device types (rows) and three heuristic policies
(columns). For instance, the first three plots in the first column report Φt1,t2,PM1,C(j, 0)
for all (t1, t2) ∈ {(30,49), (50,69), (70,99)} and j = {1,. . . , 5}, and Φt1,t2,PM2,C(j, 1) and
Φt1,t2,PM2,C(j, 0) for all (t1, t2) ∈ {(30,49), (50,69), (70,99)} and j = {2,. . . , 5}, respectively
from top to bottom. ICD with simultaneous lead failure, CRT-D with double lead failure
and CRT-D with triple lead failure are not included in Figure 4, but behave similarly.
Consistent with the results in Figure 3, in Figure 4 the largest increase in the expected
lifetime gained by following the optimal policy as opposed to a heuristic policy is always
obtained by younger patients. In fact, in Figure 4, the maximum reward reported for each
combination of number of implanted leads and patient age group (corresponding to the height
of each bar in the plots) is generally attained by the youngest patients in that subcategory.
For instance, in Figure 4, for 50- to 69-year-old patients with PM1, the maximum reward
Φ50,69,PM1,pi(j, 0) is always obtained by 50-year-old patients, regardless of the policy and
the number of implanted leads. However, this observation may not always be generalized,
especially when some states are unreachable. For instance, for 30- to 49-year-old patients
with PM1 who follow the optimal policy as opposed to the hybrid policy, the maximum
reward Φ30,49,PM1,H(j, 0) is obtained by the youngest patients when j ∈ {1, . . . , 4} and by
46-year-old patients when j = 5. That is, Φ30,49,PM1,H(5, 0) = 390.6, reported in the top plot
of the second column, is obtained by a 46-year-old patient, not a 35-year-old one.
Unlike Figure 3, in Figure 4 the increase in expected lifetime can be quite significant
for older patients. Additionally, from Figure 4, we observe that it is especially important
to make the abandon/extract decisions optimally when more leads are in place; the lifetime
extension can be well more than one year. Lastly, note that the lifetime extension for patients
with ICD and CRT-D seems to be low in comparison to PM1 and PM2. The reason behind
this observation is that patients with these two device types have shorter life expectancies
than patients with PM1 and PM2 and thus have fewer remaining life years during which to
benefit from implementing the optimal policy.
Finally, Figure 5 is structured the same as Figure 4, but plots the maximum percentage
decrease in the probability of device related death. For instance, the first three figures
in the first column report Ξt1,t2,PM1,C(j, 0) for all (t1, t2) ∈ {(30,49), (50,69), (70,99)} and
j = {1,. . . , 5}, and Ξt1,t2,PM2,C(j, 1) and Ξt1,t2,PM2,C(j, 0) for all (t1, t2) ∈ {(30,49), (50,69),
(70,99)} and j = {2,. . . , 5}, respectively, from top to bottom. In contrast to Figures 3 and
4, in Figure 5 older patients, not younger ones, who follow the optimal policy as opposed
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Figure 4: Maximum increase in expected lifetime over all starting states, Φt1,t2,d,pi(j, y), gained by
following the optimal policy as opposed to the three heuristic policies, stratified across patient age
groups and number of implanted leads when T = 31, T = 100 and the other parameters are given
by Table 4.
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Figure 5: Maximum percentage decrease in probability of device related death over all starting
states, Ξt1,t2,d,pi(j, y), realized by following the optimal policy as opposed to the three heuristic
policies starting from any combination of lead ages at the time of a lead failure, stratified across
patient age groups and number of implanted leads when T = 31, T = 100 and the other parameters
are given by Table 4.
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Table 5: Sensitivity analysis for a single-chamber device, starting from state (40,[6,2,1,-1,-1]).
Min Mean Max Min Mean Max Min Mean Max
w = 0.45 0.62 4.65 12.96 69.82 85.68 105.63 81.21 125.82 182.13
w = 0.5 0.62 4.23 12.41 67.31 82.89 102.49 79.53 124.14 180.67
w = 0.55 0.58 3.75 11.83 64.35 79.53 98.70 77.67 122.27 179.07
0.01 0.62 3.94 12.37 69.90 86.30 105.63 84.57 129.01 182.13
0.02 0.62 4.12 12.59 68.00 83.86 102.27 82.27 125.68 177.50
0.03 0.58 4.30 12.74 66.14 81.48 98.99 79.97 122.41 172.94
0.04 0.62 4.48 12.96 64.35 79.15 95.78 77.67 119.20 168.52
0.005 0.58 1.69 5.18 84.28 94.31 105.63 123.77 151.86 182.13
0.01 0.62 3.91 9.38 73.77 81.57 89.02 98.99 122.26 147.64
0.015 0.95 7.04 12.96 64.35 72.22 79.86 77.67 98.11 119.43
0.00075 0.58 4.22 12.96 64.46 82.77 105.63 77.78 124.13 182.13
0.0010 0.58 4.21 12.96 64.42 82.70 105.52 77.75 124.08 182.06
0.00125 0.58 4.20 12.92 64.35 82.62 105.45 77.67 124.02 181.95
low 2.04 7.75 12.96 68.04 82.74 100.08 77.67 106.87 138.85
average 0.73 3.62 8.40 66.17 82.11 101.32 91.69 123.50 159.10
high 0.58 1.26 3.98 64.35 83.24 105.63 105.67 141.86 182.13
0.94 0.58 3.97 12.01 64.35 82.46 105.59 79.17 124.62 182.13
0.96 0.58 4.21 12.45 64.79 82.70 105.59 78.44 124.08 181.73
0.98 0.58 4.46 12.96 65.23 82.94 105.63 77.67 123.53 181.33
Parameter Levels
Increase in the expected number of life days
under the optimal policy as opposed to
conservative hybrid aggressive
k
d
𝒑𝑿(𝒙) 
𝜶   
𝜷−𝟏(ℓ) 
𝜷𝟏 
to the hybrid or aggressive policy gain the most benefit; they may experience a dramatic
drop, by up to 90% or more, in the risk of death from device related causes. In other words,
under the optimal as opposed to hybrid and aggressive policies, older patients may live a
life that is much less affected by their implanted cardiac device. Note that in Figure 5
the maximum percentage decrease for each combination of number of implanted leads and
patient age group (corresponding to the height of each bar in the plots) is not necessarily
attained by the oldest patients in that subcategory. For instance, Ξ30,49,PM1,C(4, 0) = 19%
and Ξ50,69,PM1,H(4, 0) = 48% are obtained by 38- and 63-year-old patients, respectively.
2.5.3 Sensitivity Analysis
In this section, we present some sensitivity analyses to assess the robustness of our results
with respect to the key problem parameters. We limit our analysis to single-chamber devices
but anticipate similar results for dual-chamber and CRT-D device.
Table 5 presents the sensitivity analysis for single-chamber devices, starting from state
(40,[6,2,1,-1,-1]). For each parameter, the table reports the minimum, mean and maximum
39
increase in the expected lifetime obtained under the optimal policy as opposed to the three
heuristic policies, averaged across all other parameter combinations. For most parameters,
the results appear to be insensitive to moderate changes. For instance, the changes in the
increase in expected lifetime across various values of β1 and δ is on the order of one day.
The increase in expected lifetime is most sensitive with respect to the annual probability
of acquiring unrelated infection, κ, and the probability of death following extraction of a
lead of age `, β−1(`). The maximum difference between the obtained increase in expected
lifetime across various levels of these two parameters is on the order of two and one months,
respectively.
The results provided by Table 5 are consistent for a representative sample of ten starting
states. These additional analyses are not included for sake of brevity.
2.6 CONCLUSION
Cardiac leads are often referred to as “the weakest link” in implantable cardiac device
care. Despite their importance, lead maintenance philosophies vary widely from practice
to practice. We develop an approach that assists clinicians in making patient-specific lead
abandon/extact decisions to maximize patients lifetime. More specifically, we develop novel
MDP models that dynamically determine which leads to extract at the time of lead failure
as a function of patient age and lead ages for four major device types. We observe that
under the optimal policy, the decision to abandon or extract each lead only depends on its
age, patient age, its age rank among the lead ages, the total number of implanted leads
and, in the case of multi-chamber devices, the age of the working lead(s). In other words,
the decisions do not depend on the exact ages of all implanted leads, which simplifies the
implementation of the policy.
Following the optimal policy as opposed to commonly used heuristic policies both extends
the expected lifetime and decreases the average likelihood of device related death for all
patient subgroups. A “conservative” lead maintenance scheme that recommends extracting
the youngest failed lead(s) only when an extraction is required due to space considerations
typically preforms close to optimal; however, by following the optimal policy as opposed to
this policy, an average patient may gain four additional expected life months. The benefit
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of following the optimal policy as opposed to other commonly used heuristic policies can
be more dramatic; average patients may gain an expected lifetime extension of up to 1.2
years. Generally speaking, younger patients benefit from following the optimal policy in the
form of gaining lifetime extension. For older patient, this benefit is in the form of avoiding
device related death; by following the optimal policy as opposed to the heuristic policies, older
patients may see a dramatic drop of up to 94% in the risk of death from device related causes.
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3.0 OPTIMAL IMPLANTABLE CARDIOVERTER DEFIBRILLATOR
(ICD) GENERATOR REPLACEMENT
3.1 INTRODUCTION
Over 650,000 people in the United States currently rely on CIEDs for defibrillation
and/or pacing, and this number is growing exponentially (Meier 2010, Stellbrink and Trappe
2007, Stoepel et al. 2009) with approximately 10,000 new implantations occurring per month
(Meier 2010). Recall from Section 1 that dual-chamber ICDs are used to prevent bradycar-
dia, i.e., a slow heart rate, and manage tachycardia, i.e., a fast or irregular heart rate. More
specifically, the device can detect slow rhythms and send small electronic impulses to the
heart to make it beat faster. Additionally, it can detect dangerously fast, potentially lethal
rhythms, and deliver a “shock(s)” or “charge(s)” in an attempt to restore normal rhythm
(Neighmond 2006).
ICDs are typically powered by lithium/silver vanadium oxide or lithium/manganese diox-
ide batteries (Crespi et al. 2001, Drews et al. 2001). One major drawback of these batteries
is their limited lifetimes. In fact, ICD battery lifetimes do not typically exceed the patient’s
remaining lifetime at the time of initial implantation (Hauser 2005). Therefore, most pa-
tients undergo multiple generator replacement surgeries during the course of their lives due
to battery depletion (Hauser 2005, Stiles 2005, Thijssen et al. 2012).
Like any surgery, ICD generator replacement involves risks, is costly and can cause
patient anxiety. Some studies report the rate of major complications, e.g., pocket infection
requiring dangerous lead extraction, to be as high as 4.1% and 5.8% (Costea et al. 2008,
Gould and Krahn 2006). Klug et al. (2007) and Lekkerkerker et al. (2009) demonstrate an
association between ICD generator replacement and the occurrence of infection. In a study
by Gould and Krahn (2006), major complications resulted in death in 0.38% of ICD generator
replacements. Krahn et al. (2011) report a major complication rate of 2.6% and associate
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these complications with a mortality rate as high as 8.7% in the six months following surgery.
In terms of cost, each replacement is on the order of $24,000 (BIOTRONIK, Inc. 2012 and St.
Jude Medical, Inc. 2012). Moreover, any operation, ICD generator replacement included,
can cause anxiety both preoperatively and postoperatively (Mitchell 2003). For some or
all of these reasons, many experts argue that it would be ideal to perform two or fewer
replacements in a typical patient’s lifetime instead of the current three to four (Stiles 2005).
Although generator replacement involves risks, not performing replacements early enough
exposes the patient to other risks. The main function of an ICD is to deliver as many full-
energy charges as needed (possibly more than one per episode) to regulate dangerously fast
heart rhythms and hence prevent cardiac arrest. Because each full-energy charge consumes
almost one month of the average generator lifetime (SECURA manual, Medtronic 2012c),
determining the replacement time is a sensitive issue. Manufacturers recommend that ICDs
be replaced when they reach the recommended replacement time (RRT). At RRT, the device
has enough energy remaining to emit pacing pulses 100% of the time for an additional three
months and to deliver six full-energy charges (Medtronic 2012c). Once RRT is reached,
the device emits the RRT signal indicating that the “end of service (EOS)” will be reached
shortly and a generator replacement needs to be scheduled. Although the time it takes
different patients to reach RRT depends on each individual’s battery consumption rate, the
RRT itself is not tailored for individuals. Clearly, there is a trade-off between prematurely
exposing the patient to the risk of replacement and allowing for the possibility that the
device is unable to deliver charges/therapy when needed.
In this chapter, we focus on obtaining an optimal ICD replacement time given a set of
patient characteristics. More specifically, we use a finite horizon MDP model to investigate
the degree to which unnecessarily “conservative” (i.e., “early”) generator replacements may
be delayed to maximize the patient’s total expected life years. Furthermore, we examine the
impact of our approach on reducing the expected number of replacements during the pa-
tient’s lifetime. In current practice, replacement decisions are based solely on the estimated
remaining longevity of the device. In contrast, our approach allows clinicians to make re-
placement decisions dynamically as a function of both patient age and the remaining energy
stored in the battery, i.e., remaining battery capacity.
The burden that ICD generator replacement places on patients and the health care
system at large is widely discussed in the clinical literature (Biffi et al. 2011, 2008, Hauser
2005, Ramachandra 2010). However, to the best of our knowledge, no research addresses this
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issue from a mathematical/optimization perspective. There exists a somewhat relevant body
of work that considers using slightly larger batteries with higher capacities to extend ICD
generator longevity (Hauser 2005, Ramachandra 2010, Russo 2012, Thijssen et al. 2012).
However, these works are descriptive in nature and do not involve mathematical models
or decision making. Furthermore, in contrast to this chapter, in which the objective is to
maximize the patient’s benefit using the ICD technology currently available, these works
propose hardware changes.
The most relevant literature is in reliability and maintenance modeling, more specifically
damage models in which a device fails if the cumulative damage exceeds a damage level (see
references in Nakagawa 2007). Similar to these models, we introduce a system, i.e., an ICD
generator, whose battery is subject to depletion and fails if its battery capacity is exhausted.
In this context, depletion is equivalent to damage and the system fails if the total amount of
battery depletion, i.e., the cumulative damage, exceeds the initial battery capacity, i.e., the
damage level. In our model, depletion is caused by both randomly demanded charges as well
as continuous monitoring and pacing. The former corresponds to random shocks/damage
and is incorporated in most damage models (Nakagawa 2007); the latter corresponds to
“graceful” system deterioration over time and is considered in some damage models, e.g.,
Satow et al. (2000). Typically in damage models, costs are associated with replacements and
failures, and the objective is to minimize the cost rate over an infinite horizon (Nakagawa
2007, Ito and Nakagawa 2011 and Zhao et al. 2011). In contrast, we consider a finite horizon
problem in which the objective is to avoid premature problem termination caused by either
replacement or failures. Also, rather than incurring an economic cost, a failure terminates
the ICD replacement problem, i.e., results in the patient’s death.
The remainder of the chapter is organized as follows. In Section 3.2, we present the
model formulation and an insightful example of an optimal policy. Section 3.3 examines the
structural properties of the model and optimal policy. In Section 3.4, we calibrate the model
and obtain the transition probabilities for various classes of patients using both data from
the existing literature as well as from a clinical dataset. In Section 3.5, we report the results
from a large computational study to compare and contrast the total expected reward and
the total expected number of replacements under the optimal policy and current practice.
Lastly, we conclude in Section 3.6.
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3.2 MODEL FORMULATION
Consider an ICD pulse generator battery with a known, deterministic initial useful ca-
pacity u¯. Let the random variable D, with p.m.f. pD and c.d.f. FD, denote the number of
charges demanded per period, e.g., per week. Furthermore, let δ and δc denote the amount
of capacity consumed by the ICD per period excluding any charges and per charge, respec-
tively. Assume that the periods are defined such that δ < δc, and note that for a given set
of patient characteristics, the parameter δ is constant over time.
Let g(u) be the maximum number of charges that may be delivered in any given period
starting with a remaining battery capacity of u. Assuming that the demands for charges
occur all at once at the end of each period,
g(u) =
⌊
u− δ
δc
⌋
. (3.1)
Let ` ≥ 0 denote the age of the patient at the time of initial implantation and ¯`> ` be the
maximum reachable age. Let the pair (`, u) correspond to the state of the process where
` ≤ ` ≤ ¯` and u ≤ u¯ denote the patient age and the remaining capacity of the battery,
respectively.
A decision is made at the beginning of every period to either “replace” the battery or to
take no action, i.e., “wait.” We assume that replacement takes one period during which no
charges occur. Consequently, the patient may die due to replacement induced complications
at the end of the period. Recall that the demand for charges also occur at the end of each
period. Therefore, upon every decision the patient earns one period of lifetime independent
of the action taken. The objective is to make decisions dynamically throughout the patient’s
lifetime to maximize the patient’s total expected lifetime.
Replacement procedures are not perfect; as a result of a procedure, the patient may
suffer from recoverable complications or die. Let α∆(`) denote the probability of replacement
induced death for a patient of age `. We assume that α∆(`) is non-decreasing in patient age,
`, and procedure-related deaths occur immediately after surgery. Finally, in any period, a
patient may die due to competing risks of death, e.g., comorbidities and unrelated causes.
Let λ(`) be the per period probability of surviving the competing risks of death for a patient
of age `, 0 ≤ λ(`) < 1. We assume that λ(`) is non-increasing in patient age, `.
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Let V (`, u) denote the maximum total expected reward starting from state (`, u) (see
Bellman (1957)), i.e.,
V (`, u) =
 0, if ` = ¯`, or u ≤ 0,max{R(`), C(`, u)}, otherwise, (3.2)
where R(`) is the reward obtained under the action “replace,”
R(`) = 1 + (1− α∆(`)) · λ(`) · V (`+ 1, u¯), (3.3)
and C(`, u) is the reward obtained under the action “wait,”
C(`, u) = 1 +
g(u)∑
d=0
λ(`) · V (`+ 1, u− δ − d · δc) · pD(d). (3.4)
Independent of the decision (hence in both equations (3.3) and (3.4)), the patient instanta-
neously earns one period of life. Whenever the decision is to “replace” the generator (equa-
tion (3.3)), if the procedure is successful, then the patient continues with a new generator
with an initial capacity of u¯. When the decision is to “wait” (equation (3.4)), the patient
survives if death due to other causes is averted and the remaining battery capacity is enough
to deliver the charges demanded during the period; otherwise, the process terminates, i.e.,
the patient dies.
Figure 6 displays an example optimal policy for u¯ = 1.06 ampere hours (Ah), ¯` = 6240
weeks (120 years), ` = 2600 weeks (50 years), α∆(`) = 0.02, δ = 0.00265 Ah, δc =
0.008053 Ah and the distribution of charges given by Table 6. For this example, the optimal
policy is of threshold form. That is, there exists a replacement threshold such that for any
state (`, u) on or below the threshold, the optimal action is to “replace” the generator and
for any state (`, u) above the threshold, the optimal action is to “wait.” The sample path re-
alization in Figure 6 demonstrates possible ICD generator usage dynamics for a patient who
receives a new ICD at the age of 50. The slope of the non-vertical pieces of the sample path is
δ and the vertical decrements, which are integer multiples of δc, indicate the amount of capac-
ity consumed due to delivering charges. The optimal policy advises a generator replacement
once the sample path crosses the optimal threshold. From Figure 6, this patient undergoes
the first generator replacement surgery after almost 6 years at the age of 56.1. Once the
device is replaced, the patient receives a new ICD generator and continues to receive therapy.
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Figure 6: An example optimal policy and sample path for u¯ = 1.06 Ah, ¯`= 6240 weeks (120 years),
` = 2600 weeks (50 years), α∆(`) = 0.02, δ = 0.00265 Ah, δc = 0.008053 Ah and the distribution
of charges given by Table 6.
Table 6: Distribution of charges per week.
d 0 1 2 3 4 5 6 7 ≥ 8
pD(d) 0.953759 0.045199 0.000817 0.000154 0.000044 0.000021 0.000005 0.000001 0
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In Figure 6, the optimal replacement threshold decreases as the patient ages, advising less
conservative replacement actions. The downward steps in the optimal replacement threshold
are of size δc, the amount of energy consumed per charge. Hence, these downward steps reflect
the policy’s tendency to retain less battery capacity (in integer multiples of the capacity
consumed per charge) as the patient ages. That is, the downward steps help delay the
replacements (e.g., the second replacement in Figure 6) and, consequently, reduce their total
expected number.
3.3 STRUCTURAL PROPERTIES
In this section, we provide several intuitive structural properties. More specifically, we
establish the monotonicity of the total reward in both patient age and remaining capac-
ity and show that the optimal policy is of control-limit type. The proofs are provided in
Appendix B.1.
In Lemma 1, we prove the monotonicity of the maximum total expected reward V (`, u)
in the remaining battery capacity u. Lemma 1 demonstrates that for any given patient
age, a battery with higher remaining capacity brings a greater expected reward for the
patient. Because we proceed with the proof of Lemma 1 by induction on the remaining
battery capacity u, we discretize this dimension of the state space as follows. The capacity
increment, denoted by δ¯ ∈ R++, is defined such that the remaining battery capacity at all of
the intermediate states on any given sample path can be expressed as integer multiples of the
capacity increment. To achieve this property, we assume that the initial battery capacity u¯,
the capacity consumed per period in the absence of any shocks δ, and the capacity consumed
per charge δc can be set to integer multiples of the capacity increment, and define the capacity
increment by
δ¯ = max{δˆ ∈ R++ : δ
δˆ
∈ Z++, δc
δˆ
∈ Z++, u¯
δˆ
∈ Z++}. (3.5)
Lemma 1. For any fixed patient age `, the total reward V (`, u) is non-decreasing in u ≥ 0.
In the same vein as Lemma 1, Corollary 1 establishes the monotonicity of the expected
reward obtained upon the action “wait” in the remaining battery capacity, u.
Corollary 1. For any fixed patient age `, C(`, u) is non-decreasing in u ≥ 0.
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Lemma 2 establishes the monotonicity of the maximum total expected reward V (`, u) in
patient age `. Lemma 2 implies that for any given remaining battery capacity, under the
optimal policy, younger patients earn a greater expected reward.
Lemma 2. For any fixed remaining battery capacity u, the total reward V (`, u) is non-
increasing in ` ≥ 0.
Analogous to Lemma 2, Corollary 2 establishes the monotonicity of the reward obtained
upon the actions “replace” and “wait,” i.e., R(`) and C(`, u), respectively, in patient age `.
Corollary 2 implies that for any given remaining battery capacity and action, younger pa-
tients earn a greater expected reward.
Corollary 2. For any fixed remaining battery capacity u, C(`, u) and R(`) are non-increasing
in ` ≥ 0.
Theorem 1 establishes that for any fixed patient age `, the optimal policy is of control-
limit type, i.e., there is a battery capacity u∗(`) at and above which it is optimal to continue
with the current generator and below which it is optimal to replace the generator. Let
a∗(`, u) denote the optimal action in state (`, u) which is either to “replace” the generator
or to “wait.” Denote the former action by ‘1’ and the latter by ‘0.’ Hence,
Theorem 1. For any fixed patient age `, there exists a battery capacity u∗(`) such that
a∗(`, u) =
0, if u ≥ u
∗(`),
1, otherwise.
(3.6)
As established in Theorem 1, and seen in Figure 6, the optimal policy is of control-limit
type in the remaining battery capacity u. Although the example policy in Figure 6 is of
control-limit type in patient age ` as well, nontrivial problem instances exist in which this
property is violated.
Lemma 3, and consequently Corollary 3, establish that for any given patient age ` and
remaining capacity u, the maximum total reward and the reward obtained upon a deci-
sion, either “replace” or “wait,” is less if the surgeries are riskier, i.e., the probability of
replacement induced death is higher.
Lemma 3. Let V 1(`, u) and V 2(`, u) be two problem instances given by equation (3.2) for
which α∆(`) equals α
1
∆(`) and α
2
∆(`), respectively. If α
2
∆(`) ≥ α1∆(`) ∀` ≤ ¯`, then for any
given state (`,u), V 1(`, u) ≥ V 2(`, u).
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Corollary 3. Let Ri(`) and Ci(`, u) denote reward instances given by equations (3.3) and
(3.4) for which α∆(`) equals α
1
∆(`) and α
2
∆(`) when i = 1 and i = 2, respectively. If
α2∆(`) ≥ α1∆(`) ∀` ≤ ¯`, then for any given state (`,u), R1(`) ≥ R2(`) and C1(`, u) ≥ C2(`, u).
In the same vein as Lemma 3 and Corollary 3, Lemma 4 and Corollary 4 establish that
for any given patient age ` and remaining capacity u, the maximum total reward and the
reward obtained upon a decision, either “replace” or “wait,” is less if the number of charges
demanded per period is stochastically larger.
Lemma 4. Let V 1(`, u) and V 2(`, u) be two problem instances given by equation (3.2) for
which random variables D1 and D2 denote the number of charges demanded per period,
respectively. If D2  D1, i.e., D2 is stochastically larger than D1, then for any given state
(`,u), V 1(`, u) ≥ V 2(`, u).
Corollary 4. Let Ri(`) and Ci(`, u) denote reward instances given by equations (3.3) and
(3.4) for which D equals D1 and D2 when i = 1 and i = 2, respectively. If D2  D1, then
for any given state (`,u), R1(`) ≥ R2(`) and C1(`, u) ≥ C2(`, u).
Finally, analogous to Lemmas 3-4 and Corollaries 3-4, Lemma 5 and Corollary 5 establish
that for any given patient age ` and remaining capacity u, the maximum total reward and
the reward obtained upon a decision, either “replace” or “wait,” is less if the patient is more
pacer-dependent, i.e., the rate of battery consumption in the absence of charges is higher.
Lemma 5. Let V 1(`, u) and V 2(`, u) be two problem instances given by equation (3.2)
for which δ equals δ1 and δ2, respectively. If δ2 ≥ δ1, then for any given state (`,u),
V 1(`, u) ≥ V 2(`, u).
Corollary 5. Let Ri(`) and Ci(`, u) denote reward instances given by equations (3.3) and
(3.4) for which δ equals δ1 and δ2 when i = 1 and i = 2, respectively. If δ2 ≥ δ1, then for
any given state (`,u), R1(`) ≥ R2(`) and C1(`, u) ≥ C2(`, u).
3.4 MODEL CALIBRATION AND EXPERIMENTAL DESIGN
In this section, to calibrate the mathematical model formulated in Section 3.2, we use
values from the literature when available and estimate the remaining parameters using clin-
ical data. Also, to facilitate the analysis on the effects of the patient-specific parameters
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Table 7: Experimental-design factors and their corresponding levels. For “low,” “all” and “high”
distributions refer to Table 8.
Factor Unit No. of levels Levels
u¯ Ah 6 0.91, 0.96, 1.01, 1.06, 1.11, 1.16
δ Ah 4 0.00265, 0.00301, 0.00464, 0.00565
` weeks 11 1560, 1820, 2080, 2340, 2600, 2860, 3120, 3380, 3640, 3900, 4160
α∆(`) - 5 0.005, 0.01, 0.015, 0.02, 0.025
pD(d) - 3 low, all, high
on the optimal policy in Section 3.5, we design a computational study. In the remainder
of the chapter, we set the decision periods equal to one week in length and hence let the `
dimension of the state space be expressed in weekly increments.
Table 7 summarizes the factors of the experiment and their corresponding levels that
are estimated in Sections 3.4.1 and 3.4.2. We use this designed experiment to compare the
results obtained under the optimal policy and current practice in Section 3.5.
3.4.1 Parameters Estimated from Existing Literature
Based on the existing literature, device manuals (e.g., Medtronic 2012c) and expert
opinion, we estimate the values of parameters u¯, `, λ(`), α∆(`) and δc as follows.
Initial useful battery capacity, u¯. Battery capacity, measured in ampere hours
(Ah), is the amount of energy in the battery available for sensing (i.e., monitoring the
patient’s rhythm), pacing, and delivering charges. However, the battery capacity is not
Table 8: The estimated distribution of charges per week for patients with rates below (“low”)
or above (“high”) the median rate of demanding charges. Distribution “all,” previously given in
Table 6, is the estimated distribution of charges per week for all patients.
d Class 0 1 2 3 4 5 6 7
pD(d)
low 0.964241 0.035687 0.000069 0.000003 0 0 0 0
all 0.953759 0.045199 0.000817 0.000154 0.000044 0.000021 0.000005 0.000001
high 0.943762 0.054270 0.001530 0.000299 0.000086 0.000041 0.000009 0.000003
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Figure 7: A schematic battery capacity diagram.
consumable in its entirety. ICDs typically experience a pre-implantation shelf time during
which the battery is somewhat depleted (SECURA manual, Medtronic 2012c); the average
shelf time is on the order of five months. Also, immediately after implantation, the ICD is
typically tested to ensure proper functioning, during which the battery is further depleted.
Furthermore, when the battery capacity becomes excessively low, i.e., when EOS is reached,
the device loses its ability to perform certain functions. Therefore, we define the “useful”
battery capacity, u¯, to be the amount of energy stored in the battery after implantation, but
before device functionality is affected. Figure 7 shows a schematic battery capacity diagram.
In the remainder of this chapter, for simplicity, we refer to the useful battery capacity as
battery capacity.
The initial battery capacity varies by device family, mainly due to differences in bat-
tery size and technology. The typical initial battery capacity for ICDs is on the order
of 1.04 Ah, consisting of the usable battery capacity, 0.91 Ah, and the battery capacity
remaining at RRT, 0.13 Ah (see Section 3.5.1). To account for the differences among
various device families, we consider six values in the range of 0.91 to 1.16 Ah, i.e., u¯ ∈
{0.91, 0.96, 1.01, 1.06, 1.11, 1.16}.
Patient age at the time of initial implantation, `; and the probability of
surviving the competing risks of death, λ(`). In most clinical studies, the mean age
at first ICD implantation is between 55 and 68 years (Lee et al. 2010, 2007, Remmelts et al.
2009). Therefore, to capture a wide range of adult patients, we consider values of ` between
1560 weeks (30 years) and 4160 weeks (80 years), i.e., ` ∈ {1560, 1820, . . . , 4160}.
The values of λ(`) are obtained from the United States total population life table pro-
vided by Arias (2011), adjusted across all ages for the excess rate of mortality for patients
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with ICD devices. We estimate this excess rate of mortality by feeding a point estimate of
the compound annual mortality rate of patients wearing ICD devices, i.e., 5.8% for patients
of age 60 as reported by Bardy et al. 2005, to the DEALE method (Beck et al. 1982). The
resulting excess rate of mortality is 0.012 per year. As an example, consider patients of ages
60 to 61. From the life table provided by Arias (2011), the probability of dying between ages
60 to 61 is approximately 0.0091. Hence, the probability of surviving the competing risks of
death between ages 60 and 61 for patients with ICD devices is
λ(`) = 52
√
(1− (0.0091 + 0.012)) = 0.999590, (3.7)
where ` varies between 60×52 and 60×52+51 weeks, i.e., ` = 60×52, 60×52+1, · · · , 60×
52 + 51 weeks. (For simplicity we let the number of weeks in a year be exactly 52.)
Probability of replacement induced death, α∆(`). After a generator replacement,
significant complications may occur, e.g., infection, pulmonary edema (Krahn et al. 2011).
There is also a positive likelihood that the patient dies as a result of a generator replacement
surgery. Krahn et al. (2011) deem complications that require hospitalization, parenteral
therapy or surgical intervention as “major” and the rest as “minor.” In their study of 1,081
patients, 2.6% suffered from major complications. At 45 days, major complications originat-
ing from direct mechanical effects of surgery were associated with a 4.4% mortality. At 180
days, this number increased to 8.7%. In contrast, for those patients who did not experience
these major complications, the mortality at 45 and 180 days, is 0.66% and 1.8% respectively.
Therefore, at 45 days, we estimate the likelihood of major, recoverable complications and
replacement induced death to be
0.026× (1− 0.044) = 0.0249 (3.8)
and
0.026× 0.044 + (1− 0.026)× 0.0066 = 0.0076, (3.9)
respectively. At 180 days, the former decreases to
0.026× (1− 0.087) = 0.0237 (3.10)
while the latter increases to
0.026× 0.087 + (1− 0.026)× 0.018 = 0.0198. (3.11)
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Intuitively, the probability of replacement induced death increases in the age of the patient,
resulting in more risky, less favorable ICD generator replacement outcomes as the patient
ages. Unfortunately, as pointed out by Krahn et al. (2011), there is a relative paucity of
data when it comes to the complication rate and risk factors associated with ICD gener-
ator replacement, as opposed to initial ICD implantation. Therefore, in our experimental
design we let α∆(`) be constant in `, i.e., α∆(`) = α∆. However, to account for the ef-
fects of various comorbidities, we let α∆ assume values in a range wider than that obtained
from the point estimates of α∆ in equations (3.9) and (3.11). More specifically, we consider
α∆ ∈ {0.005, 0.01, 0.015, 0.02, 0.025}.
Capacity consumed per charge, δc. When shock therapy is demanded, the ICD
battery charges the capacitor to a high energy level within a few seconds, after which the
capacitor rapidly delivers the charge(s) as a shock(s) to the patient. The default therapy,
i.e., full energy charge, in most ICDs is fixed at 30 Joules (Medtronic 2012a, Medtronic
2012b) and it is reasonable to assume that the amount of battery capacity consumed by a
full energy charge is fixed. According to subject matter experts, the capacity consumed per
charge is consistent across most ICDs at 0.008053 Ah, i.e.,
δc = 0.008053 Ah. (3.12)
3.4.2 Parameters Estimated from Data
We use clinical data for estimating the remaining parameters. The dataset is provided by
Medtronic, one of the world’s largest medical device companies and developer of the nation’s
leading remote monitoring service for cardiac devices, Medtronic CareLinkr Network. ICDs
manufactured by Medtronic may use the CareLinkr Network to securely transmit informa-
tion about the patient and the device to clinicians for monitoring. The dataset includes
17,958 transmissions from 1,633 University of Pittsburgh Medical Center (UPMC) patients
from September, 2004 to January, 2012. On average, the dataset includes approximately 11
transmissions per patient. Each transmission includes statistics on the therapies that the
device has delivered, i.e., atrial and ventricular pacing percentages, cumulative and average
capacitor charge times, as well as information about the device itself, i.e., the average amount
of current drained from the battery per hour, or “average current drain.” The capacity de-
pletion due to initial programming that occurs shortly after implantation is included in the
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Table 9: Average current drains and estimates of the capacity consumed per week in the absence
of any charges after categorizing patients based on atrial and ventricular pacing percentages.
Ventricular pace Atrial pace Current drain(µA) δ(Ah)
≤70% ≤70% 15.80 0.00265
> 70% 17.89 0.00301
>70%
≤70% 27.63 0.00464
> 70% 33.66 0.00565
first transmission of each patient; to avoid any bias these records may introduce, we either
remove them or account for their effect in other ways when appropriate as described below.
Capacity consumed per period in the absence of any charges, δ. An ICD
continuously monitors/senses the patient’s heart rhythm and usually also functions as a pacer
to maintain a proper rhythm. The associated continuous battery depletion is a function of the
patient’s sensing and pacing currents. According to expert opinion, the sensing current drawn
for monitoring the patient’s rhythm is constant at approximately 10 micro amperes (µA) and
the pacing current varies as a function of the percentage of time the patient is paced. Hence,
to categorize patients into groups according to the rate at which their generators are depleted
in the absence of any charges, we use a threshold of 70% in both atrial and ventricular percent
pacing. We refer to a patient who is consistently paced more than 70% of the time in both the
atrium and ventricle as “pacer-dependent.” Table 9 reports the average current drains and
the values of δ estimated from the dataset for the resulting four clinically meaningful patient
categories. More specifically, the third column of Table 9 shows the average current drains
obtained from the dataset based on the 70% thresholds in both atrial and ventricular percent
pacing. Finally, using the average current drains in the third column, the last column of
Table 9 reports the estimates for the capacity consumed per week (168 hours) in the absence
of any charges, δ. The dataset used to obtain the values in Table 9 is cleansed of the first
recorded transmission of each patient, resulting in 16,325 transmissions from 1,539 patients.
Distribution of charges per period, pD(d). In Section 3.2, we assume that the patient
dies if a needed charge is not delivered. However, not all charges correspond to “appropriate”
shocks that if not delivered, may cause the patient’s death. That is, it is possible for ICDs to
misinterpret cardiac/noncardiac events and deliver inappropriate therapies (Van Welsenes
et al. 2011). Although delivering inappropriate shocks deplete the ICD battery, not delivering
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them does not cause death. Unfortunately, due to a lack of data, we have no reliable way
to differentiate between appropriate and inappropriate charges and hence assume that all
charges in the dataset are appropriate.
Furthermore, some charges are due to “reformations.” To maintain adequately quick
charge times, the capacitor is periodically “reformed” by charging the capacitor to its maxi-
mum voltage and allowing the charge to dissipate without delivering a shock to the patient.
Although capacitor reformations help preserve the low charge time by maintaining the ca-
pacitor, they also deplete the battery. For simplicity of the model, we do not explicitly
model reformations; however, we implicitly consider their depletion effect by estimating the
distribution of charges using the dataset, which includes all types of charges.
Estimating the weekly distribution of charges is not straightforward as the dataset does
not include the weekly number of charges delivered. Using average and cumulative charge
times, we first estimate the number of charges delivered between every pair of consecutive
transmissions. Next, we calculate the expected number of weeks between every pair of
consecutive transmissions, from which we may derive the weekly distribution of charges.
Let n ∈ Z+ denote the number of weeks between two consecutive transmissions from a
device and m ∈ Z+ denote the number of charges delivered in that interval as reported in the
dataset. To estimate the weekly distribution of charges, we assume that charges and weeks
are indistinguishable and all m charges are equally likely to occur in any of the n weeks.
Therefore, for any combination of m and n, we may estimate the expected number of weeks
with exactly i ∈ Z+ charges. Let the random variable Wi denote the number of weeks in
which i ∈ Z+ charges occur. Therefore, (Johnson and Kotz (1977), page 114)
E[Wi] =
1, if n = 1 and m = i,n · (m
i
) (
1
n
)i (
1− 1
n
)m−i
, otherwise.
(3.13)
The total number of weeks with i charges is obtained by summing the expected values of
the number of weeks with i charges, E[Wi]s, across all transmissions. Finally, the weekly
distribution of charges is obtained by normalizing the total number of weeks with i charges.
Before performing these calculations, we first cleanse the dataset of those transmissions
with critical missing values and repeat transmissions. We consider repeat transmissions
to be those transmissions that occurred shortly (less than half a week) after the previous
transmission(s) and carry no information, i.e., transmissions with the value zero for both the
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integer number of weeks, n, and the integer number of charges, m. If, however, a transmission
occurs shortly after the previous one and does carry a piece of information, i.e., at least one
charge occurs between the two transmissions, or m > 0, we do not consider the second
transmission to be a repeat and set its n value to one. The dataset after cleansing includes
12,640 transmissions from 1,505 patients. Finally, Table 8 gives the estimated distribution
of charges for all patients (“all”). For practical purposes, we truncate the distribution at 7
charges and re-normalize.
The best criterion for categorizing patients into classes with significantly different distri-
butions of charges is their “indication of implantation,” which is either primary or secondary
prevention. Primary prevention corresponds to implanting the device to avoid the first-time
occurrence of any life-threatening arrhythmia, whereas secondary prevention corresponds to
implanting the device to prevent arrhythmias that have already occurred from happening
again. Van Welsenes et al. (2011) show that patients who receive ICDs for secondary pre-
vention have a substantially higher propensity for appropriate shocks in the long-run than
patients who receive ICDs for primary prevention. Unfortunately, the indication of implan-
tation is not included in our dataset. Instead, to somewhat imitate the effect of categorizing
patients into two groups based on the indication of implantation, we categorize the patients
in our dataset into two classes based on how their rate of demanding charges compares with
the median rate of 0.039682 charges per week. As a result, 747 out of 1,505 patient are catego-
rized as having a charge rate below the median. Table 8 displays the estimated distribution of
charges for the two resulting classes of patients (“low” and “high”). Table 8 also displays the
distribution of charges per week for all patients (“all”) considered simultaneously. Note that,
as seen in Table 8, the number of charges for patients in “high,” “all” and “low” are stochas-
tically ordered, with the number of charges per week for patients in “high” being the largest.
3.5 COMPUTATIONAL STUDY
In this section, we first compare the performance of the replacement policy currently
recommended by manufacturers to that of the optimal policy obtained via equation (3.2).
Secondly, we conduct sensitivity analysis on the estimated parameters to investigate their
effect on the optimal replacement threshold.
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3.5.1 Policy Comparison
Expected number of replacements. Before performing the policy comparisons, we
first introduce an additional metric, namely the total expected number of replacements. To
obtain the total expected number of replacements under a given policy, N(`, u), a recursive
approach is used. Under a given policy, let a(`, u) be the action taken in state (`, u) which
is either to “replace” the generator or to “wait.” As in Section 3.3, we let the former action
be denoted by ‘1’ and the latter by ‘0.’ Hence,
N(`, u) =

0, if ` ≥ ¯` or u ≤ 0,
1 + λ(`) ·N(`+ 1, u¯) · (1− α∆(`)), if a(`, u) = 1,∑g(u)
d=0 λ(`) ·N(`+ 1, u− δ − d · δc) · pD(d), if a(`, u) = 0.
(3.14)
Equation (3.14) follows from the fact that if ` ≥ ¯` or u ≤ 0, the problem terminates and
the number of additional replacements is zero. Because replacements are assumed to take
one period to complete, under the replacement action the expected number of additional
replacements is equal to one plus the expected number of replacements starting from state
(` + 1, u¯) weighted by the probability of surviving to the next period. For any state (`, u)
in which the action taken is to wait, the expected number of additional replacements is
equal to the weighted sum of the expected number of replacements starting from states
(`+ 1, u− δ − d · δc), d = 0, 1, . . . , g(u).
Benchmark policy. Throughout the remainder of the manuscript, we refer to the re-
placement policy currently advised by manufacturers as the benchmark policy. As discussed
in Section 3.1, manufacturers recommend that ICDs be replaced when they reach RRT. Let
the remaining battery capacity at RRT be denoted by u˜. Based on communication with a
major manufacturer,
u˜ = 0.13 Ah. (3.15)
Note that the value given by equation (3.15) is consistent with the value suggested by the
data and the clinical manuals (Medtronic 2012c), as follows. Based on this literature, the
amount of battery capacity that separates RRT and EOS is defined as three months of
constant pacing and six full-energy charges. Let δˆ denote the capacity consumed per week
excluding any charges for a 100% pacer-dependent patient, our best estimate of which is
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δˆ = 0.00565 Ah (Table 9). Also, from equation (3.12), δc = 0.008053 Ah. Therefore, a
data-driven estimate for u˜, is given by
u˜ =
52
4
· δˆ + 6 · δc = 52
4
× 0.00565 + 6× 0.008053 = 0.121768 Ah. (3.16)
For our analysis, we use u˜ = 0.13 Ah.
Let au˜(`, u) denote the action advised under the benchmark policy for patient age ` and
remaining battery capacity u, i.e.,
au˜(`, u) =
0, if u ≥ u˜,1, otherwise (3.17)
and let the total expected reward under the benchmark policy starting from state (`, u) be
given by
Vu˜(`, u) =
C(`, u), if au˜(`, u) = 0,R(`), if au˜(`, u) = 1. (3.18)
Finally, let Nu˜(`, u) denote the expected number of replacements under the benchmark policy
starting from state (`, u), obtained from (3.14) with Nu˜(`, u) = N(`, u) and a(`, u) = au˜(`, u).
Optimal policy. To solve for the optimal policy we execute the backward induction al-
gorithm using equation (3.2) starting from state (¯`, 0) (see Puterman (1994), page 92). Recall
that patient age, `, is expressed in weekly increments. We discretize remaining battery ca-
pacity, u, using δ¯ in equation (3.5) for any given δ and obtain the expected number of replace-
ments under the optimal policy, N∗(`, u), using the recursive approach presented in (3.14).
That is, N∗(`, u) is obtained from (3.14) with N∗(`, u) = N(`, u) and a(`, u) = a∗(`, u).
Furthermore, to eliminate undesirable end of horizon effects involved in obtaining the
optimal policy, we artificially extend the maximum patient life beyond that reported in the
Centers for Disease Control and Prevention (CDC) tables and truncate appropriately as
follows. First, note that the probability of surviving the competing risks of death for pa-
tients of ages 99 and 100, provided by Arias (2011), are 0.698775 and 1, respectively, hence
resulting a maximum reachable age of ¯`= 5200 weeks (100 years). Unfortunately, these pa-
rameter settings induce noticeably irregular behavior of the optimal policy close to the end
of the horizon that is difficult to implement. Letting the optimal policy when the maximum
reachable age is ¯` be denoted by pi∗(¯`), we extrapolate the patient survival curve from the
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competing risks of death up to 120 years (6240 weeks), obtain pi∗(6240) and then truncate
at 100 years of age (see Figure 8). Let pi∗(6240, 5200) denote the resulting truncated policy.
Table 10 reports the total expected reward and the total expected number of replacements
across all patients types for three age groups under policies pi∗(5200) and pi∗(6240, 5200),
assuming a maximum reachable age of 100 for all patients. As seen in Table 10, the dif-
ference between the values obtained under these two policies is negligible; the maximum
difference between the total reward across all patient categories is 0.0011 weeks. Therefore,
pi∗(6240, 5200) essentially performs the same as the “optimal” policy. In the remainder of
the chapter, we refer to pi∗(6240, 5200) as optimal and use the same approach to obtain and
evaluate the benchmark policy up to 100 years of age.
Discussion. Next, we compare the results obtained under the optimal and benchmark
policies for the computational study designed in Section 3.4. First, however, we illustrate the
difference between the replacement thresholds under the optimal and benchmark policies for
the example in Figure 6. Figure 8 displays the threshold under the optimal and benchmark
policies. According to both policies, the ICD generator should be replaced once the battery
capacity falls below a threshold. However, the value of the thresholds are significantly dif-
ferent between the two policies. Also, while the optimal replacement threshold becomes less
conservative, i.e., advises “late” replacements, as the patient ages, the benchmark replace-
ment threshold remains constant.
Table 11 reports the summary of results for patients who undergo initial implantation
at age 30-40, 41-60, 61-80. Specifically, Table 11 reports the increase in the total expected
lifetime and the (percentage) decrease in the expected number of replacements under the
optimal policy versus the benchmark policy across all patient types for the three age groups.
From this table, the total expected lifetime may be extended by up to 40.6 weeks (0.78 years)
under the optimal policy. The expected number of replacements may decrease by up to 19%.
Finally, in the remainder of this section, we present more elaborate results for a few
patient categories using two detailed tables and provide general observations regarding the
patient categories that benefit the most from the optimal policy. Table 12 reports the total
expected reward and the total expected number of replacements for the optimal policy when
the patient age at the time of initial implantation, `, is 50, 60 or 70 years and the initial
battery capacity is 1.06 Ah. Table 12 also presents the differences between the total reward
and the total expected number of replacements under the optimal and the benchmark poli-
cies. In this table, the rewards and number of replacements are given for all combinations
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Figure 8: Optimal replacement policy versus benchmark policy for u¯ = 1.06 Ah, ` = 2600 weeks
(50 years), α∆ = 0.02, δ = 0.00265 Ah, δc = 0.008053 Ah and the distribution of charges given by
Table 6.
Table 10: Comparison between the total reward and the total expected number of replacements
across all patient types in the given age groups under pi∗(5200) and pi∗(6240, 5200).
Min Mean Max Min Mean Max
30-40 years 0 3.3  10-5 3.0  10-4 0 2.2  10-4 1.3  10-3
41-60 years 0 4.6  10-5 4.8  10-4 0 2.9  10-4 2.5  10-3
compariso
n - delta_c 
61-80 years 0 8.7  10-5 1.1  10-3 0 5.5  10-4 6.2  10-3
Min Mean Max Min Mean Max
age 
groups
20-40 
years41-60 
years
0 4.9E-05 0.00051 0 0.0003 0.0023 1440
61-80 
years
0 9.3E-05 0.00113 0 0.00057 0.00639 1440
With old survival probabilities:
0.00E+00 3.50E-05 3.16E-04 0.00E+00 2.30E-04 1.45E-03
Min Mean Max Min Mean Max 0.00E+00 4.90E-05 5.07E-04 0.00E+00 3.01E-04 2.30E-03
30-40 years 0 3.5  10-5 3.16  10-4 0 2.3  10-4 1.45  10-3 0.00E+00 9.30E-05 1.13E-03 0.00E+00 5.71E-04 6.39E-03
41-60 years 0 4.9  10-5 5.07  10-4 0 3.01  10-4 2.3  10-3 difference_V difference_Exp N
61-80 years 0 9.3  10-5 1.13  10-3 0 5.71  10-4 6.39  10-3 Min Mean Max Min Mean Max
age groups
30-40 years 0.00E+00 3.30E-05 3.01E-04 0.00E+00 2.18E-04 1.27E-03 1080
41-60 years 0.00E+00 4.60E-05 4.84E-04 0.00E+00 2.87E-04 2.47E-03 1440
61-80 years 0.00E+00 8.70E-05 1.09E-03 0.00E+00 5.47E-04 6.22E-03 1440
Policies
Patient age at 
initial 
implantation
Difference in total reward (wks)
Difference in expected number of 
replacements
 p*(5200) vs.  
p*(6240, 5200)
difference_V difference_Exp N
0 3.5E-05 0.00032 0 0.00023 0.00145 1080
Policies
Patient age at 
initial 
implantation
Difference in total reward (wks)
Difference in expected number of 
replacements
 p*(5200) vs.  
p*(6240, 5200)
61
Table 11: Results under the optimal policy versus benchmark policy across all patient types in the
given age groups.
Min Max Min Max Min Max
Increase in the total 
reward (wks)
1.8 40.6 0.7 25.6 0.1 9.6
Decrease in the expected 
number of replacements
0.36 1.58 0.23 1.25 0.10 0.76
Percentage decrease in 
the expected number of 
replacements
8% 14% 8% 15% 8% 19%
With old survival probabilities:
Min Max Min Max Min Max
Increase in the total 
reward (wks)
1.76 40.7 0.69 25.74 0.13 9.72
Decrease in the expected 
number of replacements
0.36 1.59 0.23 1.25 0.1 0.76
Percentage decrease in 
the expected number of 
replacements
8% 14% 8% 15% 8% 19%
Optimal policy vs.
current practice
Patient age at initial implantation
30-40 years 41-60 years 61-80 years
Optimal policy vs. 
benchmark policy
Patient age at initial implantation
30-40 years 41-60 years 61-80 years
of pacer dependency levels, two levels (“low” and “high”) of the distribution of charges and
three levels of the probability of replacement induced death. Table 13 is similar to Table 12,
except that the patient age at the time of initial implantation is fixed at 60 years and the
initial battery capacity, u¯, assumes values in {0.91, .96, 1.01, 1.06, 1 1, 1.16}.
Consider a pati nt (corresponding to the row in bold type in Table 12) who first undergoes
ICD implantation at the age of 60 and receives a device with an initial battery capacity of
1.06 Ah. Suppose this patient is paced less than or equal to 70% in the ventricle, but
more than 70% in the atrium and demands charges below the median rate. Also, let the
probability of replacement induced death for this patient assume its smallest value, i.e., 0.005.
As shown in Table 12, under the optimal policy this patient lives on average 990.1 weeks
(19.04 years) and requires 2.65 generator replacements. Following the optimal policy, as
opposed to the benchmark policy, increases the patient’s expected remaining lifetime by 1.2
weeks. Although this increase in the expected remaining lifetime may seem modest, under
the optimal policy the expected number of replacements decreases by 0.37 replacements, or
12%. The significance of this observation lies in the fact that the decrease in the number
of replacements, and consequently their associated cost, is achieved without compromising
clinical outcomes.
The significant decrease in the expected number of replacements is consistent across the
experimental design. From Table 12, for patients who first undergo ICD implantation at ages
50, 60 or 70 and receive devices with an initial battery capacity of 1.06 Ah, the expected
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Table 12: The optimal and benchmark policy comparison when the patient age at the time of initial
implantation is 50, 60 or 70 years (equivalent to 2600, 3120 and 3640 weeks, respectively) and the
initial battery capacity is 1.06 Ah. For “low” and “high” distributions refer to Table 8. V-pace
and A-pace represent the ventricular pace and atrial pace, respectively.
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Table 13: The optimal and benchmark policy comparison when the initial battery capacity, u¯,
assumes values in {0.91, 0.96, 1.01, 1.06, 1.11, 1.16} and the patient age at the time of initial im-
plantation is 60 years (3120 weeks). For “low” and “high” distributions refer to Table 8. V-pace
and A-pace represent the ventricular pace and atrial pace, respectively.
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number of replacements decreases by 9% to 14% under the optimal policy. This range is
nearly consistent across all initial capacities. From Table 12, for a patient who first receives a
device with an initial battery capacity of 1.06 Ah at age 60 (corresponding to the column in
bold type), the expected number of replacements decreases by 9% to 13% under the optimal
policy. As seen in Table 13, which reports the results for patients who first undergo ICD
implantation at the age of 60, this range only slightly widens to 8% to 15% when the initial
battery capacity assumes a wide range of values from 0.91 to 1.16 Ah.
Obviously, while all patients benefit from implementing the optimal generator replace-
ment policy, some categories of patients see more dramatic impacts than others. For instance
(Table 12), for a given set of characteristics, the younger the patient at implementation, the
longer the lifetime extension under the optimal policy. Also, the less prone to demanding
charges or the more likely to die as a result of replacement surgery, the greater the life-
time extension under the optimal policy; this observation is mainly due to the fact that the
benchmark policy is excessively conservative for such patients. As shown in Table 11, some
patients’ expected lifetimes may be extended by up to 40.6 weeks (0.78 years) under the
optimal policy. Specifically, this maximum is achieved for those patients who undergo initial
implantation at age 30, receive ICD generators with an initial battery capacity of 0.91 Ah,
are paced more than 70% in both atrium and ventricle, demand charges below the median
rate and carry the highest surgical risks. Also, as shown in Table 11, some patients may
avoid as many as 1.6 replacement surgeries in expectation by following the optimal policy.
These patients have the same characteristics as those for which the maximum lifetime exten-
sion is achieved, except for the fact that they carry the lowest surgical risks rather than the
highest. Generally, the expected lifetime extension (the expected number of avoided surg-
eries) is more pronounced in younger patients who receive generators with smaller initial
battery capacities, are more pacer dependent, demand fewer charges and are prone to high
(respectively, low) surgical risks. Finally, as shown in Table 11, under the optimal policy, the
decrease in the expected number of replacements in between 8% and 19% across all patient
types. Generally, patients who undergo initial implantation at younger ages experience a
larger reduction in the expected number of replacement surgeries than older patients; how-
ever, the percentage decrease in the expected number of replacements is greater for those
patients who undergo initial implantation at older ages. For example, the patients with the
highest percentage decrease in the expected number of replacements, i.e., 19%, are those
who undergo initial implantation at age 80, receive ICD generators with an initial battery
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Table 14: The parameter settings for Figures 9a-9c. For “low” distribution refer to Table 8.
Figure Parameter u¯ (Ah) ` (wks) ¯` (wks) δ δc α∆ pD(d)
9a α∆ 1.16 1560 (30 yrs) 5200 (100 yrs) 0.00301 0.008053 - low
9b pD(d) 1.16 1560 (30 yrs) 5200 (100 yrs) 0.00301 0.008053 0.01 -
9c δ 1.16 1560 (30 yrs) 5200 (100 yrs) - 0.008053 0.01 low
capacity of 1.06 Ah, are paced less than 70% in both atrium and ventricle, demand charges
below the median rate and carry the average surgical risk of 0.015.
The results suggest that patients who demand fewer charges (i.e., receive the device for
primary prevention) consistently benefit more from following the optimal policy. This ob-
servation is particularly promising because these patients constitute 50%-80% of new ICD
patients every year (Proclemer et al. 2009), because clinical trials have shown that these
patients benefit the most from receiving ICDs, and because the prevalence of this type of
patient is expected to rise in years to come (Seidl and Senges 2003).
3.5.2 Sensitivity Analysis
In this section, we investigate the effects of changes in the estimated parameters on the
optimal policy, the total expected reward and the total expected number of replacements
under the optimal policy.
Probability of replacement induced death, α∆. Figure 9a portrays the optimal
policy for five problem instances stratified across the probability of replacement induced
death, α∆, with the other parameter settings as given in Table 14. In these example policies,
given any fixed patient age ` and remaining battery capacity u, if it is optimal to replace the
generator for any given probability of replacement induced death, it is also optimal to replace
the generator when replacements are less risky, i.e., when the probability of replacement
induced death is smaller. Table 15 lists the total expected reward and the total expected
number of replacements obtained under the optimal replacement thresholds in Figure 9a.
Consistent with Lemma 3, the optimal reward decreases as the likelihood of replacement
induced death increases.
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Table 15: The optimal total reward and the optimal expected number of replacements across
different α∆ values where u¯ = 1.16 Ah, ` = 1560 weeks (30 years), δ = 0.00301 Ah, δc = 0.008053
Ah and the patient’s rate of demanding charges is below the median rate (see Table 8).
Probability of 
replacement 
induced death, aD
Optimal reward (wks), 
V (1560, 1.16)
Expected number of 
replacements under 
the optimal policy, 
N *(1560, 1.16)
0.005 1867.8 4.89
0.01 1840.3 4.82
0.015 1813.2 4.75
0.02 1786.7 4.68
0.025 1760.9 4.59
Table 16: The optimal total reward and the optimal expected number of replacements across
different distributions of charges per period, pD(d), where u¯ = 1.16 Ah, ` = 1560 weeks (30 years),
δ = 0.00301, δc = 0.008053 Ah and α∆ = 0.01. For “low,” “all” and “high” distributions refer to
Table 8.
Distribution of 
charges, p D (d )
Optimal reward (wks), 
V (1560, 1.16)
Expected number of 
replacements under 
the optimal policy, 
N *(1560, 1.16)
low 1840.3 4.82
all 1837.1 5.04
high 1835.1 5.22
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Table 17: The optimal total reward and the optimal expected number of replacements across
different types of pacer dependencies (δ values) where u¯ = 1.16 Ah, ` = 1560 weeks (30 years),
δc = 0.008053 Ah, α∆ = 0.01 and the patient’s rate of demanding charges is below the median rate
(see Table 8).
Pacer dependency 
Optimal reward (wks), 
V (1560, 1.16)
Expected number of 
replacements under 
the optimal policy, 
N *(1560, 1.16)
V-pace and A-pace are
both  70%; d = 0.00265 Ah
1846.9 4.28
V-pace  70%, but A-pace
> 70%; d = 0.00301 Ah
1840.3 4.82
V-pace > 70%, but A-pace
 70%; d = 0.00464 Ah
1809.7 7.30
V-pace and A-pace are
both > 70%; d = 0.00565 Ah
1790.5 8.83
Distribution of charges per period, pD(d). Figure 9b portrays the optimal policy
for three problem instances stratified across the distribution of charges per period, pD(d),
with the other parameter settings as given in Table 14. Figure 9b illustrates that opti-
mal replacement threshold becomes more conservative as the number of charges per period
stochastically increases. In other words, for any fixed patient age ` and remaining battery
capacity u, if it is optimal to replace the generator for a given distribution of charges pD(d),
it is also optimal to replace the generator when the number of charges is stochastically larger.
Also, similar to the results demonstrated for α∆, Table 16 reports a decrease in the optimal
reward as the number of charges stochastically increases, which is consistent with Lemma 4.
Capacity consumed per period in the absence of any charges, δ. Figure 9c por-
trays the optimal policy for four problem instances stratified across the capacity consumed
per period in the absence of any charges, δ, with the other parameter settings as given in Ta-
ble 14. Figure 9c illustrates that, in general, the thresholds for more pacer-dependent patients
are more conservative. However, in contrast to Figures 9a-9b, Figure 9c demonstrates that
the relationship between the optimal replacement thresholds is not necessarily monotonic in
the capacity consumption rate. That is, although it might be optimal to replace the genera-
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tor given a certain rate of capacity consumption in the absence of charges for a fixed patient
age and remaining battery capacity, it is not necessarily optimal to do so under a higher
consumption rate, and vice versa. This property is mainly due to end of horizon effects.
Finally, Table 17 reports the total reward under the optimal replacement thresholds in
Figure 9c. In this table, consistent with Lemma 5, the total reward decreases as the capacity
consumption rate in the absence of charges increases. Table 17 also reports the expected
number of replacements under the optimal policies in Figure 9c. From Table 17, under
the optimal policy, the most pacer-dependent patient with V-pace and A-pace both > 70%
(δ = 0.00565) on average requires almost twice as many generator replacement surgeries
as the least pacer-dependent patient with V-pace and A-pace both ≤ 70% (δ = 0.00265).
Therefore, the capacity consumed per period in the absence of any charges, δ, is one of
the most important factors in the decision making process, and consequently, the expected
number of generator replacements that a patient requires.
3.6 CONCLUSION
In this chapter, we consider the important problem of timing ICD generator replacements
to optimally balance the trade-off between prematurely exposing the patient to the risks of
replacement and allowing for the possibility that the device is unable to deliver therapy when
needed. In current practice, replacements are performed rather conservatively and are not
tailored to individuals based on their personal characteristics. The MDP model analyzed
here, however, determines patient-specific optimal replacement policies under the objective
of maximizing the patient’s expected lifetime.
That is, in contrast to the current one-size-fits-all replacement policy, which is a function
of remaining battery capacity only, we obtain patient-specific optimal replacement thresh-
olds, which are functions of the remaining battery capacity, patient age and other factors,
e.g., pacer dependency and propensity for shocks. Based on clinical data, we conduct a large
scale computational study to compare total expected lifetime and total expected number
of replacements under the optimal policy and current practice. For every patient category,
we obtain a threshold-type policy that is easy to implement; the policy is of threshold-
type in the remaining battery capacity typically with one or two replacement thresholds in
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patient age. Our results suggest that following the optimal policy decreases the expected
number of replacements while achieving the same or greater expected lifetime. Across all
patient types, the expected number of replacements (and consequently their associated cost
of approximately $24,000 each) decreases by a minimum of 8% under the optimal policy.
Also (Table 11), for patients with certain characteristics, following the optimal policy can
be of significant benefit, e.g., the expected lifetime (the expected number of replacement
surgeries) may be extended by 40.6 weeks (decreased by 19%) under the optimal policy.
71
4.0 OPTIMAL PLANNING OF LIFE-DEPLETING MAINTENANCE
ACTIVITIES
4.1 INTRODUCTION
Consider a system with a known, deterministic initial lifetime L < ∞ that generates
reward at a decreasing, average rate of r(t) > 0, where t is the virtual age (as defined
by Kijima et al. (1988)) of the system. Preventive maintenance (PM) may be performed
to adjust the system’s virtual age back to zero (i.e., “perfect” maintenance), but at some
“cost.” We consider the case in which this PM cost corresponds to a reduction in the system’s
remaining lifetime.
Initially, in Section 4.2, we consider the deterministic case in which the system is not
prone to failures. In this case, we assume a fixed PM interval τ > 0 is used throughout
the system’s lifetime. That is, given an initial virtual age of 0, maintenance is performed
periodically at time τ, 2τ, 3τ, . . . , nτ , until the remaining system life does not allow for any
additional maintenance, i.e., L− n(τ + f(τ)) < τ + f(τ), where f(τ) > 0 is the amount by
which PM depletes the system lifetime. The objective is to select τ such that the total reward
earned over the lifetime of the system is maximized, where the reward earned over a period
of length τ , starting from a virtual age of t, is given by R(t, τ) =
∫ t+τ
t
r(u) du. In Section
4.3, we consider failure-prone systems subject to either perfect or imperfect maintenance,
upon which the system’s virtual age is set back to either zero or some non-negative value, re-
spectively. The resulting stochastic dynamic program models incorporate lifetime-depleting
preventive and reactive maintenance to adaptively determine when PM should be performed.
This problem setting is motivated in part by the practice of remotely monitoring battery-
powered devices that are difficult to service and/or impossible to recharge, e.g., implanted
medical devices (Darce July, 2010, Yekeh Yazdandoost and Kohno 2009) or sensors (Aky-
ildiz et al. 2002). Such devices periodically transmit information about their condition and
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performance to a remote data center. Hence, an interesting trade-off exists between bat-
tery longevity and transmission frequency. That is, more frequent transmissions result in a
shorter battery life, but more timely data.
For example, consider an implanted cardiac device, e.g., a pacemaker or cardiac defibril-
lator. The lithium iodine batteries used in these devices exhibit stable voltage, resulting in
predictable initial useful lifetimes (Mallela et al. 2004) given a set of patient characteristics.
Data logging, however, can constitute a serious drain on battery life (Mallela et al. 2004).
On the other hand, the more frequently the device remotely transmits data to clinicians, the
more “protection” it provides for the patient. In this context, transmissions correspond to
“maintenance actions” as they allow for device/patient inspections and possible adjustments.
Some advanced systems transmit data daily; however, for other systems, daily transmission
has a high impact on battery longevity, and hence weekly or bi-weekly intervals are typically
used (Jung et al. 2008). Similarly, “failures” correspond to “adverse events” experienced
by the patient due to device malfunction or a change in health condition (e.g., syncope,
inappropriate shock).
Wireless sensor networks serve as another motivating application. One of the main con-
straints in these networks is the limited, typically irreplaceable power sources of the sensors
(Akyildiz et al. 2002). Hence, a trade-off exists between achieving high quality service of the
network and conserving power to prolong the lifetime of the network. Again, “maintenance
actions” correspond to data transmissions. The more frequent the data transmissions, the
more timely the decisions can be made; hence, the “reward rate” decreases in the time since
the last transmission. In this context, “failures” correspond to sudden changes in the system
(e.g., fatigue cracking in a building or an airframe) being monitored by the sensors.
Admittedly, in both contexts, the approach taken herein is myopic in that it does not
consider the cost of device replacement, but rather maximizes the reward generated by the
device currently in operation. Although beyond the scope of this work, the generalization
could be handled by assigning a cost to replacement and taking a renewal reward approach.
Such an approach would seek the transmission interval that maximizes the ratio of the total
reward generated by the current device (less the replacement cost) to the replacement time
induced by the transmission interval selected.
The majority of the existing maintenance optimization literature considers infinite hori-
zon formulations and models the cost of performing maintenance as either a literal, economic
cost or as downtime during which the system does not age, or both. In contrast, we model
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the “cost” of performing PM as a depletion of the remaining, finite system lifetime, which
can be equivalently viewed as a finite horizon formulation with non-instantaneous PM –
a combination examined by relatively few (Dedopoulos and Smeers 1998, Jayabalan and
Chaudhuri 1992, Singh et al.).
Singh et al. consider a finite horizon maintenance and production planning problem for
a non-failure-prone system, but make decisions based on machine condition, which deteri-
orates according to a discrete time Markov chain, as opposed to (continuous) virtual age.
The objective is to maximize total expected profit while meeting a known demand, subject
to machine-condition-dependent production yield (analogous to our age-dependent reward
rate). In contrast to the models considered here, however, the duration of each maintenance
activity is assumed to take exactly one period regardless of the amount of time that has
elapsed since the last maintenance activity was performed.
Dedopoulos and Smeers (1998) and Jayabalan and Chaudhuri (1992) both consider cost
minimizing, non-instantaneous PM planning problems for failure-prone systems over finite
horizons. In these models, however, reactive maintenance is assumed to be instantaneous and
corresponds to a minimal repair (i.e., no change in virtual age), in which case all decisions
can be made a priori. In contrast, the models in Section 4.3 consider reactive maintenance
that depletes the system’s remaining lifetime and alters the virtual age to either zero (in
Section 4.3.1) or possibly a non-negative value (in Section 4.3.2), in which case decisions
must be made adaptively.
Although our main contribution is the consideration of life-depleting (or time consuming)
PM in a finite horizon setting, the literature that examines instantaneous PM planning as a
function of virtual age over a finite horizon is also relevant. Chun (1992) and Nakagawa and
Mizutani (2009), for example, determine the optimal number of periodic PMs for a failure
prone system over a finite warranty period. They require that every time interval, including
the interval following the last PM prior to the warranty’s expiration, be of equal length.
Jack and Dagpunar (1994) consider the same problem, but relax this requirement (as do
we). Dagpunar and Jack (1994) generalize further by allowing the amount by which each
PM reduces the virtual age to be a decision variable. Boland (1982), Boland and Proschan
(1982), and Popova et al. (2010) consider the same finite-horizon, periodic maintenance
planning problem as Jack and Dagpunar (1994) do, but with renewing PMs and different
cost structures. Moghaddam and Usher (2010) consider a similar problem as Nakagawa and
Mizutani (2009) do, but with periodic decisions as to whether to perform an imperfect PM,
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perfect PM (replacement) or nothing. Lastly, Yeh et al. (2009), who consider a problem
similar to Chun (1992), claim that the cost of PM includes downtime cost, however the
dynamics of their model assume that PM is instantaneous.
We make the following assumptions throughout the remainder of the chapter:
A1: For t ∈ [0, L], r(t) > 0 is differentiable and strictly decreasing, i.e., r′(t) < 0.
A2: For τ ∈ [0, L], f(τ) > 0 is twice differentiable, nondecreasing, and convex, i.e.,
f ′(τ) ≥ 0, f ′′(τ) ≥ 0. Additionally, let f ′(0) = 0.
A3: L > f(0).
The intuition behind A1 follows from the fact that the greater the virtual age, the poorer
the performance of the device and therefore the smaller the reward rate. In terms of A2, non-
decreasing f(τ) reflects the fact that the longer the maintenance interval, the greater the bur-
den of decreasing the virtual age. Additionally, because the greater the maintenance interval
the more data there are to transmit, a convex f(τ) reflects the fact that the energy required to
transmit data is typically convex in the data quantity; we also assume that the rate of increase
is initially zero (Sengul et al. 2008). Assumption A3 ensures that a non-trivial solution exists.
The remainder of the chapter is organized as follows. In Section 4.2, we consider the case
in which the system is not subject to failure and preventive maintenance is perfect, i.e., the
system’s virtual age is renewed after each PM. Section 4.3 generalizes to the case in which
the system is subject to random failures, which are both economically costly and lifetime-
depleting, and maintenance activities may be imperfect. Lastly, we conclude in Section 4.4.
All proofs are included in Appendix B.2.
4.2 PERFECT MAINTENANCE FOR FAILURE-FREE SYSTEMS
In this section, we assume that PM resets the virtual age of the system to zero. For a
given feasible maintenance interval, τ , i.e., an interval that satisfies
τ ≤ L− f(τ), (4.1)
the total number of PMs performed, n(τ), is given by
n(τ) =

L
τ+f(τ)
− 1, if L
τ+f(τ)
∈ Z+,⌊
L
τ+f(τ)
⌋
, otherwise.
(4.2)
75
Hence, the remaining lifetime after the last PM is equal to L− n(τ) · (τ + f(τ)). Equation
(4.2) assumes that for any given τ , we perform the maximum number of PMs possible unless
the final PM would result in a remaining lifetime of zero. For example, if L = 100, τ = 3
and f(3) = 2, then only 19 PMs are performed. Furthermore, from equation (4.2), n(0) is
the maximum number of PMs possible, which we denote by
nmax ≡ n(0). (4.3)
Figure 10 illustrates the problem dynamics for the perfect maintenance case. Initially, as
illustrated in Figure 10a, both the actual age and the virtual age of the system is zero, the
reward rate is r(0), and the remaining lifetime is L. By assumption A1, as time passes, the
reward rate decreases. At time τ , the first perfect PM is performed which resets the virtual
age of the system back to zero. However, this PM also depletes the remaining lifetime
by f(τ). Therefore, after the first PM, the remaining lifetime is L − 1 · (τ + f(τ)). The
total reward obtained between time zero and time τ is R(0, τ). The PMs are performed
periodically at times 2τ, 3τ, . . . , n(τ), when the remaining lifetime is such that another PM
is not possible. Hence, as shown in Figure 10b, the last interval is of size L−n(τ) ·(τ+f(τ)),
in which the reward R(0, L− n(τ) · (τ + f(τ))) is earned.
The overall goal is to maximize the total reward earned over the system’s lifetime. This
objective can be expressed as
max
τ>0
{n(τ)R(0, τ) +R(0, L− n(τ) · (τ + f(τ)))} , (4.4)
which is discontinuous and neither concave nor convex. Note that by (4.2), any feasible
n ∈ Z+ must satisfy
0 ≤ n ≤ nmax. (4.5)
Furthermore, given a feasible non-zero n ∈ Z+, the corresponding maintenance interval,
τ > 0, must satisfy
L
n+ 1
− f(τ) ≤ τ < L
n
− f(τ). (4.6)
To facilitate further analysis, define the continuous function V (·, ·) for any pair (τ, n) as
follows
V (τ, n) = nR(0, τ) +R
(
0, L− n · (τ + f(τ))). (4.7)
When n ∈ [1, nmax]∩Z+ and τ is given by (4.6), or when n = 0, equation (4.7) provides the
total reward for a feasible solution to the problem given by (4.4)-(4.6). Note that for any
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Figure 10: Illustration of the problem dynamics under perfect maintenance and no failures at (a)
the beginning of the system’s lifetime and (b) the end of the system’s lifetime.
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given feasible interval length, τ , the number of PMs, n, is uniquely determined; however, for
any given feasible non-zero n, any τ that satisfies (4.6) gives a feasible interval length. For
this reason, the total reward function, given by equation (4.7), is expressed as a function
of both τ and n, i.e., V (τ, n). In Theorem 2, we establish a simple solution procedure that
exploits the underlying structure of the problem. Prior to presenting Theorem 2, however,
we present three technical lemmas.
Define n¯max =
L
f(0)
, which serves as an upper bound for nmax as nmax < n¯max. Also, let
τ¯n be the solution to τ =
L
n
−f(τ) when solved for τ . Note that for any fixed n ∈ (0, n¯max), a
unique τ¯n exists and satisfies 0 < τ¯n ≤ Ln − f(0) due to equation (4.3) as well as assumptions
A2 and A3.
First, Lemma 6 establishes the concavity of the function V (τ, n) in the interval length,
τ , for any fixed n ∈ (0, n¯max). Subsequently, we use this result to show that the total reward
function V (τ, n) can be locally maximized for any fixed, positive integer n.
Lemma 6. For any fixed n ∈ (0, n¯max) ⊂ R+ the function V (τ, n) is strictly concave in τ ,
τ ∈ (0, τ¯n) ⊂ R+.
Lemma 6 implies that for any fixed n ∈ (0, n¯max), the maximum of V (τ, n) over τ ∈ (0, τ¯n)
exists if the following equation is solvable for some τ ∈ (0, τ¯n):
∂V (τ, n)
∂τ
= n ·
(
r(τ)− (1 + f ′(τ)) r(L− n · (τ + f(τ)))) = 0. (4.8)
For a given n ∈ (0, n¯max), let τn be the solution to (4.8) if it is solvable for τ , i.e.,
r(τn) = r(L− n · (τn + f(τn)))
(
1 + f ′(τn)
)
. (4.9)
Next, Lemma 7 establishes that (4.8) is indeed solvable under assumptions A1-A3.
Lemma 7. For any fixed n ∈ (0, n¯max) ⊂ R+ there exists a unique τn ∈ (0, τ¯n) ⊂ R+ such
that τn = arg max
τ
{V (τ, n) | τ ∈ (0, τ¯n)}.
Note, however, that for a fixed n ∈ [1, nmax] ∩ Z+, τn maximizes the total reward given
by (4.4) only if τn satisfies (4.6). If (4.6) does not hold, then it can be formally shown that
the optimal interval is equal to the solution of τ = L
n+1
− f(τ) when solved for τ . We discuss
the situation in which (4.6) does not hold in more detail in Section 4.2.2.
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Next lemma, Lemma 8, establishes the concavity of V (τn, n) in n, n ∈ (0, n¯max) ⊂ R+.
Lemma 8. The function V (τn, n) is concave in n, n ∈ (0, n¯max) ⊂ R+.
By Lemma 8 and equation (4.9), the maximum of V (τn, n) over n ∈ [1, nmax] ⊂ R+ is
attained either at n = 1, or at n = nmax, or at some point in (1, nmax) ⊂ R+ that satisfies
∂V (τn, n)
∂n
=
∫ τn
0
r(t) dt− r(τn)
1 + f ′(τn)
(
τn + f(τn)
)
= 0. (4.10)
Let n˜ be the solution to (4.10) if it is solvable for n.
Finally, let the optimal maintenance interval for the problem given by (4.4)-(4.6) be de-
noted by τ ∗ and the corresponding number of PMs by n∗. Also, without loss of generality, let
τ0 ≡ L (4.11)
and V (τ0, 0) = R(0, L). Theorem 2 establishes conditions under which we can solve for the
optimal maintenance interval τ ∗, by
(i) solving equations (4.9) and (4.10) simultaneously to obtain n˜ ∈ R++;
(ii)obtaining τbn˜c, if bn˜c ∈ (1, nmax), and τdn˜e, if dn˜e ∈ (1, nmax), using equation (4.9); and
(iii) setting n∗ equal to the value from {0, 1, {bn˜c, dn˜e} ∩ (1, nmax), nmax} that results in
the greater total reward in (4.7).
Theorem 2. If τn satisfies (4.6) for all n ∈ [1, nmax] ∩ Z+, then τ ∗ = τn∗, where
n∗ = arg max
n∈{0,1,{bn˜c,dn˜e}∩(1,nmax),nmax}
V (τn, n). (4.12)
For this solution procedure to be valid, however, τn must satisfy (4.6) for all n ∈ [1, nmax]∩
Z+. In the following subsection we perform a more detailed analysis of one special case under
which these conditions hold.
Lastly, Proposition 1 establishes a technical property of τn, n ∈ (0, n¯max), that is neces-
sary for our further discussion in Section 4.2.2. Namely, Proposition 1 implies that for any
fixed number of PMs n ∈ [1, nmax] ∩ Z+, the last maintenance interval, i.e., the (n + 1)st
interval, is at least as long as the first n intervals.
Proposition 1. For a fixed n ∈ (0, n¯max)
L− n · (τn + f(τn)) ≥ τn.
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4.2.1 Constant Maintenance Cost
Consider the special case in which the amount of life depletion is independent of the
length of the maintenance interval, i.e.,
f(τ) = ∆ ∀τ ∈ R++, (4.13)
where ∆ > 0. A simple example of this case may arise when the amount of data transmit-
ted is predetermined, e.g., a sensor or implanted cardiac device transmits a snapshot of the
patient/device’s most recent status, as opposed to an entire history collected since the last
transmission. Note that because constant f(τ) satisfies assumptions A2 and A3, Lemmas
6, 7 and 8 as well as Proposition 1 hold.
Next, Proposition 2 provides closed form expressions for τn, the optimal maintenance in-
terval length for any fixed n, as well as for n˜, the (non-integer) optimal number of PMs. As a
result of Proposition 2, it is clear that τn satisfies (4.6) for all n ∈ [1, nmax]∩Z+; hence, The-
orem 2 applies to this special case. Furthermore, under a constant amount of life depletion,
the optimal total reward is achieved when the last interval is of the same length as the rest,
i.e., all maintenance intervals are of equal length. This result is similar in spirit to analogous
results obtained by Belyi et al. (2009), Boland (1982) and Boland and Proschan (1982).
Proposition 2. If f(τ) is given by (4.13), then
(i) τn =
L−n∆
n+1
for all n ∈ (0, n¯max),
(ii) τn satisfies (4.6) for all n ∈ [1, nmax] ∩ Z+, and
(iii) the solution of (4.10) satisfies
n˜ =
(L+ ∆) r(τn˜)∫ τn˜
0
r(t) dt
− 1.
Recall that for any fixed number of PMs, the interval length that maximizes the total
reward is chosen from a range of feasible interval lengths, and hence, there is a possibility of
miscalculation of this interval length by a decision maker. Proposition 3 provides a bound on
the amount of total reward loss that a decision maker may incur by choosing a sub-optimal
interval length, e.g., due to parameter misspecification, for any given positive number of PMs.
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Proposition 3. Suppose f(τ) is given by (4.13). For any positive number of PMs, n,
max
L
n+1
−∆≤τ<L
n
−∆
{V (τn, n)− V (τ, n)} ≤ max
{
n∆
n+ 1
·
(
r
(
L
n+ 1
−∆
)
− r
(
L
n+ 1
))
,
L− n∆
(n+ 1)
·
(
r(0)− r
(
L
n
−∆
))}
. (4.14)
For the case in which the maintenance cost is constant and the reward function is linear,
i.e.,
r(t) = −at+ b > 0 a, b > 0, ∀t ∈ [0, L], (4.15)
Corollaries 6 and 7 (to Propositions 2 and 3, respectively), provide closed form expressions
for n˜ and the upper bound established in Proposition 3.
Corollary 6. Suppose f(τ) and r(t) are given by (4.13) and (4.15), respectively. Then the
solution to (4.10) is given by
n˜ =
a(L+ ∆)√
a∆(2b+ a∆)
− 1. (4.16)
Corollary 7. Suppose f(τ) and r(t) are given by (4.13) and (4.15), respectively. For any
positive number of PMs, n,
max
L
n+1
−∆≤τ<L
n
−∆
{V (τn, n)− V (τ, n)} =

an∆2
2(1+n)
, if L
2
≤ n∆,
a(L−n∆)2
2n(1+n)
, otherwise.
(4.17)
Corollary 7 formally establishes the intuitive fact that when the reward function is linear,
the maximum penalty associated with performing maintenance at a sub-optimal interval
length is linear in the slope of the reward function, a. Also from Corollary 7, the maximum
penalty for choosing a sub-optimal interval length is quadratic in the maintenance “cost,”
∆. Therefore, given any predetermined number of PMs, it is important to perform the PMs
near their optimal times for large values of ∆.
Next, we present a numerical example that illustrates the results established in this sec-
tion. Let a = 0.5, b = 30, ∆ = 5 and L = 50. Figure 11 provides a plot of the total reward
function. As mentioned at the beginning of Section 4.2, the function is discontinuous and
neither concave nor convex. However, as established in Lemma 6 and illustrated in Figure 11,
V (τ, n) is concave in τ for each feasible n. Maximizing the function for a given n (as in equa-
tion (4.8)) yields τn, the optimal maintenance interval length for the given n. In Figure 11, the
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Figure 11: Total reward versus maintenance interval length for linear reward rate of r(t) = −0.5t+
30, L = 50 and f(τ) = 5 ∀τ .
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points (τn, V (τn, n)) are indicated by bold dots. Furthermore, as established in Lemma 8 and
illustrated in Figure 12, V (τn, n) is concave in n. However, only the integral points are fea-
sible solutions. In Figure 12, the non-integer maximum point and the points (n, V (τn, n)) at
integral values of n are indicated by bold dots. To solve for the optimal policy, we substitute
a, b,∆ and L into equation (4.16) which yields n˜ = 1.2, and hence, by Proposition 2, τbn˜c =
τ1 = 22.5 and τdn˜e = τ2 = 13.33. Using equation (4.7), we see that V (τ1, 1) = 1096.88 >
V (τ2, 2) = 1066.67 > V (L, 0) = 875, hence, by equation (4.12), n
∗ = 1 and τ ∗ = 22.5. That
is, in this example, chosen simply to illustrate the solution procedure, PM is performed only
once at time 22.5. From equation (4.17), the maximum total reward loss associated with
performing maintenance at a feasible time different from 22.5 is bounded above by 253.13.
4.2.2 An Ill-behaved Case
If τn does not satisfy (4.6) for at least one n ∈ [1, nmax] ∩ Z+, then Theorem 2 does not
hold and finding the optimal maintenance interval length τ ∗ is no longer straightforward.
We illustrate this situation with a numerical example. Figure 13 provides a plot of the total
reward function for the same scenario depicted in Figure 11, but with f(τ) redefined to be
the quadratic function τ
2
4
+ 0.5. The points (τn, V (τn, n)), n = 1, 2, 3, are indicated by bold
dots; the solid portions of the curves satisfy (4.6) and the dashed portions do not. Note that
τn, n = 1, 2, 3 (and others) do not satisfy (4.6). Hence, the solution procedure established
in Theorem 2 cannot be applied to obtain the optimal interval length τ ∗, and a different
approach must be used.
Let τn be the solution of equation τ =
L
n+1
− f(τ) when solved for τ . Note that τn exists
for any integer n such that 0 < n ≤ nmax− 1 due to assumptions A2 and A3. Proposition 4
establishes that this solution maximizes the total reward if the solution to (4.9) falls outside
the interval given by (4.6).
Proposition 4. For any fixed n ∈ [1, nmax] ∩ Z+, if τn does not satisfy (4.6), then the
maximum total reward is attained at τn.
As a result, to determine the overall optimal interval length τ ∗, we can compare the total
reward function values for each feasible n at its corresponding optimal interval length which
is either τn (if (4.6) holds) or τn (if (4.6) does not hold) and report the one which yields the
greatest total reward function value. In the example illustrated in Figure 13, it is optimal
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to perform n∗ = 19 PMs spaced τ ∗ = τ 19 = 1.46 time units apart. The optimal total reward
is V (τ ∗, n∗) = V (τ 19, 19) = 897.79 > V (L, 0) = 875.0.
4.2.3 Computational Examples
In this section, we more deeply explore how changes in the form of the reward and
lifetime depletion functions affect the optimal policy. More specifically, we let the reward
function, r(t), and the lifetime depletion function, f(τ), assume various forms (Figure 14)
and compute the total reward and the optimal interval length for each combination. Table 18
summarizes these combinations and the corresponding results.
First, consider the effect of the form of r(t) on the maximum total reward and the optimal
interval length. The results in Table 18 indicate that as the total reward in the absence of
any PMs (i.e., the area beneath the curves in Figure 14a) decreases: (i) the maximum total
reward decreases and (ii) the PMs are to be performed with at least the same (or greater)
frequency. For instance, when f(τ) = 0.5, the optimal number of PMs increases from 6 to 8
and then to 11 across the three reward functions depicted in Figure 14a.
Next, consider the effect of the form of f(τ) on the maximum total reward and the
optimal interval length. As the PMs grow more “costly,” i.e., deplete a greater amount of
battery lifetime for any given interval length, the maximum total reward decreases. Also, as
the rate of growth of the lifetime depletion function increases, the optimal number of PMs
increases sharply to maintain a short interval length and reduce PM costs. For instance,
when r(t) = 30
60
· (60− t), the optimal number of PMs increases from 6 to 19 and then to 22
across the three lifetime depletion functions depicted in Figure 14b.
As seen in Table 18, the increase in the optimal number of PMs across the three reward
functions depends on the form of the lifetime depletion function, i.e., the increase is less
pronounced as f(τ) grows faster in τ . This observation is due to the fact that when f(τ)
is independent of the interval length, i.e., is constant, the rate of decrease of r(t) is the
only factor that affects the optimal number of PMs. However, as the rate of growth of f(τ)
increases, the effect of f(τ) on the optimal number of PMs becomes more pronounced and
dwarfs the effect of r(t) on n∗.
86
Table 18: The maximum total reward and the optimal interval length across all combinations of
the reward and lifetime depletion functions plotted in Figure 14 for L = 50.
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Figure 14: (a) Reward functions, r(t); (b) lifetime depletion functions, f(τ).
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4.3 FAILURE PRONE SYSTEMS
In this section, we investigate the case in which the system is prone to failures, which
require immediate reactive maintenance. First, we assume that maintenance (both preven-
tive and reactive) is perfect. Second, we generalize to the case of imperfect, and possibly
damaging, maintenance. For both cases we assume that the lifetime depletion function is
constant and given by ∆.
Here, because the virtual age may be altered at any time due to a random failure,
decisions are made adaptively rather than a priori. We assume that a decision is made at
the beginning of each time period and implemented at the end of the period. Let the state
of the process be given by s = (t, α) ∈ S where t is the remaining system lifetime, α is the
virtual age, and S = {0, 1, 2, . . . , L} × {0, 1, 2, . . . , L}. For t ≤ ∆, the only possible decision
is to ‘do nothing.’ For t > ∆, the possible decisions are to either ‘perform PM’ at the end of
the period or ‘do nothing.’ The overall objective is to maximize the total reward obtained
over the system’s lifetime. Let V ∗(t, α) denote the maximum total reward obtained starting
from virtual age α with remaining lifetime t. Clearly,
V ∗(0, α) = 0 ∀α ≥ 0. (4.18)
Let the random variable Y with p.m.f. pY and c.d.f. FY denote the time to failure starting
from virtual age zero. Also, let hY (α) denote the probability of failure in the next period
given a current virtual age of α, i.e.,
hY (α) =
pY (α + 1)
1− FY (α) . (4.19)
Reactive maintenance (RM) is mandatory upon failure, costs c units of reward and depletes
the remaining system lifetime by ∆. PMs, in contrast, are free, although they also deplete
the remaining system lifetime by ∆. Finally, for ease of notation, let R(α) ≡ R(0, α).
In our formulation, we assume both failures and PM occur at the end of the period. How-
ever, we assume that the former (if occurring) occurs before the latter. Hence, if the system
fails at the end of a period, the extra charge of c units is imposed even if PM is already sched-
uled. We also make the following additional assumption in the remainder of this section:
A4: The random variable Y has increasing failure rate (IFR), i.e., hY (α) is nondecreas-
ing in α.
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4.3.1 Perfect Maintenance
In this section, the virtual age of the system is renewed to zero after every maintenance
activity, both preventive and reactive. Therefore, because ‘do nothing’ is the only possible
decision when t ≤ ∆, the maximum total reward starting from (t, α) is simply
V ∗(t, α) = R(α + 1)−R(α) + hY (α) ·
(
0− c)+ (1− hY (α)) · V ∗(t− 1, α + 1). (4.20)
For t ≥ ∆ + 1,
V ∗(t, α) = R(α + 1)−R(α) + hY (α) ·
(
V ∗(t−∆− 1, 0)− c)
+
(
1− hY (α)
) ·max
 V ∗(t−∆− 1, 0) (perform PM),V ∗(t− 1, α + 1) (do nothing)
 . (4.21)
Finally, given that the initial virtual age of the system is zero, the optimal total reward is
given by V ∗(L, 0).
Lemma 9 establishes that, under no additional conditions, for a given remaining lifetime,
the maximum total reward is nonincreasing in the virtual age. The same is not necessarily
true, however, for the behavior of the total reward function in the remaining lifetime for
any fixed virtual age. For instance, when r(t) = −t + 1100, L = 1000, ∆ = 30, c = 10000
and FY (y) = 1 − e−( y200 )1.5 , under the optimal policy V ∗(0, 930) = 0, V ∗(15, 930) = 23.63
and V ∗(30, 930) = −128.91. In Lemma 10, we present a sufficient condition under which
V ∗(t, α) is monotone in t for any fixed α ∈ [0, L]. The intuition behind the condition, (4.22),
is simply that in order to have a monotone total reward in the remaining lifetime for any
fixed virtual age, the reward obtained in the next period should be no less than the expected
loss due to a possible random failure during that period.
Lemma 9. For any fixed t ∈ [0, L], V ∗(t, α) is nonincreasing in α, α ∈ [0, L− t].
Lemma 10. If
R(L)−R(L− 1) ≥ c · hY (L− 1), (4.22)
then for any fixed α ∈ [0, L], V ∗(t, α) is nondecreasing in t, t ∈ [0, L− α].
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Theorem 3 establishes that the optimal policy is of threshold type in the virtual age, i.e.,
for every t there is a virtual age α∗(t) at and below which it is optimal to do nothing and
above which it is optimal to perform PM. Note that the proof of Theorem 3 relies only on
Lemma 9. Let a∗(t, α) denote the optimal decision at remaining lifetime t and virtual age
α, where ‘0’ corresponds to ‘do nothing’ and ‘1’ corresponds to ‘perform PM.’
Theorem 3. For any system remaining lifetime t, there exists a virtual age α∗(t) such that
a∗(t, α) =
0, if α ≤ α
∗(t),
1, otherwise.
(4.23)
Figure 15 presents the optimal policy for a failure prone system with r(t) = −t + 1100,
L = 1000, ∆ = 30, c = 500 and FY (y) = 1−e−( y400 )3 . Note that because PMs are perfect, any
given remaining system lifetime states with virtual ages greater than L− t are unreachable
and hence excluded. For this problem instance, the failure rate is relatively low, E[Y ] is
approximately 357.2 and performing PM optimally results in a 4.3% greater total expected
reward than performing only reactive maintenance. The optimal PM threshold indicates the
virtual age at and below which it is optimal to do nothing and above which it is optimal to
perform PM for any given remaining system lifetime, as established in Theorem 3.
The optimal PM threshold in Figure 15 has a noticeably irregular shape. Consider the two
failure free sample paths, I, in light grey, and II, in dark grey. Starting from state (1000, 0),
along sample path I the virtual age increases and t decreases until PM is scheduled in state
(763, 237). After performing this PM, the virtual age becomes zero, however, ∆ = 30 units
of lifetime is lost, rendering the process in state (733, 0), and the process continues. Sample
path I indicates that starting from state (L, 0), in the absence of any failures, it is optimal to
perform three PMs. However, as indicated by sample path II, if the system’s initial lifetime is
825, it is optimal to perform PM only twice in the absence of any failures. This difference be-
tween the optimal number of PMs is due to the saw-shaped form of the optimal PM threshold.
Figures 16 and 17 illustrate how the optimal policy is affected by the parameter ∆ and
the c.d.f. of Y , FY , respectively. Figures 16a and 16b present the optimal policy for the same
scenario as in Figure 15 with ∆ = 60 and ∆ = 30, respectively. As expected, a smaller value
of ∆ results in a greater number of states in which PM is optimal.
Figures 17a and 17b compare the optimal policies for four problem instances. In both
figures, r(t) = −t + 1100, L = 1000 and the random time to failure Y has c.d.f. FY (y) =
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1 − e−( yλ )2 , with λ = 200 and λ = 350. In Figure 17a, ∆ = 120 and c = 500, whereas
in Figure 17b, ∆ = 5 and c = 4000. Clearly, the system is less prone to failure when the
expected time to failure is higher, i.e., when λ is larger. As expected, and seen in Figure
17a, when the economic cost of RM (i.e., the value of c) is relatively small compared to
the lifetime depletion of PMs and RMs (i.e., the value of ∆), it is optimal to wait longer
before performing PM thereby relying on RMs to renew the virtual age of the system to zero.
However, as seen in Figure 17b, when the value of c is relatively large compared to the value
of ∆, PM is performed sooner. Also, as seen in Figure 17a, for the majority of the values of t,
the optimal PM threshold when λ = 350 falls below the optimal PM threshold when λ = 200.
This observation is due to the fact that when λ = 350, the system is less prone to failure
and performing PMs more frequently is the only way of maintaining a high reward rate.
4.3.2 Imperfect Maintenance
In this section, we consider the case in which maintenance does not necessarily reset
the system’s virtual age to zero. As explained by Pham and Wang (1996), performing
maintenance sometimes renders the system in a worse condition than it was in prior to the
maintenance action, typically due to human error. In the context of the implanted cardiac
device follow-up care example mentioned in Section 4.1, imperfect maintenance may occur
due to misinterpretation of the transmitted data by technicians/nurses.
Let the random variables Xp and Xr, with p.m.f.s pXp and pXr and c.d.f.s FXp and FXr ,
denote the virtual age of the system after preventive and reactive maintenance, respectively.
We assume that the virtual age after a maintenance action is always less than the maximum
remaining system lifetime, L, i.e., FXp(L− 1) = FXr(L− 1) = 1. We also assume that RM
is immediately performed whenever the virtual age reaches L and the resulting remaining
lifetime is positive, i.e.,
V ∗(t, L) =
0, if t ≤ ∆,∑L−1
x=0 V
∗(t−∆− 1, x) · pXr(x)− c, otherwise.
(4.24)
Because ‘do nothing’ is the only possible action when t ≤ ∆, the maximum total reward
starting from state (t, α) remains the same as in the perfect maintenance scenario and is
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given by equation (4.20). In contrast to the perfect maintenance scenario, for t ≥ ∆ + 1 we
now have
V ∗(t, α) = R(α + 1)−R(α) + hY (α) ·
(
L−1∑
x=0
V ∗(t−∆− 1, x) · pXr(x)− c
)
+
(
1− hY (α)
) ·max

∑L−1
x=0 V
∗(t−∆− 1, x) · pXp(x) (perform PM),
V ∗(t− 1, α + 1) (do nothing)
 .(4.25)
Finally, given that the initial virtual age of the system is zero, the optimal total reward is
given by V ∗(L, 0).
Figure 18 presents an example optimal policy for a failure-prone system subject to im-
perfect preventive and reactive maintenance with r(t) = −t + 1100, L = 1000, c = 60,
∆ = 120, FY (y) = 1 − e−( y250 )2 and pXp(x) and pXr(x) given by Table 19. Clearly, this
optimal policy is not of threshold type. Also, note that as opposed to the perfect mainte-
nance scenario, here, under imperfect, possibly damaging maintenance, some of the states
in {(t, α) ∈ S : α > L − t} are reachable. For instance, if the system is preventively
maintained at t = 980 in the absence of any prior RMs, the system may transit to state
(980− 120− 1, 990) = (859, 990) with probability 0.07.
Now, let the random variable X with p.m.f. pX and c.d.f. FX denote the virtual age of
the system after any maintenance activity, i.e., either preventive or reactive maintenance.
Analogous to Lemmas 9 and 10, Lemma 11 establishes the monotonicity of the total reward
function V ∗(t, α) in both t and α under the sufficient condition given by equation (4.22). In
contrast to Lemma 9, Lemma 11 requires condition (4.22) for establishing the monotonicity
of the total reward function in α, mainly because of the additional boundary condition given
by equation (4.24). Furthermore, Theorem 4, which is analogous to Theorem 3, establishes
that for any fixed system remaining lifetime t, the optimal policy is of control-limit type in
α < L. (Recall that at α = L, RM is instantaneously initiated.)
Lemma 11. Let the random variable X denote the virtual age of the system after both
preventive and reactive maintenance. If equation (4.22) holds, then
(i) V ∗(t, α) is nonincreasing in α,
(ii) V ∗(t, α) is nondecreasing in t.
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Figure 18: The shaded area indicates (t, α) ∈ S for which the optimal action is to perform PM
when r(t) = −t + 1100, L = 1000, c = 60, ∆ = 120, FY (y) = 1 − e−(
y
250
)2 and pXp(x) and pXr(x)
are given by Table 19.
Table 19: Probability distribution of the virtual age after preventive maintenance and reactive
maintenance.
X 0 50 100 150 990
pXp(x) 0.7 0.08 0.08 0.07 0.07
pXr(x) 0.68 0.27 0.03 0.02 0.00
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Theorem 4. Let the random variable X denote the virtual age of the system after both
preventive and reactive maintenance. If equation (4.22) holds, then for any system remaining
lifetime t, there exists a virtual age α∗(t) such that for all α < L,
a∗(t, α) =
0, if α ≤ α
∗(t),
1, otherwise.
(4.26)
Lastly, Lemma 12 establishes that for any given system remaining lifetime t and virtual
age α, the maximum total reward is less if the virtual age of the system after maintenance
is stochastically larger.
Lemma 12. Let V 1(t, α) and V 2(t, α) be two problem instances given by (4.20),(4.24)-(4.25)
for which the random variable X i denotes the virtual age of the system after both preventive
and reactive maintenance for i = 1, 2. If X2  X1, i.e., X2 is stochastically larger than X1,
then for any given state (t, α), V 1(t, α) ≥ V 2(t, α).
Figure 19 presents the optimal PM threshold for three problem instances (referred to as
problems I-III) with r(t) = −t + 1100, L = 1000, ∆ = 50, c = 4000, FY (y) = 1 − e−( y350 )2
and different maintenance outcomes: in I, both PM and RM are perfect, in II, PM is perfect
and RM is imperfect, and in III, PM and RM have identical, imperfect outcomes. Table 19
provides the probability distribution of the virtual age after RM for problems II and III. For
illustrative purposes, the unreachable states are not excluded from Figure 19. Consistent
with Theorem 4, the optimal policy for problem III is of threshold type. As shown in
Figure 19, the optimal PM threshold for problem II is lower than that for I because RMs
are imperfect in problem II, whereas in problem I, they are perfect. Therefore, it is optimal
to perform PMs more frequently in II. In problem III, PMs are imperfect. Therefore, among
the three problem instances, performing PM is clearly least beneficial in problem III, hence
the highest optimal PM threshold. In terms of the total reward, problems I-III generate
822, 188, 815, 031 and 807, 853 in units of reward starting from state (1000,0), respectively.
This decrease in the reward from problem I, with perfect PM and RM, to problem III, with
imperfect, but identical PM and RM outcomes, is consistent with Lemma 12.
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)2 where pXr(x) is given by Table 19.
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4.4 CONCLUSION
In this chapter, we consider a system with a deterministic initial lifetime that generates
reward at a decreasing rate as its virtual age increases. Maintenance can be performed to de-
crease the system’s virtual age, and hence, increase the reward rate. However, maintenance
shortens the remaining lifetime of the system. Given this trade-off, we analyze the lifetime-
reward-maximizing maintenance policies under various maintenance scenarios. This problem
is motivated in part by the practice of remotely monitoring battery-powered devices that
periodically transmit information about their condition and performance to a remote data
center, e.g., implanted cardiac devices. In this application, the more frequent the transmis-
sions, the more timely the collected data, but the greater the reduction in battery longevity.
First, we consider non-failure-prone systems and develop a solution procedure to obtain
the reward-maximizing maintenance interval under the assumption that maintenance restores
the virtual age to zero. In this setting, we also derive closed form results for the special case
of constant maintenance life depletion. Next, we investigate failure prone systems under
both perfect and imperfect maintenance where failures not only incur an economic cost, but
also shorten the system’s lifetime. We formulate stochastic dynamic programs under both
perfect and imperfect maintenance, prove the monotonicity of the total reward in both the
system’s virtual age and the remaining lifetime (under certain conditions) and establish a
structural property of the optimal maintenance policy.
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5.0 CONCLUSIONS AND FUTURE RESEARCH
In this dissertation, we address three problems concerning follow-up care for patients with
CIEDs. This work is particularly timely given the lack of clinical guidelines for management
of patients with implanted cardiac devices, despite the aging population and the ever growing
number of these patients. There is a tremendous need for clinicians to justify their actions and
to be able to make challenging treatment choices based on particular patient characteristics;
however, mostly due to large policy spaces, traditional clinical approaches are not viable to
provide such solutions. Here, we use a host of mathematical methodologies and powerful
optimization techniques to develop customized treatment policies that provide patients with
better quality of care. The resulting policies, which are easy to implement, can decrease the
burden on the healthcare system by reducing the number of surgeries, in-office visits, and so
on, without compromising the patients’ well-being.
This work contributes to the operations research and clinical literature in novel and
important ways. In Chapter 2, we develop MDP models to determine patient-specific CIED
lead abandon/extract policies for four major types of CIEDs as a function of patient age and
the age of every implanted lead. We carefully calibrate these models and present insightful
numerical results, including comparisons to heuristic policies that are commonly used in
practice. We observe that under the optimal policy, the abandon/extract decision for each
failed lead does not depend on the exact ages of all implanted leads; this decision only
depends on the lead’s age, patient age, lead’s age rank among the lead ages, the total number
of implanted leads and, in the case of multi-chamber devices, the age of the working lead(s).
Hence, the optimal policy is easy to implement. Additionally, we show that in comparison
to the commonly used heuristic policies, following the optimal policy can extend an average
patient’s expected lifetime by up to 1.2 years and decrease the likelihood of device related
death by up to 94%. Note that by using MDPs, we may only compare the expected values
(e.g., the expected lifetime of patients) under various policies. Hence, in the future, we
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may build simulation models to measure the variability between the results under different
policies and possibly introduce new metrics that are not easy to measure using MDPs.
Chapter 3 presents a MDP model to optimally time the otherwise conservatively per-
formed ICD generator replacement surgeries with the objective of maximizing the patient’s
expected lifetime. We carefully calibrate this model using clinical data and expert opinion
to obtain results tailored for given individuals. Our large computational study shows that
following the optimal policy both extends the patient expected lifetime and decreases the
total expected number of replacements. Under the optimal policy, patient expected lifetime
may be extended by up to 40.6 weeks (0.78 years). Additionally, patients undergoing initial
implantation at age 30-40, 41-60, and 61-80 experience an approximate decrease in the total
expected number of replacements of 8-14%, 8-15% and 8-19%, respectively, while achieving
the same or greater expected lifetime.
Finally, in Chapter 4, inspired by the practice of remote monitoring of CIEDs, we build
mathematical models to examine the trade-off between battery longevity and the frequency
of life-depleting, remote follow-ups of cardiac devices in a finite horizon setting. These
stylized models capture novel battery life considerations and yet are compact and amenable
to structural analysis. In future research, these models may serve as a basis for a more
clinically relevant investigation of the problem based on clinical data.
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APPENDIX A
EXTENDED DISCUSSION FOR CHAPTER 2
A.1 DUAL-CHAMBER DEVICES WITH IDENTICAL LEADS: MODEL
FORMULATION
Similar to Sections 2.2.1 and 2.2.2.1, let the random variable X with p.m.f. pX , c.d.f. FX
and survival function F¯X denote the time to failure for a new lead. We also assume that
all leads survive up to specified maximum age, ¯`, with some positive probability. Lastly, for
t = T , the maximum total expected reward is given by equation (2.16).
Decision epoch due to infection. For t < T , first consider the case in which θ = 0.
Here, the total expected reward νt(n) is given by equation (2.17), where
ϕi(t, n) = pX(n)
1{i∈{1,2}}+2·1{i∈{0}} · F¯X(n)1{i∈{1,2}}
·
(
rt(n) +
n−1∑
m=1
ρ(m) · Vt+m(`′(m), w, 0)
+η(n) · γ · Vt+n(`′(n),1{i∈{1,2}}, 1)
)
, i ∈ {0, 1, 2} (A.1)
ϕ∆(t, n) = F¯X(n− 1)2 ·
(
rt(n) +
n−1∑
m=1
ρ(m) · Vt+m(`′(m), w, 0)
)
. (A.2)
Equations (A.1)-(A.2) are analogous to equation (2.18). Note that in (A.1)-(A.2), because
the current leads are of the same age and type at patient age t+n, without loss of generality,
we assume the lead with the smaller index continues working; hence, when i = 2, w = 1
in the last expression in equation (A.1). Finally, for t < T , the maximum total expected
reward at a decision epoch with θ = 0 is given by equation (2.19).
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Decision epoch due to failure. Next, for t < T , consider the case in which θ = 1.
We redefine `′′(a,m) from Section 2.2.2.1 to denote the lead age vector m years after a tran-
sition from state st = (`, w, 1) under action a, i.e., `
′′(a,m) = [(`′′(1), `
′′
(2)), . . . , `
′′
(L)], where
`′′(1) and `
′′
(2) denote the ages of the current P leads at patient age t+m, when ordered non-
increasingly, and `′′(i), i ∈ {3, . . . , L}, denotes the age of the ith oldest, previously abandoned
lead, if present, and assumes the value −1, otherwise. Hence, the vector `′′(a,m) is as given
in Section 2.2.2.1, with the exception that its two first components are now ordered non-
increasingly. For example, let ¯` = 40 and consider a decision epoch at which the process is
in state s60 = ([(8, 3), 5, 4,−1], 2, 1), i.e., `(1) = 8, `(2) = 3, `(3) = 5, `(4) = 4, `(5) = −1, w = 2
and θ = 1. Because the only working lead is the younger, current P lead, a ⊆ {1, 3, 4}. Now,
suppose action a = {3} is taken and the newly implanted lead fails 3 years later. Therefore,
from equation (2.20), the first two components of `′′(a,m) are 3 and 6 and from equation
(2.21), ψ{[(8, 3), 5, 4,−1], {3}, 3} = {11, 7}; hence, at the next decision epoch the process is
in state s63 = ([(6, 3), 11, 7,−1], ·, ·), i.e., `′′(1) = 6, `′′(2) = 3, `′′(3) = 11, `′′(4) = 7, `′′(5) = −1.
The total expected reward ut(`, w, a, n) is given by equation (2.22), where for w = 0,
υi(t, `, w, a, n), i ∈ {1, . . . , 4}, is given by a set of equations similar to (A.1)-(A.2), in which
`′(m) and `′(n) are substituted with `′′(a,m) and `′′(a, n), respectively, and for w > 0,
υi(t, `, w, a, n) = Pr(X = `(w) + n|X > `(w))1{i∈{0,2}} · pX(n)1{i∈{0,1}}
·Pr(X > `(w) + n|X > `(w))1{i∈{1}} · F¯X(n)1{i∈{2}}(
rt(n) +
n−1∑
m=1
ρ(m) · Vt+m(`′′(a,m), w, 0)
+η(n) · γ · Vt+n(`′′(a, n), i, 1)
)
, i ∈ {0, 1, 2} (A.3)
υ∆(t, `, w, a, n) = Pr(X > `(w) + n− 1|X > `(w)) · F¯X(n− 1)
·
(
rt(n) +
n−1∑
m=1
ρ(m) · Vt+m(`′′(a,m), w, 0)
)
. (A.4)
Equations (A.3)-(A.4) are analogous to equation (2.23). Therefore, when θ = 1, the maxi-
mum total expected reward is given by equation (2.24).
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A.2 CRT-D DEVICES: MODEL FORMULATION
Similar to Section 2.2.2.1, let the random variable Xj, j = 1, 2, with p.m.f. pXj , c.d.f.
FXj and survival function F¯Xj denote the time to failure for a new P lead and a new D lead,
respectively, and assume that all leads survive up to a specified maximum age, ¯`, with some
positive probability. Additionally, we let µ((`, w, θ), a) be given by equation (2.15), where
φ(w, θ) is given by equation (2.27). We redefine Vt(`, w, θ) to denote the maximum total
expected reward starting from state st = (`, w, θ). Clearly, VT (`, w, θ) = 0.
Decision epoch due to infection. For t = T , first consider the case in which θ = 0.
Redefine `′(m) to denote the lead age vector m years after an infection for a CRT-D device,
i.e., `′(m) = [(m,m,m),−1,−1]. Also, redefine νt(n) to denote the total expected reward
obtained starting from state st = (`, w, 0), conditional on surviving the infection and the
requisite lead procedures, weighted by the likelihood of the next lead failure occurring in n
periods, i.e.,
νt(n) =

∑
i∈{3¯,...,3} ϕi(t, n), if n < T − t,
ϕ∆(t, n), if n = T − t,
(A.5)
where
ϕi(t, n) = F¯X1(n)
1{i∈{3¯,2¯,1}} · pX1(n)1{i∈{1¯,0,2,3}} · F¯X1(n)1{i∈{3¯,1¯,2}} · pX1(n)1{i∈{2¯,0,1,3}}
·F¯X2(n)1{i∈{2¯,1¯,3}} · pX2(n)1{i∈{3¯,0,1,2}} ·
(
rt(n) +
n−1∑
m=1
ρ(m) · Vt+m(`′(m), w, 0)
+η(n) · γ · Vt+n(`′(n),1{i∈1,2} + 2¯ · 1{i∈2¯,1¯} + i · 1{i∈3¯,0,3}, 1)
)
,
i ∈ {3¯, . . . , 3} (A.6)
ϕ∆(t, n) = F¯X1(n− 1)2 · F¯X2(n− 1) ·
(
rt(n) +
n−1∑
m=1
ρ(m) · Vt+m(`′(m), w, 0)
)
. (A.7)
Equations (A.6)-(A.7) are analogues to equations (2.18) and (A.1)-(A.2). More specifically,
equation (A.6) corresponds to the total expected reward obtained when w = i at patient age
t+ n, with the exception that w = 1 when i = 2 and w = 2¯ when i = 1¯. The reason is that,
without loss of generality, we assume if exactly one of the current P leads fail at t+ n while
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the leads are of the same age, the one with the smaller index continues working. Therefore,
for t < T , the maximum total expected reward at a decision epoch with θ = 0 is given by
Vt(`, w, 0) = µ((`, w, 0), a¯(`)) ·
T−t∑
n=1
νt(n), ∀w ∈ W. (A.8)
Decision epoch due to failure. Next, for t < T , consider the case in which θ = 1. We
redefine `′′(a,m) from Section 2.2.2 to denote the lead age vector m years after a transition
from state st = (`, w, 1) under action a, i.e., `
′′(a,m) = [(`′′(1), `
′′
(2), `
′′
(3)), . . . , `
′′
(L)], where `
′′
(1)
and `′′(2) denote the ages of the current P leads at patient age t + m, when ordered non-
increasingly, `′′(3) denotes the age of the current D lead, and `
′′
(i), i ∈ {4, . . . , L}, denotes
the age of the ith oldest, previously abandoned lead, if present, and assumes the value −1,
otherwise. For j = 1, 2, let
ˆ`′′
(j) =
m, if w = 0, or w ∈ {1, 2, 3} and j 6= w, or w ∈ {3¯, 2¯, 1¯} and j¯ = w,`(j) +m, otherwise. (A.9)
Also, we have
`′′(3) =
m, if w = 3¯, 0, 1, 2,`(j) +m, otherwise. (A.10)
Lastly, we modify the set ψ(`, a,m,w) to be
ψ(`, a,m,w) =
{
min{`(i) +m, ¯`} : 1 ≤ i ≤ L, i /∈ a, `i 6= −1, i 6= w, i¯ = w or w = 0
}
.
(A.11)
Hence, the first two components of vector `′′(a,m) are given by equation (A.9), where
the components ˆ`′′(1) and ˆ`
′′
(2) are ordered non-increasingly, the third component of vector
`′′(a,m) is given by equation (A.10), and its remaining components are given by the non-
increasingly ordered members of the set ψ(`, a,m,w), with the unfilled components set to
−1. For example, let ¯` = 40 and consider a decision epoch at which the process is in
state s60 = ([(6, 3, 4), 9,−1], 1¯, 1), i.e., `(1) = 6, `(2) = 3, `(3) = 4, `(4) = 9, `(5) = −1,
w = 1¯ and θ = 1. Because the only working leads are the younger, current P lead and
the current D lead, a ⊆ {1, 4}. Now, suppose action a = ∅ is taken and the newly im-
planted P lead fails 5 years later. Therefore, from equation (A.9), ˆ`′′(1) = 5, ˆ`
′′
(2) = 8, from
equation (A.10), `′′(3) = 9, and from equation (A.11), ψ([(6, 3, 4), 9,−1], ∅, 3) = {11, 14};
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hence, at the next decision epoch the process is in state s65 = ([(8, 5, 9), 14, 11], ·, ·), i.e.,
`′′(1) = 8, `
′′
(2) = 5, `
′′
(3) = 9, `
′′
(4) = 14, `
′′
(5) = 11.
Now, we redefine ut(`, w, a, n) to denote the total expected reward obtained starting from
state st = (`, w, 1) under action a, conditional on the next lead failure occurring in n periods
and weighted by its likelihood, i.e.,
ut(`, w, a, n) =

∑
i∈{3¯,...,3} υi(`, w, a, n), if n < T − t,
υ∆(`, w, a, n). if n = T − t,
(A.12)
If w = 3¯, the only working leads are the current P leads; hence
υi(`, 3¯, a, n) = Pr(X1 > `(1) + n|X1 > `(1))1{i∈{3¯,2¯,1}}
·Pr(X1 = `(1) + n|X1 > `(1))1{i∈{1¯,0,2,3}}
·Pr(X1 > `(2) + n|X1 > `(2))1{i∈{3¯,1¯,2}}
·Pr(X1 = `(2) + n|X1 > `(2))1{i∈{2¯,0,1,3}}
·F¯X2(n)1{i∈{2¯,1¯,3}} · pX2(n)1{i∈{3¯,0,1,2}}
·
(
rt(n) +
n−1∑
m=1
ρ(m) · Vt+m(`′′(a,m), w, 0)
+η(n) · γ · Vt+n(`′′(a, n), i, 1)
)
, i ∈ {3¯, . . . , 3} (A.13)
υ∆(`, 3¯, a, n) = Pr(X1 > `(1) + n− 1|X1 > `(1)) · Pr(X1 > `(2) + n− 1|X1 > `(2))
·F¯X2(n− 1) ·
(
rt(n) +
n−1∑
m=1
ρ(m) · Vt+m(`′′(a,m), w, 0)
)
. (A.14)
Analogous to equation (A.6), equation (A.13) corresponds to the total expected reward ob-
tained when w = i at patient age t+n. Equation (A.14) is also analogous to equation (A.7).
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The total expected reward ut(`, w, a, n) for w ∈ {2¯, 1¯, 0, 1, 2, 3} is given by the same logic. If
w = 2¯, the older, current P lead and the current D lead are working; hence,
υi(`, 2¯, a, n) = Pr(X1 > `(1) + n|X1 > `(1))1{i∈{3¯,2¯,1}}
·Pr(X1 = `(1) + n|X1 > `(1))1{i∈{1¯,0,2,3}}
·F¯X1(n)1{i∈{3¯,1¯,2}} · pX1(n)1{i∈{2¯,0,1,3}}
·Pr(X2 > `(3) + n|X2 > `(3))1{i∈{2¯,1¯,3}}
·Pr(X2 = `(3) + n|X2 > `(3))1{i∈{3¯,0,1,2}}
·
(
rt(n) +
n−1∑
m=1
ρ(m) · Vt+m(`′′(a,m), w, 0)
+η(n) · γ · Vt+n(`′′(a, n), i, 1)
)
, i ∈ {3¯, . . . , 3} (A.15)
υ∆(`, 2¯, a, n) = Pr(X1 > `(1) + n− 1|X1 > `(1)) · F¯X1(n− 1)
·Pr(X2 > `(3) + n− 1|X2 > `(3))
·
(
rt(n) +
n−1∑
m=1
ρ(m) · Vt+m(`′′(a,m), w, 0)
)
. (A.16)
Analogously, if w = 1¯, the younger, current P lead and the current D lead are working;
hence, υi(`, 1¯, a, n) and υ4(`, 1¯, a, n) are given by equations (A.15) and (A.16) in which ‘`(1)’
is replaced with ‘`(2).’ If w = 1, 2, the only working lead is the older and the younger current
P lead, respectively; hence
υi(`, w, a, n) = Pr(X1 > `(w) + n|X1 > `(w))1{i∈{3¯,2¯,1}}
·Pr(X1 = `(w) + n|X1 > `(w))1{i∈{1¯,0,2,3}}
·F¯X1(n)1{i∈{3¯,1¯,2}} · pX1(n)1{i∈{2¯,0,1,3}} · F¯X2(n)1{i∈{2¯,1¯,3}} · pX2(n)1{i∈{3¯,0,1,2}}
·
(
rt(n) +
n−1∑
m=1
ρ(m) · Vt+m(`′′(a,m), w, 0)
+η(n) · γ · Vt+n(`′′(a, n), i, 1)
)
, i ∈ {3¯, . . . , 3} (A.17)
υ∆(`, w, a, n) = Pr(X1 > `(w) + n− 1|X1 > `(w)) · F¯X1(n− 1) · F¯X2(n− 1)
·
(
rt(n) +
n−1∑
m=1
ρ(m) · Vt+m(`′′(a,m), w, 0)
)
. (A.18)
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If w = 0, all the leads are failed; hence,
υi(`, 0, a, n) = F¯X1(n)
1{i∈{3¯,2¯,1}} · pX1(n)1{i∈{0,3}} · F¯X1(n)1{i∈{3¯}} · pX1(n)1{i∈{2¯,0,1,3}}
·F¯X2(n)1{i∈{2¯,3}} · pX2(n)1{i∈{3¯,0,1}}
·
(
rt(n) +
n−1∑
m=1
ρ(m) · Vt+m(`′′(a,m), w, 0)
+η(n) · γ · Vt+n(`′′(a, n), i, 1)
)
, i ∈ {3¯, 2¯, 0, 1, 3} (A.19)
υ2(`, 0, a, n) = υ1(`, 0, a, n) (A.20)
υ1¯(`, 0, a, n) = υ2¯(`, 0, a, n) (A.21)
υ∆(`, 0, a, n) = F¯X1(n− 1)2 · F¯X2(n− 1)
·
(
rt(n) +
n−1∑
m=1
ρ(m) · Vt+m(`′′(a,m), w, 0)
)
. (A.22)
Equations (A.19)-(A.22) are similar in structure to equations (A.6)-(A.7). Lastly, if w = 3,
the only working lead is the current D lead; hence
υi(`, 3, a, n) = F¯X1(n)
1{i∈{3¯,2¯,1}} · pX1(n)1{i∈{0,3}} · F¯X1(n)1{i∈{3¯}} · pX1(n)1{i∈{2¯,0,1,3}}
·Pr(X2 > `(w) + n|X2 > `(3))1{i∈{2¯,3}} · Pr(X2 = `(3) + n|X2 > `(3))1{i∈{3¯,0,1}}
·
(
rt(n) +
n−1∑
m=1
ρ(m) · Vt+m(`′′(a,m), w, 0)
+η(n) · γ · Vt+n(`′′(a.n), i, 1)
)
, i ∈ {3¯, 2¯, 0, 1, 3} (A.23)
υ2(`, 3, a, n) = υ1(`, 3, a, n) (A.24)
υ1¯(`, 3, a, n) = υ2¯(`, 3, a, n) (A.25)
υ∆(`, 3, a, n) = F¯X1(n− 1)2 · Pr(X2 > `(3) + n− 1|X2 > `(3))
·
(
rt(n) +
n−1∑
m=1
ρ(m) · Vt+m(`′′(a,m), w, 0)
)
. (A.26)
Therefore, when θ = 1, the maximum total expected reward is given by (2.24), where
µ((`, w, 1), a) is updated as defined earlier in this section and V (`′′(a, 0), w, 0) is given by
equation (A.8).
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A.3 MODEL CALIBRATION
Probability of surviving the competing risks of death, λ(`). From Saxon et al.
(2010), patients on average receive ICD devices at age 66 and their one- and five-year survival
probabilities are 92% and 68%, respectively. By applying the DEALE method to these values,
the former survival probability results in an excess rate of mortality of 0.028, whereas the
latter yields 0.022. Hence, we use their midpoint, i.e., 0.025, as the excess rate of mortality
for patients with ICD devices, regardless of their age at initial implantation. Applying the
same method to CRT-D data yields an excess rate of mortality of 0.075.
Distribution of the time to failure of a new lead, pX(x) (or pX1(x)) and pX2(x).
As discussed in Section 2.4, to obtain pX(x), we fit a Gompertz distribution (Cox and Oakes
1984) to the appended data and discretize to obtain a p.m.f., pX˜(x), which we then adjust so
that it exhibits constant hazard after age `. More specifically, we solve the following convex
optimization problem that guarantees the probability distribution pX(x) (i) is “smooth,”
(ii) has a mean as close as possible to the mean of the p.m.f. and (iii) has constant hazard
after `:
min
pX ,hX ,c
( ¯`∑
i=1
i · pX(i)−
¯`∑
i=1
i · pX˜(i)
)2
(A.27a)
subject to
¯`∑
i=1
pX(i) = 1, (A.27b)
hX(i) =
pX(i)
F¯X(i− 1) = c, i = `, `+ 1, . . . ,
¯`− 1, (A.27c)
hX(¯`) =
pX(¯`)
F¯X(¯`− 1)
= 1, (A.27d)
hX(i) =
pX(i)
F¯X(i− 1) ≤
pX(i+ 1)
F¯X(i)
, i = 1, 2, . . . , `− 1, (A.27e)
|pX(i)− pX˜(i)| ≤ 1, i = 1, 2, . . . , 8, (A.27f)
pX(i)− pX(i− 1) ≤ 2, i = 9, . . . , `, (A.27g)
pX(i) ≥ 0, hX(i) ≥ 0, i = 1, 2, . . . , `− 1, (A.27h)
c ≥ 0. (A.27i)
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Table 20: Estimated hazard function for both pacemaker and ICD leads for all values of ω.
(a) pacemaker lead
w = 0.45 w = 0.5 w = 0.55
0 0 0 0
1 0.005980 0.006197 0.006456
2 0.006341 0.006597 0.006898
3 0.006817 0.007114 0.007454
4 0.007444 0.007783 0.008158
5 0.008276 0.008651 0.009053
6 0.009380 0.009779 0.010190
7 0.010849 0.011247 0.011638
8 0.012806 0.013160 0.013483
9 0.023678 0.024070 0.024432
10 0.035217 0.035662 0.036078
11 0.047868 0.048387 0.048876
12 0.062212 0.062833 0.063423
13 0.079067 0.079835 0.080568
14 0.099675 0.099492 0.091316
15 0.108319 0.099492 0.091316
16-68 0.108324 0.099492 0.091317
69 1 1 1
Lead age
(yrs)
Estimated hazard function when
(b) ICD lead
w = 0.4 w = 0.45 w = 0.5
0 0 0 0
1 0.030700 0.032162 0.033672
2 0.032678 0.033800 0.034924
3 0.034808 0.035541 0.036239
4 0.037104 0.037395 0.037624
5 0.039584 0.039371 0.039082
6 0.042265 0.041480 0.040622
7 0.045168 0.043736 0.042251
8 0.048320 0.046069 0.043754
9 0.063774 0.060759 0.052099
10 0.073465 0.063082 0.052099
11 0.073465 0.063082 0.052099
12 0.073465 0.063082 0.052099
13 0.073465 0.063082 0.052099
14 0.073465 0.063082 0.052099
15 0.073465 0.063082 0.052099
16-68 0.073465 0.063082 0.052099
69 1 1 1
Lead age
(yrs)
Estimated hazard function when
The objective function minimizes the difference between the means of X˜ and X. Constraint
(A.27b) guarantees that pX is a discrete probability distribution. Constraints (A.27c) and
(A.27d) ensure the constant hazard property after age ` and certain lead failure at age ¯`,
respectively. Constraint (A.27e) enforces the increasing failure rate property before age `.
Constraint (A.27f) ensures the estimated distribution closely follows pX˜(x) in the first 8
years, for which published data are readily available. Constraint (A.27g) ensures a smooth
distribution after the first 8 years by limiting the magnitude of variation in the estimated
probabilities from one year to another. Finally, we let 1 = 0.005 and 2 = 0.01 and solve the
model given by (A.27) using GAMS/Baron (BARON version 9.0.6. Built: LNX Sat May 22
23:10:41 EDT 2010, with GAMS Rev 235 LEX-LEI 23.5.1 x86 64/Linux). Table 20 provides
the estimated hazard functions.
We obtain the values of the decision variables by up to eight significant digits. To ensure
that the constant hazard property after ` is not compromised due to possible precision errors,
we use the values of variables hX(i), i = 1, . . . , ¯`, and c to estimate the values of pX(i), i =
1, . . . , ¯`, when needed. It is worth mentioning that the estimated and the software-generated
optimal solution values of pX(i), i = 1, . . . , ¯`, match by up to seven significant digits.
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Table 21: Estimated probability of death following lead extraction, β−1(`).
a b c d - low d - avg d - high
 low average   high 1 -6.182234 -0.01981 -0.00051 0 0.000511
0 0.001555 0.002066 0.002577 0.000000 0.000000 0.000000
1 0.001821 0.002332 0.002843 0.000000 0.000000 0.000000
2 0.002116 0.002627 0.003138 0.000000 0.000000 0.000000
3 0.002440 0.002951 0.003462 0.000000 0.000000 0.000000
4 0.002798 0.003309 0.003820 0.000000 0.000000 0.000000
5 0.003190 0.003701 0.004212 0.000000 0.000000 0.000000
6 0.003619 0.004130 0.004641 0.000000 0.000000 0.000000
7 0.004089 0.004600 0.005111 0.000000 0.000000 0.000000
8 0.004601 0.005112 0.005623 0.000000 0.000000 0.000000
9 0.005158 0.005669 0.006180 0.000000 0.000000 0.000000
10 0.005764 0.006275 0.006786 0.000000 0.000000 0.000000
11 0.006420 0.006931 0.007442 0.000000 0.000000 0.000000
12 0.007130 0.007641 0.008152 0.000000 0.000000 0.000000
13 0.007897 0.008408 0.008919 0.000000 0.000000 0.000000
14 0.008723 0.009234 0.009745 0.000000 0.000000 0.000000
15 0.009612 0.010123 0.010634 0.000000 0.000000 0.000000
16 0.010566 0.011077 0.011588 0.000000 0.000000 0.000000
New
Probability of death following
lead extraction,              . 
Lead age,   . 
(yrs)
𝜷−𝟏(ℓ)  
ℓ 
    + 
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Probability of death following extraction of a lead of age `, β−1(`). Recall that
Table 3 summarizes the published data on lead extraction procedure-induced mortality. In
this table, the mean lead dwell time is the reported mean lead implant duration in each study.
Note that in Table 3, to obtain the number of deceased patients, we consider all procedure-
induced deaths during the perioperative period, from admission to recovery, plus a short
term follow-up whenever data is available. We exclude infection-induced mortality when the
indication of death is given. Finally, the observed mortality following lead extraction is given
by the ratio of the number of reported deaths to the number of extracted leads.
The number of reported deaths in Table 3 are obtained as follows. Byrd et al. (1999)
report one instance of death in 2,338 patients undergoing lead extraction. In a study by Ep-
stein et al. (1999), using the three comparably safe and effective methods of lead extraction,
four, one and two out of, respectively, 248, 177, 438 patients died during the perioperative
period. At one month follow-up, complications associated with lead extraction had resulted
in death in three additional patients in the first group and four additional patients in the
third group, resulting the final death tally of seven, one and six as reported in Table 3. In
a study by Kennergren (1999), no mortality is reported during the somewhat short mean
hospital stay of three days. Wilkoff et al. (1999) report one case of mortality out of 153
patients. Byrd et al. (2002) report 13 in-hospital deaths in 1,684 patients who underwent
lead extraction. In this study, 10 additional patients died in the following 69 ± 66 days.
However, because of the somewhat long mean follow-up length and the unspecified indica-
tion of death, we use 13 as the number of procedure-induced deaths. Saad et al. (2003),
Roux et al. (2007) and Bongiorni et al. (2008) report one, one and three cases of death,
respectively. No in-hospital death was reported by Jones IV et al. (2008). In a study by
Agarwal et al. (2009), only one case of death is observed. In a study by Kennergren et al.
(2009), 592 patients underwent 647 extraction procedures, resulting in the death of three;
however, one death is excluded from Table 3 as it was caused by infection. Finally, in a
study by Wazni et al. (2010), out of 1,449 patients, 27 died during the hospitalization, out
of which only four were specified as lead extraction procedure-induced.
As discussed in Section 2.4, to estimate β−1(`), we fit a Gompertz function to the observed
probability of death reported in Table 3, which we then shift by ±10% of its mid-range value
to obtain two additional estimates for β−1(`). Table 21 reports the estimated probability of
death following lead extraction for the three resulting functions.
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Probability of surviving infection, δ. Sohail et al. (2007a) report seven out of 189
patients with infected pacemaker or ICD devices died during hospitalization and two addi-
tional patients died following a three month follow-up, partially due to the mismanagement
of the infection. In this study, 40 patients were lost to follow-up. Considering that two out
of 142 patients died in a three month period after the infection occurred, we estimate the
total number of deaths from direct or indirect consequences of the infection to be ten out
of 189 patients, i.e., almost 5%. Hence, a point estimate for the probability of surviving
infection is on the order of 95%.
Because the total number of extracted leads and the mean lead dwell time is not given in
the study by Sohail et al. (2007a), we use Table 3 to obtain a point estimate for the average
ratio of extracted leads to patients. First, note that although the number of extracted leads
in the study by Saad et al. (2003) is reported as 161 in Table 3, the total number of leads
removed in this study is 262. (The number 161 is the size of a subgroup of leads to which
the analysis in the study by Saad et al. (2003) is restricted.) An estimated ratio of extracted
leads to patients from the studies reported in Table 3 is as follows:
1
14
·
(
3, 540
2, 338
+
413
248
+
201
177
+
671
438
+
179
149
+
244
153
+
2, 561
1, 684
+
262
161
+
270
175
+
2, 065
1, 193
+
975
498
+
456
212
+
1, 032
592
+
2, 405
1, 449
)
' 1.6. (A.28)
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APPENDIX B
PROOFS
B.1 PROOFS FOR CHAPTER 3
Proof of Lemma 1. Clearly, the lemma holds for patient age ` = ¯`. For ` < ¯`, the proof
follows by induction on u. We discretize the state space in the u dimension using δ¯ given by
equation (3.5). Therefore, for any fixed patient age ` < ¯` and remaining battery capacity
u = δ¯, by equations (3.2)-(3.5), we have
V (`, δ¯) = max{R(`), C(`, δ¯)}
= max
{
1 + (1− α∆(`)) · λ(`) · V (`+ 1, u¯),
1 +
g(δ¯)∑
d=0
λ(`) · V (`+ 1, δ¯ − δ − d · δc) · pD(d)
}
≥ 0. (B.1)
Hence, V (`, δ¯) ≥ V (`, 0) = 0.
Now, suppose for any given ` < ¯` and u = δ¯, 2δ¯, . . . , (k − 1)δ¯ we have
V (`, u+ δ¯) ≥ V (`, u). (B.2)
Next, we show that V (`, u+ δ¯) ≥ V (`, u) for u = kδ¯.
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From equations (3.2), (3.3) and (3.4), for any fixed patient age ` < ¯` and remaining
battery capacity u = kδ¯, we have
V (`, kδ¯ + δ¯) = max{R(`), C(`, (k + 1)δ¯)}
= max
{
R(`), 1 +
g((k+1)δ¯)∑
d=0
λ(`) · V (`+ 1, (k + 1)δ¯ − δ − d · δc) · pD(d)
}
(B.3)
≥ max
R(`), 1 +
g(kδ¯)∑
d=0
λ(`) · V (`+ 1, kδ¯ − δ − d · δc) · pD(d)
 (B.4)
= max
{
R(`), C(`, kδ¯)
}
= V (`, kδ¯). (B.5)
Inequality (B.4) follows from equation (3.2), equation (B.2), the induction hypothesis, and
the fact that g(u), given by equation (3.1), is non-decreasing in u. Therefore, the result
follows.
Proof of Corollary 1. The result follows from Lemma 1 and the fact that g(u), given by
equation (3.1), is non-decreasing in u.
Proof of Lemma 2. Clearly, from equation (3.2), the lemma holds for battery capacity
u ≤ 0. For any battery capacity u > 0 and patient age ` = ¯`, we have
V (¯`, u) = 0. (B.6)
Also, for any fixed remaining battery capacity u > 0 and patient age ` = ¯`− 1, by (3.2), we
have
V (¯`− 1, u) = max{R(¯`− 1), C(¯`− 1, u)} = 1. (B.7)
Hence, V (¯`− 1, u) ≥ V (¯`, u).
Now suppose for any fixed remaining battery capacity u > 0 we have
V (`, u) ≥ V (`+ 1, u) (B.8)
where ` = ¯`− 2, ¯`− 3, . . . , k and k > `. Next, we show V (`, u) ≥ V (`+ 1, u) for ` = k − 1.
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From equations (3.2), (3.3) and (3.4), for any fixed remaining battery capacity u > 0
and patient age ` = k − 1 we have
V (k − 1, u) = max{R(k − 1), C(k − 1, u)}
= max
{
1 + (1− α∆(k − 1)) · λ(k − 1) · V (k, u¯),
1 +
g(u)∑
d=0
λ(k − 1) · V (k, u− δ − d · δc) · pD(d)
}
≥ max
{
1 + (1− α∆(k)) · λ(k) · V (k + 1, u¯),
1 +
g(u)∑
d=0
λ(k) · V (k + 1, u− δ − d · δc) · pD(d)
}
(B.9)
= max{R(k), C(k, u)}, (B.10)
where equation (B.9) follows from equation (3.2), equation (B.8), the induction hypothe-
sis, and the assumptions that λ(`) and α∆(`) are non-increasing and non-decreasing in `,
respectively. Hence, the result follows.
Proof of Corollary 2. The result follows from Lemma 2 and the assumptions that λ(`)
and α∆(`) are non-increasing and non-decreasing in `, respectively.
Proof of Theorem 1. From equation (3.3), for any fixed patient age `, R(`) is constant in
u. Also, by Corollary 1, for any fixed patient age `, C(`, u) is non-decreasing in u. Since by
equation (3.2), V (`, u) is given as the maximum of R(`) and C(`, u), the result follows.
Proof of Lemma 3. Let Ci(`, u) and Ri(`) denote the reward obtained if the decision is
to “wait” or “replace,” respectively, where α∆(`) = α
i
∆(`). Let
α2∆(`) ≥ α1∆(`), ∀` ≤ ¯`. (B.11)
Clearly, from equation (3.2), the lemma holds for battery capacity u ≤ 0. For battery
capacity u > 0, the proof follows using an induction on `.
For any given u > 0 and ` = ¯`− 1, from equation (3.2) we have,
V i(¯`− 1, u) = 1 i = 1, 2. (B.12)
Hence, V 1(¯`− 1, u) = V 2(¯`− 1, u).
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Suppose, for ` = ¯`− 2, ¯`− 3, . . . , k and any given u > 0, we have
V 2(`, u) ≤ V 1(`, u). (B.13)
Therefore, for any given u > 0 and ` = k − 1, from equation (3.2) we have
V 2(k − 1, u) = max{R2(k − 1), C2(k − 1, u)}
= max
{
1 + (1− α2∆(k − 1)) · λ(k − 1) · V 2(k, u¯),
1 +
g(u)∑
d=0
λ(k − 1) · V 2(k, u− δ − d · δc) · pD(d)
}
≤ max
{
1 + (1− α1∆(k − 1)) · λ(k − 1) · V 1(k, u¯),
1 +
g(u)∑
d=0
λ(k − 1) · V 1(k, u− δ − d · δc) · pD(d)
}
(B.14)
= max{R1(k − 1), C1(k − 1, u)}
= V 1(k − 1, u), (B.15)
where equation (B.14) follows by equations (3.2) and (B.11) and the induction hypothesis,
equation (B.13). Therefore, the result follows.
Proof of Corollary 3. The result follows from Lemma 3 and equation (B.11).
Proof of Lemma 4. The proof is completed similar to the proof of Lemma 3, when using
Lemma 1 and Lemma 4.7.2 on page 106, Puterman (1994).
Proof of Corollary 4. The result follows from Lemmas 1 and 4 as well as Lemma 4.7.2
on page 106, Puterman (1994).
Proof of Lemma 5. The proof is completed similar to the proof of Lemma 3, when using
Lemma 1 and equation (3.1).
Proof of Corollary 5. The result follows from Lemmas 1 and 5 and equation (3.1).
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B.2 PROOFS FOR CHAPTER 4
Proof of Lemma 6. Differentiating V (τ, n) twice yields
∂2V (τ, n)
∂τ 2
= n r′(τ) + n2 r′
(
L− n · (τ + f(τ)))(1 + f ′(τ))2
−n r(L− n · (τ + f(τ)))f ′′(τ)
< 0, (B.16)
where (B.16) follows from A1 and A2.
Proof of Lemma 7. For a fixed n ∈ (0, n¯max), consider the function
ρ(τ) =
(
1 + f ′(τ)
)
r(L− n · (τ + f(τ))).
By assumptions A1-A3, ρ(0) = r(L− nf(0)) < r(0). Similarly,
ρ(τ¯n) = (1 + f
′(τ¯n)) r(0) ≥ r(0) > r(τ¯n).
Because the functions ρ(τ) and r(τ) are continuous for τ ∈ [0, τ¯n], τn exists and 0 < τn < τ¯n.
Uniqueness follows because r(τ) is strictly decreasing and ρ(τ) is increasing. Lemma 6
with (4.8) and (4.9) implies that τn maximizes V (τ, n) over τ ∈ (0, τ¯n) for any fixed n ∈
(0, n¯max).
Proof of Lemma 8. Define
g(n, τ) = r(τ)− (1 + f ′(τ)) r(L− n · (τ + f(τ))),
where (n, τ) ∈ {(n, τ) ∈ R2+ | n ∈ (0, n¯max), τ ∈ (0, τ¯n)}. By Lemma 7, for any fixed
n ∈ (0, n¯max), g(n, τn) = 0. Note that ∂g(n,τ)∂τ |τ=τn < 0 and hence, it is always non-zero.
Therefore, by the Implicit Function Theorem, τn is a continuously differentiable function of
n (see Knapp (2005), page 155). Equation (4.9) implies that ∂τn
∂n
≤ 0, i.e., τn is decreasing
in n, since otherwise, due to assumptions A1 and A2, equation (4.9) would be violated as
its left-hand-side would decrease while its right-hand-side would increase. Differentiating
V (τn, n) twice yields
∂2V (τn, n)
∂n2
= −
(
τn + f(τn)
)
1 + f ′(τn)
· ∂τn
∂n
·
(
r′(τn)− f ′′(τn) · r
(
L− n · (τn + f(τn))
))
≤ 0, (B.17)
which follows by A1 and A2 and the fact that ∂τn
∂n
≤ 0.
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Proof of Theorem 2. The proof directly follows from Lemmas 6 and 8 as well as the
definition of n˜.
Proof of Proposition 1. The result follows from equation (4.9) and assumptions A1
and A2.
Proof of Proposition 2. (i) From equation (4.9) and assumption A1
τn = L− n · (τn + ∆). (B.18)
Therefore, the optimal interval is
τn =
L− n∆
n+ 1
. (B.19)
(ii) Consider a fixed n ∈ [1, nmax] ∩ Z+. Then
L
n+ 1
−∆ ≤ L
n+ 1
− n∆
n+ 1
<
L
n
−∆.
(iii) Substituting (B.19) into equation (4.10) yields
∫ τn
0
r(t) dt = (τn + ∆)r(τn)
=
(
L+ ∆
n+ 1
)
r(τn), (B.20)
and hence
n˜ =
(L+ ∆) r(τn˜)∫ τn˜
0
r(t) dt
− 1. (B.21)
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Proof of Proposition 3. From Proposition 2, for any feasible non-zero n ∈ Z, the optimal
maintenance interval τn is given by equation (B.19) and satisfies equation (4.6). Also, by
Lemma 6, V (τ, n) is strictly concave in τ . As a result, the total lost reward attains its
maximum at one of the endpoints in (4.6). Therefore,
max
L
n+1
−∆≤τ<L
n
−∆
{V (τn, n)− V (τ, n)} =
max
{
V
(
L− n∆
n+ 1
, n
)
− V
(
L
n+ 1
−∆, n
)
, V
(
L− n∆
n+ 1
, n
)
− V
(
L
n
−∆, n
)}
(B.22)
≤ max
{
max
L
n+1
−∆≤τ≤L−n∆
n+1
∣∣∣∣∂V (τ, n)∂τ
∣∣∣∣ · ((L− n∆n+ 1
)
−
(
L
n+ 1
−∆
))
,
max
L−n∆
n+1
≤τ<L
n
−∆
∣∣∣∣∂V (τ, n)∂τ
∣∣∣∣ · ((Ln −∆
)
−
(
L− n∆
n+ 1
))}
= max
{
max
L
n+1
−∆≤τ≤L−n∆
n+1
|n · (r(τ)− r(L− n · (τ + ∆)))| ·
(
∆
n+ 1
)
,
max
L−n∆
n+1
≤τ<L
n
−∆
|n · (r(τ)− r(L− n · (τ + ∆)))| ·
(
L− n∆
n(n+ 1)
)}
= max
{
n ·
(
r
(
L
n+ 1
−∆
)
− r
(
L
n+ 1
))
· ∆
n+ 1
,
n ·
∣∣∣∣r(Ln −∆
)
− r(0)
∣∣∣∣ · L− n∆n(n+ 1)
}
= max
{
n∆
n+ 1
·
(
r
(
L
n+ 1
−∆
)
− r
(
L
n+ 1
))
,
L− n∆
(n+ 1)
·
(
r(0)− r
(
L
n
−∆
))}
. (B.23)
Hence, the result follows.
Proof of Corollary 7. The result follows from equations (4.15) and (B.22).
Proof of Proposition 4. Lemma 7 and Proposition 1 imply that L
n
−f(τn) ≥ (n+1)τnn > τn;
thus, if for τ = τn condition (4.6) does not hold, then τn <
L
n+1
− f(τn). Furthermore,
n < nmax because τn > 0 (Lemma 7) and
L
nmax+1
− f(τnmax) ≤ Lnmax+1 − f(0) ≤ 0, where the
last inequality follows from the definition of nmax. Therefore, 0 < n ≤ nmax − 1, in which
case τn exists. Moreover, τn > τn due to assumption A2 and the fact that (4.6) does not
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hold. Finally, because Lemma 6 still holds, V (τ, n) is concave in τ and the optimal total
reward for the given n is attained at τn.
Proof of Lemma 9. First, we prove by induction that the result holds for t ≤ ∆. For
t = 0, by (4.18),
V ∗(0, α) = 0 ≥ V ∗(0, α + 1) = 0 ∀α ≥ 0. (B.24)
Now, suppose for t = 1, 2, . . . , t¯− 1, where 0 < t¯− 1 < ∆,
V ∗(t, α) ≥ V ∗(t, α + 1) ∀α ≥ 0. (B.25)
For t = t¯ we have,
V ∗(t¯, α) =
(
R(α + 1)−R(α))+ hY (α) · (0− c)+ (1− hY (α)) · V ∗(t¯− 1, α + 1)
≥ (R(α + 2)−R(α + 1))+ hY (α + 1) · (0− c)
+
(
1− hY (α + 1)
) · V ∗(t¯− 1, α + 2) (B.26)
= V ∗(t¯, α + 1), (B.27)
where (B.26) follows from A1, A4 and the induction hypothesis (B.25). Therefore, the
reward function is monotone in α for t ≤ ∆, i.e., for t = 0, 1, . . . ,∆,
V ∗(t, α) ≥ V ∗(t, α + 1) ∀α ≥ 0. (B.28)
Next, we complete the proof by establishing the monotonicity of the function in α for
∆ + 1 ≤ t ≤ L. As before, we proceed by induction. By (4.21), for t = ∆ + 1 we have
V ∗(∆ + 1, α) =
(
R(α + 1)−R(α))+ hY (α) · (V ∗(0, 0)− c)
+(1− hY (α)) ·max{V ∗(0, 0), V ∗(∆, α + 1)}
≥ (R(α + 2)−R(α + 1))+ hY (α + 1) · (V ∗(0, 0)− c)
+(1− hY (α + 1)) ·max{V ∗(0, 0), V ∗(∆, α + 2)} (B.29)
= V ∗(∆ + 1, α + 1), (B.30)
where (B.29) follows from A1, A4 and (B.28). Suppose for t = ∆+2,∆+3, . . . , t¯−1, where
∆ + 1 < t¯− 1 < L, we have
V ∗(t, α) ≥ V ∗(t, α + 1) ∀α ≥ 0, (B.31)
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and consider V ∗(t¯, α). First, let
V ∗(t¯− 1−∆, 0) = ϑ, (B.32)
V ∗(t¯− 1, α + 1) = ι, (B.33)
and V ∗(t¯− 1, α + 2) = κ, (B.34)
and note that by (B.31),
ι ≥ κ. (B.35)
Therefore, for t = t¯,
V ∗(t¯, α) =
(
R(α + 1)−R(α))+ hY (α) · (ϑ− c) + (1− hY (α)) ·max{ϑ, ι} (B.36)
and
V ∗(t¯, α + 1) =
(
R(α + 2)−R(α + 1))+ hY (α + 1) · (ϑ− c)
+(1− hY (α + 1)) ·max{ϑ, κ}. (B.37)
The relation between (B.36) and (B.37) can be established using the three possible
relations between (B.32), (B.33) and (B.34):
(i) ϑ ≥ ι. By (B.35), ϑ ≥ ι ≥ κ. Hence,
V ∗(t¯, α) =
(
R(α + 1)−R(α))+ hY (α) · (ϑ− c) + (1− hY (α)) · ϑ
=
(
R(α + 1)−R(α))+ hY (α) · (−c) + ϑ
≥ (R(α + 2)−R(α + 1))+ hY (α + 1) · (−c) + ϑ (B.38)
=
(
R(α + 2)−R(α + 1))+ hY (α + 1) · (ϑ− c) + (1− hY (α + 1)) · ϑ
= V ∗(t¯, α + 1), (B.39)
where (B.38) follows from A1 and A4.
(ii) ϑ ≤ ι and ϑ ≤ κ. By (B.35),
ι ≥ κ ≥ ϑ. (B.40)
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Hence,
V ∗(t¯, α) =
(
R(α + 1)−R(α))+ hY (α) · (ϑ− c) + (1− hY (α)) · ι
≥ (R(α + 1)−R(α))+ hY (α) · (ϑ− c) + (1− hY (α)) · κ (B.41)
=
(
R(α + 1)−R(α))+ hY (α) · (−c) + κ+ hY (α) · (ϑ− κ)
≥ (R(α + 2)−R(α + 1))+ hY (α + 1) · (−c) + κ+ hY (α + 1) · (ϑ− κ)(B.42)
=
(
R(α + 2)−R(α + 1))+ hY (α + 1) · (ϑ− c) + (1− hY (α + 1)) · κ
= V ∗(t¯, α + 1), (B.43)
where (B.41) follows from (B.40) and (B.42) follows from A1, A4 and (B.40).
(iii) ϑ ≤ ι and ϑ ≥ κ. By (B.35),
ι ≥ ϑ ≥ κ. (B.44)
Hence,
V ∗(t¯, α) =
(
R(α + 1)−R(α))+ hY (α) · (ϑ− c) + (1− hY (α)) · ι
=
(
R(α + 1)−R(α))+ hY (α) · (−c) + (1− hY (α)) · (ι− ϑ) + ϑ
≥ (R(α + 2)−R(α + 1))+ hY (α + 1) · (−c) + ϑ (B.45)
=
(
R(α + 2)−R(α + 1))+ hY (α + 1) · (ϑ− c) + (1− hY (α + 1)) · ϑ
= V ∗(t¯, α + 1), (B.46)
where (B.45) follows from A1, A4 and (B.44).
Hence, V ∗(t¯, α) ≥ V ∗(t¯, α+ 1) ∀α ≥ 0, which implies that V ∗(t, α) is nonincreasing in α for
t ≥ ∆ + 1 and the result follows.
Proof of Lemma 10. First, we establish the monotonicity of the reward function in t for
t ≤ ∆. Next, we show that for every virtual age, the reward function is greater at t = ∆ + 1
than at t = ∆. Finally, by proving the monotonicity of the reward function in t ≥ ∆ + 1,
the result follows.
Note that by A1 and A4, R(α)−R(α− 1) and hY (α) are decreasing and nondecreasing
in α, respectively. Hence, by (4.22), for all α = 1, 2, . . . , L− 1,
R(α)−R(α− 1) ≥ c · hY (α− 1). (B.47)
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First, consider the case where t ≤ ∆. When t = 1, by (4.20),
V ∗(1, α) = R(α + 1)−R(α) + hY (α) · (0− c) + (1− hY (α)) · V ∗(0, α + 1)
= R(α + 1)−R(α)− c · hY (α) (B.48)
≥ V ∗(0, α) = 0, (B.49)
where (B.48) follows from (4.18) and (B.49) follows from (B.47).
Now, suppose for t = 2, 3, . . . , t¯− 1, where 1 < t¯− 1 < ∆, we have
V ∗(t− 1, α) ≤ V ∗(t, α) ∀α ≥ 0. (B.50)
For t = t¯ we obtain
V ∗(t¯, α) = R(α + 1)−R(α) + hY (α) · (0− c) + (1− hY (α)) · V ∗(t¯− 1, α + 1)
≥ R(α + 1)−R(α) + hY (α) · (0− c) + (1− hY (α)) · V ∗(t¯− 2, α + 1)(B.51)
= V ∗(t¯− 1, α), (B.52)
where (B.51) follows from the induction hypothesis given by (B.50). Therefore, the reward
function is monotone in t ≤ ∆.
Next, we show that V ∗(∆ + 1, α) ≥ V ∗(∆, α). When t = ∆ + 1, by equation (4.21) we
have
V ∗(∆ + 1, α) = R(α + 1)−R(α) + hY (α) · (V ∗(0, 0)− c)
+(1− hY (α)) ·max{V ∗(0, 0), V ∗(∆, α + 1)}
= R(α + 1)−R(α) + hY (α) · (0− c) + (1− hY (α)) · V ∗(∆, α + 1)
≥ R(α + 1)−R(α) + hY (α) · (0− c) + (1− hY (α)) · V ∗(∆− 1, α + 1) (B.53)
= V ∗(∆, α), (B.54)
where (B.53) follows from the monotonicity of V ∗(t, α) in t ≤ ∆ and (B.54) follows from
equation (4.20). Hence, for t = 1, 2, . . . ,∆ + 1,
V ∗(t− 1, α) ≤ V ∗(t, α) ∀α ≥ 0. (B.55)
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Now consider the case where t ≥ ∆ + 1. By (4.21), for t = ∆ + 2 we have
V ∗(∆ + 2, α) = R(α + 1)−R(α) + hY (α) · (V ∗(1, 0)− c)
+(1− hY (α)) ·max{V ∗(1, 0), V ∗(∆ + 1, α + 1)}
≥ R(α + 1)−R(α) + hY (α) · (V ∗(0, 0)− c)
+(1− hY (α)) ·max{V ∗(0, 0), V ∗(∆, α + 1)} (B.56)
= V ∗(∆ + 1, α), (B.57)
where (B.56) follows by (B.55). Suppose for t = ∆+3,∆+4, . . . , t¯−1, where ∆+2 < t¯−1 < L,
we have
V ∗(t− 1, α) ≤ V ∗(t, α) ∀α ≥ 0. (B.58)
For t = t¯ we have,
V ∗(t¯, α) = R(α + 1)−R(α) + hY (α) · (V ∗(t¯− 1−∆, 0)− c)
+(1− hY (α)) ·max{V ∗(t¯− 1−∆, 0), V ∗(t¯− 1, α + 1)}
≥ R(α + 1)−R(α) + hY (α) · (V ∗(t¯− 2−∆, 0)− c)
+(1− hY (α)) ·max{V ∗(t¯− 2−∆, 0), V ∗(t¯− 2, α + 1)} (B.59)
= V ∗(t¯− 1, α), (B.60)
where (B.59) follows from the monotonicity of the reward function in t ≤ ∆ + 1 and the
induction hypothesis given by (B.58). Therefore, the reward function is also monotone in
t ≥ ∆ + 1 for any fixed α ∈ [0, L] and the result follows.
Proof of Theorem 3. If t ≤ ∆, performing PM is not an option, hence the result follows.
For t ≥ ∆ + 1, suppose a∗(t, α′) = 1, i.e.,
V ∗(t− 1−∆, 0) ≥ V ∗(t− 1, α′ + 1), (B.61)
using equation (4.21). Recall that by Lemma 9, V ∗(t, α) is nonincreasing in α for all t ∈ [0, L].
Hence,
V ∗(t− 1−∆, 0) ≥ V ∗(t− 1, α′ + 2). (B.62)
Therefore, from equation (4.21), at α = α′ + 1 we have
a∗(t, α′ + 1) = 1. (B.63)
Therefore, the result follows.
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Proof of Lemma 11. (i) The proof is similar to the proof of Lemma 9. We only need the
sufficient condition given by equation (4.22) to show that for t ≤ ∆ + 1,
V ∗(t, L− 1) = R(L)−R(L− 1) + hY (L− 1) · (0− c) + (1− hY (L− 1)) · V ∗(t− 1, L)
= R(L)−R(L− 1) + hY (L− 1) · (0− c) (B.64)
≥ V ∗(t, L) = 0, (B.65)
where equation (B.64) follows from equation (4.24). The rest of the proof is completed
when for t ≥ ∆ + 1, we modify equation (B.32) to
L−1∑
x=0
V ∗(t−∆− 1, x) · pX(x) = ϑ. (B.66)
(ii) The proof of is similar to the proof of Lemma 10.
Proof of Theorem 4. The proof is similar to the proof of Theorem 3 and uses Lemma 11.
Proof of Lemma 12. The proof is completed by induction on t, when using Lemma 11
and Lemma 4.7.2 on page 106, Puterman (1994).
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